Document:

EX-10.5

 Exhibit 10.5 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not
material and would likely cause competitive harm to the registrant if publicly disclosed. 
 Execution Copy 

CONFIDENTIAL 

Collaboration and License Agreement 
 This
Agreement is entered into with effect as of the Effective Date (as defined below) 
 by and between 

F. Hoffmann-La Roche Ltd 

a corporation organized under the laws of Switzerland with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche
Basel”) 
 and 
 Hoffmann-La Roche Inc. 
 a corporation organized under the laws of New Jersey with an office and place of
business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”) 

on the one hand 
 and 

4D Molecular Therapeutics Inc. 
 a company organized
under the laws of Delaware with an office and place of business at 5980 Horton Street, Suite 460, Emeryville, CA 94608, U.S.A. (“4DMT”) 

on the other hand. 
  

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Table of Contents 

 

							
	 1. Definitions
	  	 	8	 
	 1.1
	 	4DMT Know-How	  	 	8	 
	 1.2
	 	4DMT Product Class Status Notice	  	 	8	 
	 1.3
	 	AAV	  	 	9	 
	 1.4
	 	Affiliate	  	 	9	 
	 1.5
	 	Agreement	  	 	9	 
	 1.6
	 	Agreement Term	  	 	9	 
	 1.7
	 	Applicable Law	  	 	9	 
	 1.8
	 	Available Product Class	  	 	9	 
	 1.9
	 	Biosimilar Product	  	 	10	 
	 1.10
	 	BLA	  	 	10	 
	 1.11
	 	Calendar Quarter	  	 	10	 
	 1.12
	 	Calendar Year	  	 	10	 
	 1.13
	 	cGMP	  	 	10	 
	 1.14
	 	Change of Control	  	 	10	 
	 1.15
	 	Change of Control Group	  	 	10	 
	 1.16
	 	Choroideremia	  	 	11	 
	 1.17
	 	Choroideremia GMP Lot	  	 	11	 
	 1.18
	 	Clinical Study	  	 	11	 
	 1.19
	 	CMO	  	 	11	 
	 1.20
	 	CMO/CRO	  	 	11	 
	 1.21
	 	Collaboration	  	 	11	 
	 1.22
	 	Collaboration Product Class	  	 	11	 
	 1.23
	 	Collaboration Project	  	 	11	 
	 1.24
	 	Combination Product	  	 	11	 
	 1.25
	 	Commercially Reasonable Efforts	  	 	12	 
	 1.26
	 	Companion Diagnostic	  	 	12	 
	 1.27
	 	Completion	  	 	12	 
	 1.28
	 	Compulsory Sublicense	  	 	12	 
	 1.29
	 	Construct	  	 	13	 
	 1.30
	 	Confidential Information	  	 	13	 
	 1.31
	 	Continuation Election Notice	  	 	13	 
	 1.32
	 	Control	  	 	14	 
	 1.33
	 	Cover	  	 	14	 
	 1.34
	 	Development Event	  	 	14	 
	 1.35
	 	Effective Date	  	 	14	 
	 1.36
	 	Enabled Product	  	 	14	 
	 1.37
	 	EU	  	 	14	 
	 1.38
	 	Excluded Construct	  	 	14	 
	 1.39
	 	Excluded Product	  	 	14	 
	 1.40
	 	Excluded Variant	  	 	14	 
	 1.41
	 	Expert	  	 	15	 
	 1.42
	 	FDA	  	 	15	 
	 1.43
	 	FDCA  	  	 	15	 

  
 - ii - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

							
	 1.44
	 	Field	  	 	15	 
	 1.45
	 	Filing	  	 	15	 
	 1.46
	 	First Commercial Sale	  	 	15	 
	 1.47
	 	FTE	  	 	16	 
	 1.48
	 	FTE Rate	  	 	16	 
	 1.49
	 	Full Range 4DMT Patent Right	  	 	16	 
	 1.50
	 	Generic Product	  	 	16	 
	 1.51
	 	GLP Tox Study	  	 	16	 
	 1.52
	 	GMP Package Approval	  	 	16	 
	 1.53
	 	Handle	  	 	17	 
	 1.54
	 	Highest Priority Efforts	  	 	17	 
	 1.55
	 	High Volume Roche Solo Scenario	  	 	17	 
	 1.56
	 	IFRS	  	 	17	 
	 1.57
	 	IND	  	 	17	 
	 1.58
	 	Initiation	  	 	17	 
	 1.59
	 	JOT	  	 	17	 
	 1.60
	 	JSC	  	 	17	 
	 1.61
	 	Know-How	  	 	17	 
	 1.62
	 	Licensed Combination Product	  	 	18	 
	 1.63
	 	Licensed Construct	  	 	18	 
	 1.64
	 	Licensed Product	  	 	18	 
	 1.65
	 	Like-Substance Product	  	 	18	 
	 1.66
	 	NDA	  	 	18	 
	 1.67
	 	Net Sales	  	 	18	 
	 1.68
	 	Non-Optionable 4DMT Product Class	  	 	19	 
	 1.69
	 	Non-Optionable Patent Right	  	 	19	 
	 1.70
	 	Optionable 4DMT Product Class	  	 	19	 
	 1.71
	 	Optionable Patent Right	  	 	19	 
	 1.72
	 	Optionable Payload	  	 	19	 
	 1.73
	 	Optionable Product Patent Right	  	 	19	 
	 1.74
	 	Optionable Project Work	  	 	20	 
	 1.75
	 	Optionable Variant	  	 	20	 
	 1.76
	 	Optionable Variant Patent Right	  	 	20	 
	 1.77
	 	Optioned Patent Right	  	 	20	 
	 1.78
	 	Other Product Class	  	 	20	 
	 1.79
	 	Party	  	 	20	 
	 1.80
	 	Patent Right	  	 	20	 
	 1.81
	 	Payload	  	 	20	 
	 1.82
	 	Pharmacovigilance Agreement	  	 	21	 
	 1.83
	 	Phase I/IIa Study	  	 	21	 
	 1.84
	 	Phase II Study	  	 	21	 
	 1.85
	 	Pivotal Study	  	 	21	 
	 1.86
	 	Pre-Clinical Success Criteria	  	 	22	 
	 1.87
	 	Preferred CMO	  	 	22	 
	 1.88
	 	Product  	  	 	22	 

  
 - iii - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

							
	 1.89
	 	Product Class	  	 	22	 
	 1.90
	 	Project Patent Right	  	 	22	 
	 1.91
	 	Project Payload	  	 	22	 
	 1.92
	 	Project Product Patent Right	  	 	22	 
	 1.93
	 	Project Variant	  	 	22	 
	 1.94
	 	Project Variant Patent Right	  	 	22	 
	 1.95
	 	Regents License Agreement	  	 	23	 
	 1.96
	 	Regents Patent Right	  	 	23	 
	 1.97
	 	Regulatory Approval	  	 	23	 
	 1.98
	 	Regulatory Authority	  	 	23	 
	 1.99
	 	Retina Field	  	 	23	 
	 1.100
	 	RFO Agreement	  	 	23	 
	 1.101
	 	Roche Group	  	 	23	 
	 1.102
	 	Roche Materials	  	 	24	 
	 1.103
	 	Roche Patent Right	  	 	24	 
	 1.104
	 	Roche Solo Product Class	  	 	24	 
	 1.105
	 	Royalty Term	  	 	24	 
	 1.106
	 	Sales	  	 	25	 
	 1.107
	 	Shared Products	  	 	25	 
	 1.108
	 	Start of GLP Tox Study	  	 	25	 
	 1.109
	 	Sublicensee	  	 	26	 
	 1.110
	 	Territory	  	 	26	 
	 1.111
	 	Third Party	  	 	26	 
	 1.112
	 	Third Party Supplier	  	 	26	 
	 1.113
	 	US	  	 	26	 
	 1.114
	 	US$	  	 	26	 
	 1.115
	 	Valid Claim	  	 	26	 
	 1.116
	 	Variant	  	 	26	 
	 1.117
	 	XLRP	  	 	26	 
	 1.118
	 	Additional Definitions	  	 	26	 
	 2. Product Classes
	  	 	28	 
	 2.1
	 	High-Level Overview	  	 	28	 
	 2.2
	 	Roche Product Class	  	 	29	 
	 2.3
	 	4DMT Product Class	  	 	31	 
	 2.4
	 	Available Product Class	  	 	32	 
	 3. Research and Development Collaboration
	  	 	33	 
	 3.1
	 	Overview	  	 	33	 
	 3.2
	 	Collaboration Product Class	  	 	33	 
	 3.3
	 	Project Plans	  	 	33	 
	 3.4
	 	4DMT Reporting	  	 	34	 
	 3.5
	 	Project Plan Termination	  	 	34	 
	 3.6
	 	Roche Materials	  	 	36	 
	 4. Grant of License
	  	 	36	 
	 4.1
	 	License	  	 	36	 
	 4.2
	 	Sublicenses  	  	 	37	 

  
 - iv - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

							
	 4.3
	 	Research Cross License	  	 	37	 
	 4.4
	 	Grant-Back License	  	 	38	 
	 5. Diligence
	  	 	38	 
	 5.1
	 	Collaboration	  	 	38	 
	 5.2
	 	Roche Commercially Reasonable Efforts	  	 	38	 
	 5.3
	 	4DMT Commercially Reasonable Efforts	  	 	38	 
	 5.4
	 	Progression to IND Filing	  	 	39	 
	 5.5
	 	Additional Development Progression	  	 	39	 
	 6. Program Transfer
	  	 	41	 
	 6.1
	 	IND and Regulatory	  	 	41	 
	 6.2
	 	Other Program Transfer	  	 	41	 
	 7. Development and Regulatory Affairs
	  	 	42	 
	 7.1
	 	By 4DMT	  	 	42	 
	 7.2
	 	By Roche	  	 	42	 
	 7.3
	 	Shared Product	  	 	43	 
	 8. Manufacturing
	  	 	43	 
	 9. Commercialization
	  	 	44	 
	 10. Governance
	  	 	44	 
	 10.1
	 	Joint Steering Committee	  	 	44	 
	 10.2
	 	Members	  	 	44	 
	 10.3
	 	Responsibilities of the JSC	  	 	44	 
	 10.4
	 	Meetings	  	 	45	 
	 10.5
	 	Minutes	  	 	45	 
	 10.6
	 	Progress Reports	  	 	45	 
	 10.7
	 	Decisions	  	 	46	 
	 10.8
	 	Alliance Director	  	 	46	 
	 10.9
	 	Limitations of Authority	  	 	46	 
	 10.10
	 	Expenses	  	 	46	 
	 10.11
	 	Lifetime	  	 	47	 
	 11. Project Plan Payments to 4DMT
	  	 	47	 
	 11.1
	 	Collaboration Costs	  	 	47	 
	 11.2
	 	Third Party Supplier and Third Party Expenses	  	 	47	 
	 11.3
	 	Payment Schedule	  	 	47	 
	 11.4
	 	Fair Market Value	  	 	48	 
	 11.5
	 	Optionable 4DMT Product Class Work	  	 	48	 
	 12. Payment to 4DMT (other than Project Plan Payments)
	  	 	48	 
	 12.1
	 	Initiation Payment	  	 	48	 
	 12.2
	 	Roche Product Class Initiation Payment (other than Optioned Product Class)	  	 	48	 
	 12.3
	 	Option Exercise Fee	  	 	49	 
	 12.4
	 	Development Event Payments	  	 	49	 
	 12.5
	 	Sales Based Events	  	 	50	 
	 12.6
	 	Royalty Payments	  	 	51	 
	 13. General Payment Provisions
	  	 	53	 
	 13.1
	 	Invoices	  	 	53	 
	 13.2
	 	Late Payment  	  	 	54	 

  
 - v - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

							
	 13.3
	 	Disclosure of Payments	  	 	54	 
	 14. Royalty accounting and reporting
	  	 	54	 
	 14.1
	 	Timing of Payments	  	 	54	 
	 14.2
	 	Method of Payment	  	 	54	 
	 14.3
	 	Currency Conversion	  	 	54	 
	 14.4
	 	Reporting	  	 	54	 
	 15. Taxes
	  	 	55	 
	 16. Royalty Auditing
	  	 	55	 
	 16.1
	 	4DMT Right to Audit	  	 	55	 
	 16.2
	 	Audit Reports	  	 	56	 
	 16.3
	 	Over-or Underpayment	  	 	56	 
	 16.4
	 	Duration of Audit Rights	  	 	56	 
	 17. Payments to Roche
	  	 	56	 
	 18. Intellectual Property
	  	 	57	 
	 18.1
	 	Inventorship	  	 	57	 
	 18.2
	 	Ownership	  	 	57	 
	 18.3
	 	Patent Coordination Team	  	 	58	 
	 18.4
	 	Prosecution	  	 	58	 
	 18.5
	 	List of Licensed 4DMT Patent Rights	  	 	61	 
	 18.6
	 	Infringement	  	 	61	 
	 18.7
	 	Defense	  	 	63	 
	 18.8
	 	Common Interest Disclosures	  	 	63	 
	 18.9
	 	Patent Term Extensions	  	 	64	 
	 19. Representations and Warranties
	  	 	64	 
	 19.1
	 	By both Parties	  	 	64	 
	 19.2
	 	By 4DMT	  	 	65	 
	 19.3
	 	Disclaimer	  	 	66	 
	 20. Indemnification and Liability
	  	 	66	 
	 20.4
	 	Insurance	  	 	68	 
	 20.5
	 	Disclaimer	  	 	68	 
	 21. Obligation Not to Disclose Confidential Information
	  	 	68	 
	 21.1
	 	Non-Use and Non-Disclosure	  	 	68	 
	 21.2
	 	Permitted Disclosure	  	 	68	 
	 21.3
	 	Press Releases	  	 	68	 
	 21.4
	 	Commercial Considerations	  	 	69	 
	 21.5
	 	4D Materials	  	 	69	 
	 22. Term and Termination
	  	 	70	 
	 22.1
	 	Commencement and Term	  	 	70	 
	 22.2
	 	Termination	  	 	70	 
	 22.3
	 	Consequences of Termination	  	 	70	 
	 22.4
	 	Survival	  	 	75	 
	 23. Bankruptcy
	  	 	75	 
	 24. Change of Control
	  	 	75	 
	 25. Miscellaneous
	  	 	76	 
	 25.1
	 	Governing Law  	  	 	76	 

  
 - vi - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

							
	 25.2
	 	Disputes	  	 	76	 
	 25.3
	 	Arbitration	  	 	76	 
	 25.4
	 	Assignment	  	 	76	 
	 25.5
	 	Debarment	  	 	77	 
	 25.6
	 	Anti-Bribery	  	 	77	 
	 25.7
	 	Product Class	  	 	77	 
	 25.8
	 	Independent Contractor	  	 	78	 
	 25.9
	 	Unenforceable Provisions and Severability	  	 	78	 
	 25.10
	 	Waiver	  	 	78	 
	 25.11
	 	Interpretation	  	 	78	 
	 25.12
	 	Appendices	  	 	78	 
	 25.13
	 	Entire Understanding	  	 	78	 
	 25.14
	 	Amendments	  	 	78	 
	 25.15
	 	Notice	  	 	79	 

  

  
 - vii - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

Collaboration and License Agreement 

WHEREAS, 4DMT has expertise and technology in the field of adeno-associated virus vectors useful as a favored delivery vehicle for gene therapy in the human
body using 4DMT’s therapeutic vector evolution technology and is pursuing research and development of such products; 
 WHEREAS, Roche has expertise in
the research, development, manufacture and commercialization of pharmaceutical and diagnostic products; and 
 WHEREAS, 4DMT and Roche desire to collaborate
on researching and developing certain ocular adeno-associated virus-based gene therapy products; and 
 WHEREAS, 4DMT is willing to grant to Roche rights to
use certain of its intellectual property rights to make, use, offer for sale, sell and import and export certain such products, including options for Roche to license 4DMT’s rights to certain such products that will be developed by 4DMT. 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 
 1. Definitions 

As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 

1.1 4DMT Know-How 

The term “4DMT Know-How” shall mean the Know-How that 4DMT Controls
at the Effective Date regarding any Construct or Product, or thereafter Controlled by 4DMT and necessary to develop, make, have made, use, or sell a Construct or Product in each case in the Field. For purposes of clarity, 4DMT shall not be obligated
to provide Roche with Know-How that is none of the following: 
  

	 	a)	 Controlled by 4DMT as of the Effective Date, 

 

	 	b)	 used or created in the Collaboration, and 

 

	 	c)	 used or created by 4DMT for Products associated with a 4DMT Product Class that becomes a Roche Product
Class, 

 if the provision, license or sublicense of such Know-How to Roche would result in payment
being due to a Third Party; in which case, so long as 4DMT does not provide Roche with such Know-How, then “4DMT Know-How” shall not include such Know-How. 
 1.2 4DMT Product Class Status Notice 

The term “4DMT Product Class Status Notice” shall mean a written notice from 4DMT to Roche requesting the change of Status of a specified
Available Product Class to a 4DMT Product Class in accordance with Section 2.3.2. 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.3 AAV 

The term “AAV” shall mean adeno-associated virus. 

1.4 Affiliate 
 The term “Affiliate” shall mean
any individual, corporation, association or other business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term
“control” shall mean the direct or indirect ownership of more than fifty percent (>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business
entity whether through the ownership of voting securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, [***] shall be deemed as Affiliates of Roche unless Roche provides written
notice to 4DMT of its desire to include [***] as Affiliate(s) of Roche. 
 Upon the completion of a Change of Control, the Change of Control Group shall not
be deemed as an Affiliate of 4DMT under this Agreement so long as such Change of Control Group and 4DMT have agreed to the restrictions specified in Article 24. 

1.5 Agreement 
 The term “Agreement” shall mean
this document including any and all appendices and amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 

1.6 Agreement Term 
 The term “Agreement Term”
shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided in Section 22.2, expiring on the later of (i) the date when no royalty or other payment obligations under this
Agreement are or will become due or (ii) the date when there are no Product Classes with the status of either an Optionable 4DMT Product Class or a Roche Product Class. 

1.7 Applicable Law 
 The term “Applicable Law”
shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the
Agreement Term, in each case to the extent that the same is applicable to the performance by the Parties of their respective obligations under this Agreement. 

1.8 Available Product Class 
 The term “Available
Product Class” shall mean any Product Class other than a 4DMT Product Class or a Roche Product Class. 

  
 - 9 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.9 Biosimilar Product 

The term “Biosimilar Product” shall mean a Product that is not produced, licensed or owned by the Roche Group and is, according to the relevant
Regulatory Authority for the given country or jurisdiction, highly similar with respect to a given Roche Group’s Product, notwithstanding minor differences in clinically inactive components, and with no clinically meaningful differences between
the Biosimilar Product and the given Roche Group’s Product in terms of the safety, purity and potency of the product. 
 For countries or jurisdictions
where no explicit biosimilar regulations exist, Biosimilar Product includes Products that (i) have been deemed to be a Biosimilar Product by a Regulatory Authority in another country or jurisdiction or (ii) have the same amino acid
sequence. 
 1.10 BLA 
 The term “BLA” shall
mean a Biologics License Application, or similar application for marketing approval of the Products for use in the Field submitted to the FDA, or a foreign equivalent of the FDA. 

1.11 Calendar Quarter 
 The term “Calendar
Quarter” shall mean each period of three (3) consecutive calendar months, ending March 31, June 30, September 30, and December 31. 

1.12 Calendar Year 
 The term “Calendar Year”
shall mean the period of time beginning on January 1 and ending December 31, except for the first year which shall begin on the Effective Date and end on December 31. 

1.13 cGMP 
 The term “cGMP” shall mean the FDA
Current Good Manufacturing Practice regulations and guidance documents, for example under 21 C.F.R. §210 and 211. 
 1.14 Change of Control 

The term “Change of Control” shall mean: (a) the acquisition after the Effective Date by any Third Party of beneficial ownership of fifty
percent (50%) or more of the then outstanding common shares or voting power of 4DMT, other than acquisitions by employee benefit plans sponsored or maintained by 4DMT; (b) the consummation of a business combination involving 4DMT, unless,
following such business combination, the stockholders of 4DMT immediately prior to such business combination beneficially own directly or indirectly more than fifty percent (50%) of the then outstanding common shares or voting power of the entity
resulting from such business combination; or (c) the sale of all or substantially all of 4DMT’s assets or business relating to the subject matter of the Agreement. 

1.15 Change of Control Group 
 The term “Change of
Control Group” shall mean the person or entity, or group of person or entities, that is the acquirer of, or a successor to, 4DMT in connection with a Change of Control, together with affiliates of such persons or entities that are not
Affiliates of 4DMT immediately prior to the completion of such Change of Control. 

  
 - 10 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.16 Choroideremia 

The term “Choroideremia” shall mean a Product Class comprising the set of Products where the Payload is [***]. For clarity, [***]. 

1.17 Choroideremia GMP Lot 
 The term “Choroideremia
GMP Lot” shall mean a Licensed Product associated with Choroideremia manufactured by a CMO on behalf of 4DMT according to cGMP, available in the amounts and to the specifications set forth in the Choroideremia Project Plan and released to
conduct the first Phase I/IIa Study of such Licensed Product. 
 1.18 Clinical Study 

The term “Clinical Study” shall mean a Phase I/IIa Study or Pivotal Study, as applicable. 

1.19 CMO 
 The term “CMO” shall mean a contract
manufacturing organization. 
 1.20 CMO/CRO 
 The term
“CMO/CRO” shall mean a contract manufacturing organization or contract research organization, as applicable. 
 1.21 Collaboration 

The term “Collaboration” shall mean the research and development collaboration described in Article 3. The Collaboration Projects collectively
constitute the Collaboration. For clarity, the Collaboration does not include research and development work on 4DMT Product Classes, although JSC responsibilities include certain activities set forth in Article 10 with respect to a given
Optionable 4DMT Product Class. 
 1.22 Collaboration Product Class 

The term “Collaboration Product Class” shall mean a Roche Product Class that is designated as a Collaboration Product Class in accordance
with Section 3.2. 
 1.23 Collaboration Project 

The term “Collaboration Project” shall mean the research and development project for a given Collaboration Product Class, to be conducted under the
corresponding Project Plan. 
 1.24 Combination Product 

The term “Combination Product” shall mean 

  
 - 11 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	a)	 a single pharmaceutical formulation containing as its active ingredients both a Construct and one or more other
therapeutically or prophylactically active ingredients, 

  

	b)	 a combination therapy comprised of a Construct and one or more other therapeutically or prophylactically active
products, priced and sold in a single package containing such multiple products or packaged separately but sold together for a single price, or 

  

	c)	 a combination therapy comprised of a Construct and a Companion Diagnostic, priced and sold in a single package
containing such multiple products or packaged separately but sold together for a single price, 

 in each case, including all dosage
forms, formulations, presentations, line extensions, and package configurations. All references to Product in this Agreement shall be deemed to include Combination Product. 

1.25 Commercially Reasonable Efforts 
 The term
“Commercially Reasonable Efforts” shall mean such level of efforts required to carry out such obligation in sustained manner consistent with the efforts Roche or 4DMT, as applicable, devotes at the same stage of research, development or
commercialization, as applicable, for its own internally developed pharmaceutical products in a similar area with similar market potential, at a similar stage of their product life taking into account the existence of other competitive products in
the market place or under development, the proprietary position of the product, the regulatory structure involved, the anticipated profitability of the product, and other relevant factors. It is understood that such product potential may change from
time to time based upon changing scientific, business and marketing and return on investment considerations. 
 [***]. 

1.26 Companion Diagnostic 
 The term “Companion
Diagnostic” shall mean, with respect to a given Product, any product that is used for predicting and/or monitoring the response of a human being to treatment with a such Product (e.g. device, compound, kit, biomarker or service that contains a
component that is used to detect or quantify the presence or amount of an analyte in body or tissue that affects the pathogens of the disease). 
 1.27
Completion 
 The term “Completion” shall mean the date that the final report for an associated Phase I/IIa Study is available. For
clarity, as used in this agreement, to achieve Completion such Phase I/IIa Study must include minimum endpoints (“Endpoints”) that would be reasonably deemed as functional readouts of treatment efficacy and safety. 

1.28 Compulsory Sublicense 
 The term “Compulsory
Sublicense” shall mean a license or sublicense granted to a Third Party, through the order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to manufacture, use, sell, offer for sale,
import or export a Product in any country in the Territory. 

  
 - 12 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.29 Construct 

The term “Construct” shall mean any Variant carrying a Payload, but not (and specifically excluding) any Excluded Variant carrying a Payload. In
addition to the applicable Variant and Payload, a Construct may contain a regulatory sequence or regulatory sequences that control the gene expression of the Payload, but a Construct shall not otherwise contain any other genetic material beyond the
Variant, Payload and such regulatory sequence or regulatory sequences, or else it will fall outside this definition. 
 1.30 Confidential Information

 The term “Confidential Information” shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or
its Affiliates (“Receiving Party”), whether under this Agreement or under the RFO Agreement, except that the results of the Collaboration are the Confidential Information of both Parties (to avoid doubt, subject to Roche’s
right to use such results within the Field and 4DMT’s right to use such results outside the Field or inside the Field for Non-Optionable 4DMT Product Classes under the terms of this Agreement).
Confidential Information shall not include any information, data or know-how that: 
  

	 	(i)	 was generally available to the public at the time of disclosure, or becomes available to the public after
disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving Party or its Affiliates, 

  

	 	(ii)	 can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior
to its receipt from the Disclosing Party, 

  

	 	(iii)	 is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure,

  

	 	(iv)	 is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than
through knowledge or use of Confidential Information, 

  

	 	(v)	 is required to be disclosed by the Receiving Party or its Affiliates to comply with a court or administrative
order providing the Receiving Party or its Affiliates furnishes prompt notice (in no event less than [***] ([***]) days) to the Disclosing Party to enable it to resist such disclosure, or 

 

	 	(vi)	 is approved in writing by the Disclosing Party for release by the Receiving Party. 

The terms of this Agreement shall be considered Confidential Information of the Parties. Information disclosed under the RFO Agreement shall be deemed to be
disclosed under this Agreement, however for clarity Confidential Information that was deemed as being 4DMT Confidential Information as a consequence of Roche’s failure to exercise the Option (as such term is defined in the RFO Agreement) shall
remain as the Confidential Information of 4DMT. 
 1.31 Continuation Election Notice 

The term “Continuation Election Notice” shall mean the notice 4DMT provides to Roche under Section 22.3.1 describing (i) 4DMT’s
bona fide intentions to continue ongoing development and commercialization of Product(s) and, if applicable, (ii) 4DMT’s request for Roche’s continuation of activities during the termination period and/or transfer of the data,
material and information relating to the Product(s) in accordance with Section 22.3. 

  
 - 13 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.32 Control 

The term “Control” shall mean (as an adjective or as a verb including conjugations and variations such as “Controls” “Controlled”
or “Controlling”) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a Party of the ability to supply such
proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 

1.33 Cover 
 The term “Cover” shall mean, with
respect to a particular item or product and a particular claim in a given Patent Right, that such claim covers (a) the composition of such item or product or any of its ingredients or formulations; (b) a method of making or using it or
them; or (c) an item used or present in the manufacture of such item or product. 
 1.34 Development Event 

The term “Development Event” shall mean a development event listed in the Section 12.4 table. 

1.35 Effective Date 
 The term “Effective Date”
shall mean November 16, 2017. 
 1.36 Enabled Product 

The term “Enabled Product” shall mean a product for which 4DMT has provided a timely Continuation Election Notice under Section 22.3.1. 

1.37 EU 
 The term “EU” shall mean the European
Union and all its then-current member countries but including in any case [***] regardless of whether they are then-current member countries. 
 1.38
Excluded Construct 
 The term “Excluded Construct” shall mean any Excluded Variant carrying a Payload. 

1.39 Excluded Product 
 The term “Excluded
Product” shall mean any product containing an Excluded Construct. 
 1.40 Excluded Variant 

The term “Excluded Variant” shall have the meaning set forth in the Memorandum of Understanding (“Memo”) between the Parties
effective as of the Effective Date, as may be amended. 

  
 - 14 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.41 Expert 

The term “Expert” shall mean a person with no less than [***] years of pharmaceutical industry experience and expertise having occupied at least one
senior position within a large biopharmaceutical company relating to product commercialization and/or licensing, but excluding any current or former employee or consultant of either Party. Such person shall be fluent in the English language. 

1.42 FDA 
 The term “FDA” shall mean the Food and
Drug Administration of the United States of America. 
 1.43 FDCA 

The term “FDCA” shall mean the Food, Drug and Cosmetics Act. 

1.44 Field 
 The term “Field” shall mean all
biopharmaceutical and biomedical uses for delivery to the eye of any Product in order to treat ophthalmological diseases and disorders, but specifically excluding: 
  

	(a)	 treatment or prevention of cancer (including pre-cancerous conditions),

  

	(b)	 treatment or prevention of diseases and conditions of the central nervous system (with the understanding that
the central nervous system does not include retinal nerves), and 

  

	(c)	 delivery of ddRNAi. 

1.45 Filing 
 The term “Filing” shall mean the
filing of an application by the FDA as defined in the FDCA and applicable regulations, or the equivalent application to the equivalent agency in any other country or group of countries, the official approval of which application is required before
any lawful (a) commencement of clinical trials for with respect to INDs and (b) commercial sale or marketing with respect to BLAs or NDAs, of Licensed Products. To avoid doubt 

 

	(i)	 with respect to INDs, “Filing” shall mean the IND going into effect in accordance with 21 C.F.R.
312.40(b); and 

  

	(ii)	 with respect to BLAs or NDAs, “Filing” does not refer to such ultimate official approval, rather, it
refers to the FDA or equivalent agency accepting the application as filed for review in order to determine whether or not to approve it. 

1.46 First Commercial Sale 
 The term “First
Commercial Sale” shall mean, on a country-by-country basis, the first invoiced sale of a Licensed Product to a Third Party by the Roche Group following the receipt
of any Regulatory Approval required for the sale of such Licensed Product, or if no such Regulatory Approval is required, the date of the first invoiced sale of a Licensed Product to a Third Party by the Roche Group in such country. 

  
 - 15 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.47 FTE 

The term “FTE” shall mean a full-time equivalent person-year, based upon a total of no less than [***] working hours per year. 

1.48 FTE Rate 
 The term “FTE Rate” shall mean
the amount of [***] US Dollars (US$ [***]) per FTE, on a fully burdened cost basis. 
 1.49 Full Range 4DMT Patent Right 

The term “Full Range 4DMT Patent Right” shall mean any Patent Right that 4DMT Controls as of the Effective Date and during the Agreement Term that
(a) is not a Regents Patent Right and (b) Covers any Construct or Product in each case in the Field, including any of the foregoing Patent Rights that are Project Variant Patent Rights and Project Product Patent Rights (irrespective of the
ownership of such Patent Rights). 
 A Full Range 4DMT Patent Right may be further subcategorized by Product Class Status, specifically as a Full Range
4DMT Patent Right that Covers any Product associated with a Product Class that has the following Status at the applicable time (and Constructs associated with such Products) as follows: 

 

	(i)	 (x) a 4DMT Product Class that is an Optionable Product Class, (y) an Available Product Class or
(z) a Roche Product Class (“Broad Range 4DMT Patent Right”); 

  

	(ii)	 an Available Product Class or a Roche Product Class (“Mid Range 4DMT Patent Right”);

  

	(iii)	 a Roche Product Class (“Licensed 4DMT Patent Right”). 

1.50 Generic Product 
 The term “Generic Product”
shall mean a Product that is not produced, licensed or owned by the Roche Group that (i) contains a Construct that is the same as the Construct in the Roche Group’s Product and (ii) has the same or substantially the same labelling as
the applicable Roche Group’s Product for at least one indication of such Roche Group’s Product. 
 1.51 GLP Tox Study 

The term “GLP Tox Study” shall mean a toxicology study on a Licensed Product the outcome of which is expected (if successful) to provide data
sufficient to support the filing of an IND covering such Licensed Product. Such toxicology study, however, need not actually be successful in order to qualify as a GLP Tox Study. 

1.52 GMP Package Approval 
 The term “GMP Package
Approval” shall mean, with respect to a Licensed Product associated with Choroideremia, the earlier to occur of 
  

	(i)	 the first Filing of an IND with Choroideremia GMP Lot by or on behalf of 4DMT with no clinical hold due to such
Choroideremia GMP Lot, and 

  
 - 16 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(ii)	 the first Initiation by or on behalf of 4DMT of the first Phase I/IIa Study using Choroideremia GMP Lot.

 1.53 Handle 
 The term
“Handle” shall mean preparing, filing, prosecuting (including interference and opposition proceedings) and maintaining (including interferences, reissue, re-examination, post-grant reviews,
inter-parties reviews, derivation proceedings and opposition proceedings). 
 1.54 Highest Priority Efforts 

The term “Highest Priority Efforts” shall mean [***], in no event less than Commercially Reasonable Efforts. 

1.55 High Volume Roche Solo Scenario 
 The term “High
Volume Roche Solo Scenario” shall mean, with respect to a given Calendar Quarter, the existence of [***]. 
 1.56 IFRS 

The term “IFRS” shall mean International Financial Reporting Standards. 

1.57 IND 
 The term “IND” shall mean an
application as defined in the FDCA and applicable regulations promulgated by the FDA, or the equivalent application to the equivalent agency in any other country or group of countries, the filing of which is necessary to commence clinical testing of
the Products in humans. 
 1.58 Initiation 
 The term
“Initiation” shall mean the date that a human is first dosed with the applicable Product in the applicable Clinical Study approved or permitted (such as in the case of IND non-rejection) by
the respective Regulatory Authority. 
 1.59 JOT 
 The
term “JOT” shall mean a joint operating team that may be established by the JSC. 
 1.60 JSC 

The term “JSC” shall mean the joint steering committee described in Article 10. 

1.61 Know-How 
 The
term “Know-How” shall mean data, knowledge and information, including materials, samples, chemical manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms,
formulations, specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development or commercialization of Products. 

  
 - 17 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.62 Licensed Combination Product 

The term “Licensed Combination Product” shall mean 
  

	d)	 a single pharmaceutical formulation containing as its active ingredients both a Licensed Construct and one or
more other therapeutically or prophylactically active ingredients, 

  

	e)	 a combination therapy comprised of a Licensed Construct and one or more other therapeutically or
prophylactically active products, priced and sold in a single package containing such multiple products or packaged separately but sold together for a single price, or 

 

	f)	 a combination therapy comprised of a Licensed Construct and a Companion Diagnostic, priced and sold in a single
package containing such multiple products or packaged separately but sold together for a single price, 

 in each case, including all
dosage forms, formulations, presentations, line extensions, and package configurations. All references to Licensed Product in this Agreement shall be deemed to include Licensed Combination Product. 

1.63 Licensed Construct 
 The term “Licensed
Construct” shall mean a Construct associated with a given Licensed Product. 
 1.64 Licensed Product 

The term “Licensed Product” shall mean a Product associated with a Product Class that has the Status of a Roche Product Class. 

1.65 Like-Substance Product 
 The term “Like-Substance
Product” shall mean a Generic Product or Biosimilar Product. 
 1.66 NDA 

The term “NDA” shall mean a new drug application, including all necessary documents, data, and other information concerning a Product, required for
Regulatory Approval of the Product as a pharmaceutical product by the FDA or an equivalent application to the equivalent agency in any other country or group of countries (e.g. the marketing authorization application (MAA) in the EU). 

1.67 Net Sales 
 The term “Net Sales” shall mean,
for a Licensed Product in a particular period, the amount calculated by subtracting from the Sales of such Licensed Product for such period: (i) a lump sum deduction of [***] percent ([***]%) of Sales in lieu of those deductions that are not
accounted for on a Product-by-Product basis (e.g., freight, postage charges, transportation insurance, packing materials for dispatch of goods, custom duties);
(ii) uncollectible amounts accrued during such period based on a proportional allocation of the total bad debts accrued during such period and not already taken as a
gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Licensed Product for such period; (iii) credit card
charges (including processing fees) accrued during such period on such Sales and not already taken as a gross-to-net deduction in accordance with the then currently used
IFRS in the calculation of Sales of such Licensed Product for such period; and (iv) government mandated fees and taxes and other government charges accrued during such 

  
 - 18 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
period not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the
calculation of Sales of such Licensed Product for such period, including, for example, any fees, taxes or other charges that become due in connection with any healthcare reform, change in government pricing or discounting schemes, or other action of
a government or regulatory body. 
 1.68 Non-Optionable 4DMT Product Class 

The term “Non-Optionable 4DMT Product Class” shall mean a Product Class that has the Status of a 4DMT
Product Class and is further deemed as a Non-Optionable 4DMT Product Class. In accordance with this Agreement, a Non-Optionable 4DMT Product Class becomes
deemed as such either by (i) Roche failing to provide a timely Clinical Stage Roche Product Class Conversion Notice for an Optioned Product Class under Section 2.3.3 or (ii) in connection with 4DMT providing a Continuation
Election Notice under the terms of Section 22.3.1. 
 1.69 Non-Optionable Patent Right 

The term “Non-Optionable Patent Right” shall mean a Patent Right that was an Optionable Patent Right, if,
when and from the time that the Status of the applicable Product Class changes from being an Optionable Product Class to a 4DMT Product Class that is a Non-Optionable 4DMT Product Class or
to an Available Product Class. 
 1.70 Optionable 4DMT Product Class 

The term “Optionable 4DMT Product Class” shall mean any 4DMT Product Class that is not a Non-Optionable
4DMT Product Class. 
 1.71 Optionable Patent Right 
 The
term “Optionable Patent Right” shall mean a Patent Right claiming inventions conceived or reduced to practice by or on behalf of 4DMT in the performance of Optionable Project Work. To the extent that a Patent Right is both an Optionable
Patent Right and a Project Patent Right, the conditions of Handling shall be governed by the conditions for Handling the Project Patent Right. 
 1.72
Optionable Payload 
 The term “Optionable Payload” shall mean a Payload that, at the time of the applicable invention, was associated with an
Optionable 4DMT Product Class. 
 1.73 Optionable Product Patent Right 

The term “Optionable Product Patent Right” shall mean 
  

	(i)	 an Optionable Patent Right the independent claims of which are directed specifically to the combination of
specific Optionable Payloads with specific Optionable Variants, and 

  

	(ii)	 an Optionable Product Dependent Claim. 

  
 - 19 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.74 Optionable Project Work 

The term “Optionable Project Work” shall mean work conducted by or on behalf of 4DMT on Product Classes that are Optionable 4DMT Product Classes at
the time of such work, including for the XLRP 4DMT Product Class under the XLRP 4DMT Product Class Work Plan (and for clarity only such work as is conducted prior to such Optionable 4DMT Product Class becoming a Non-Optionable 4DMT Product Class or prior to the Status of such Product Class changing to a Roche Product Class or an Available Product Class). 

1.75 Optionable Variant 
 The term “Optionable
Variant” shall mean a Variant that has been identified through in vivo non-human animal testing, and/or in vitro testing, under Optionable Project Work. 

1.76 Optionable Variant Patent Right 
 The term
“Optionable Variant Patent Right” shall mean any Optionable Patent Right that Covers Optionable Variant(s) but does not explicitly claim (although it may more generically encompass) the combination of Optionable Variant(s) with specific
Optionable Payload(s). For purposes of clarity, an Optionable Variant Patent Right may contain claims directed to the combination of Optionable Variant(s) and (i) generic payloads encompassing, but not specifically naming, Optionable Payload(s)
or (ii) specific payloads other than Optionable Payload(s). 
 1.77 Optioned Patent Right 

The term “Optioned Patent Right” shall mean an Optionable Patent Right if, when, and from the time that the Status of the applicable Product
Class changes from an Optionable Product Class (under which the applicable work was done) to a Roche Product Class. 
 1.78 Other Product Class

 The term “Other Product Class” shall mean a Roche Product Class that is not Choroideremia or an Optioned Product Class. 

1.79 Party 
 The term “Party” shall mean 4DMT or
Roche, as the case may be, and “Parties” shall mean 4DMT and Roche collectively. 
 1.80 Patent Right 

The term “Patent Right” shall mean all rights under a given patent or patent application, in any country of the Territory, including any patent
issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or
continuation-in-part of any of the foregoing. 
 1.81 Payload 

The term “Payload” shall mean 

  
 - 20 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(i)	 any gene (including its variants) or functional fragment thereof, where a mutation to the gene (or its
variants) results in an ophthalmological disease or disorder, or 

  

	(ii)	 the nucleotide sequence encoding a protein, that when introduced into the retina, is expected to provide
therapeutic benefit for an ophthalmological disease or disorder. 

 For purposes of this Agreement, a Payload consisting of a gene variant
is deemed to be the same Payload as a Payload consisting of such gene or a Payload consisting of a second variant of such gene. 
 1.82 Pharmacovigilance
Agreement 
 The term “Pharmacovigilance Agreement” shall mean an agreement entered into by the Parties to set forth the responsibilities and
obligations of the Parties with respect to the procedures and timeframes for compliance with Applicable Laws pertaining to safety of a Shared Product and its related activities. 

1.83 Phase I/IIa Study 
 The term “Phase I/IIa
Study” shall mean for a Product associated with given Product Class the first to occur of the following: 
  

	(a)	 a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA),
as amended from time to time, and the foreign equivalent thereof or 

  

	(b)	 the portion of a Phase II Study in which a human clinical trial is performed to estimate the biologic or
clinical effect of a pharmaceutical product in a target population, and to support the design and execution of a subsequent Pivotal Study. 

1.84 Phase II Study 
 The term “Phase II Study”
shall mean a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from
time to time, and the foreign equivalent thereof. 
 1.85 Pivotal Study 

The term “Pivotal Study” shall mean for a Product associated with a given Product Class the first to occur of the following: 

 

	(a)	 the portion of a Phase II Study in which a placebo or active drug controlled, randomized human clinical trial
performed to gain evidence of the efficacy of the Product in a target population, and/or to establish the optimal dosing regimen for such Product, or 

  

	(b)	 a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe
and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time,
and the foreign equivalent thereof. 

  
 - 21 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.86 Pre-Clinical Success Criteria 

The term “Pre-Clinical Success Criteria” shall mean a set of criteria to be achieved prior to conducting IND-enabling activities and to be included in a given Project Plan, the XLRP 4DMT Product Class Work Plan or a work plan for an Optionable Product Class that is not the XLRP 4DMT Product Class. 

1.87 Preferred CMO 
 The term “Preferred CMO”
shall mean [***]. 
 1.88 Product 
 The term
“Product” shall mean any product, including without limitation any Combination Product, containing a Construct, regardless of its finished form or formulation or dosage. 

1.89 Product Class 
 The term “Product Class”
shall mean a set of Products containing the same Payload. 
 1.90 Project Patent Right 

The term “Project Patent Right” shall mean each of: 
  

	(i)	 a Patent Right claiming inventions conceived or reduced to practice in the performance of a Collaboration
Project and 

  

	(ii)	 an Optioned Patent Right. 

1.91 Project Payload 
 The term “Project Payload”
shall mean a Payload associated with a given Collaboration Product Class. 
 1.92 Project Product Patent Right 

The term “Project Product Patent Right” shall mean each of: 
  

	(i)	 a Project Patent Right the independent claims of which are directed specifically to the combination of specific
Project Payloads with specific Project Variants, 

  

	(ii)	 a Product Dependent Claim and 

 

	(iii)	 an Optioned Patent Right. 

1.93 Project Variant 
 The term “Project Variant”
shall mean a Variant that has been identified through in vivo non-human animal testing and/or in vitro testing under the RFO or a Collaboration Project. 

1.94 Project Variant Patent Right 
 The term “Project
Variant Patent Right” shall mean each of: 
  

	(a)	 Any Project Patent Right that Covers Project Variants but does not explicitly claim (although it may more
generically encompass) the combination of Project Variants with specific Project Payloads. For purposes of clarity, a Project Variant Patent Right may contain claims directed to the combination of Project Variants and (i) generic payloads
encompassing, but not specifically naming, Project Payloads or (ii) specific payloads other than Project Payloads, and 

  
 - 22 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(b)	 Any Optionable Variant Patent Right that is an Optioned Patent Right. 

1.95 Regents License Agreement 
 The term “Regents
License Agreement” shall mean [***]. 
 1.96 Regents Patent Right 

The term “Regents Patent Right” shall mean [***] and all continuing applications thereof, including divisionals, substitutions, extensions and continuation-in-part applications (only to the extent, however, that claims in the
continuation-in-part applications are entitled to the priority filing date of the parent patent application); any patents issuing on said application or continuing
applications, including all reexaminations, reissues and extensions thereof; and any corresponding foreign patents or applications. 
 1.97 Regulatory
Approval 
 The term “Regulatory Approval” shall mean any approvals, licenses, registrations or authorizations by Regulatory Authority,
necessary for the sale of a Product in the Field in a regulatory jurisdiction in the Territory. 
 1.98 Regulatory Authority 

The term “Regulatory Authority” shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the
European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of Regulatory Approval for the Product. 

1.99 Retina Field 
 The term “Retina Field” shall
mean the Field where the ophthalmological disease or disorder treated is a disease or disorder of the retina. 
 1.100 RFO Agreement 

The term “RFO Agreement” shall mean the Research Funding and Option Agreement between the Parties effective on February 16, 2015. 

1.101 Roche Group 
 The term “Roche Group” shall
mean collectively Roche, its Affiliates and its Sublicensees. 

  
 - 23 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.102 Roche Materials 

The term “Roche Materials” shall mean any chemical or biological substances including any: (i) organic or inorganic chemical or compound;
(ii) gene; (iii) vector or construct, whether plasmid, phage, virus or any other type; (iv) host organism, including bacteria and eukaryotic cells; (v) eukaryotic or prokaryotic cell line or expression system; (vi) protein,
including any peptide or amino acid sequence, enzyme, antibody or protein conferring targeting properties and any fragment of a protein or peptide or enzyme; (vii) genetic material, including any genetic control element (e.g., promoters);
(viii) virus; or (ix) assay or reagent, all to the extent provided by Roche to 4DMT for use under a given Project Plan in the Collaboration. 

1.103 Roche Patent Right 
 The term “Roche Patent
Right” shall mean a Patent Right Controlled by Roche as of the date of any license grant to 4DMT that Covers the applicable Products in the Field and either (i) claims inventions made by or on behalf of Roche after the Effective Date in
the course of researching, developing or commercializing Products in the Field, or (ii) Covers Products advanced by Roche into human clinical trials and without the grant of a license therewith, 4DMT, its Affiliates or sublicensees would be
unable to develop or commercialize such Products using the formulations then in development or commercialized and the production methods then used to manufacture such Products. Irrespective of the foregoing, the Patent Rights identified in
Appendix 1.103 (the “Excluded Patent Rights”) are specifically excluded from the Roche Patent Rights. 
 1.104 Roche Solo Product
Class 
 The term “Roche Solo Product Class” shall mean a Roche Product Class that is not a Collaboration Product Class and for which
an associated Licensed Product has yet to enter into human clinical trials. 
 1.105 Royalty Term 

The term “Royalty Term” shall mean, with respect to a Licensed Product and for a given country, the period of time commencing on the date of First
Commercial Sale of the Licensed Product in such country and ending on the later of the date that is 
  

	(a)	 ten (10) years after the date of the First Commercial Sale of the Licensed Product in such country, or

  

	(b)	 the expiration of the last to expire Licensed 4DMT Patent Right in such country where the manufacture, use,
import or offer for sale such Licensed Product or the Licensed Construct within it would have infringed a Valid Claim in the applicable Licensed 4DMT Patent Right in the absence of ownership of or a license under the Patent Right in which such Valid
Claim resides, with the determination of whether the Licensed Product, Licensed Construct, process or use would have otherwise infringed a particular Valid Claim to be made on a
country-by-country basis. 

 With regard to the
calculation of the ten (10) year period, [***]. 

  
 - 24 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.106 Sales 

The term “Sales” shall mean, for a Licensed Product in a particular period, the sum of (i) and (ii): 

 

	(i)	 the amount stated in the Roche Holding AG “Sales” line of its externally published audited
consolidated financial statements with respect to such Licensed Product for such period (excluding sales to any Sublicensees that are not Affiliates of Roche). This amount reflects the gross invoice price at which such Licensed Product was sold or
otherwise disposed of (other than for use as clinical supplies or free samples) by Roche and its Affiliates to such Third Parties (excluding sales to any Sublicensees that are not Affiliates of Roche) in such period reduced by gross-to-net deductions, if not previously deducted from such invoiced amount, taken in accordance with the then currently used IFRS. 

By way of example, the gross-to-net deductions taken in
accordance with IFRS as of the Effective Date include the following: 
  

	 	(a)	 credits, reserves or allowances granted for (i) damaged, outdated, returned, rejected, withdrawn or
recalled Licensed Product, (ii) wastage replacement and short-shipments; (iii) billing errors and (iv) indigent patient and similar programs (e.g., price capitation); 

 

	 	(b)	 governmental price reductions and government mandated rebates; 

 

	 	(c)	 chargebacks, including those granted to wholesalers, buying groups and retailers; 

 

	 	(d)	 customer rebates, including cash sales incentives for prompt payment, cash and volume discounts; and

  

	 	(e)	 taxes, duties and any other governmental charges or levies imposed upon or measured by the import, export, use,
manufacture or sale of a Licensed Product (excluding income or franchise taxes). 

 For purposes of clarity, sales by Roche
and its Affiliates to any Sublicensee shall be excluded from “Sales”. 
  

	(ii)	 for Sublicensees that are not Roche Affiliates (and excluding Compulsory Sublicensees), the sales amounts
reported to Roche and its Affiliates in accordance with the sublicensee contractual terms and their then-currently used accounting standards. For the purpose of clarity, any such Sublicensee sales as reported to Roche in accordance with Compulsory
Sublicense agreements shall be excluded from “Sales”. 

 1.107 Shared Products 

The term “Shared Products” shall mean, on the one hand, a Licensed Product that is developed and/or commercialized by the Roche Group and, on the
other hand, a related product that is sold by or on behalf of 4DMT, its Affiliates or sublicensees. Such a related product may, for example, contain the same Variant as the Licensed Product. 

1.108 Start of GLP Tox Study 
 The term “Start of GLP
Tox Study” shall mean the date that an animal is first dosed with the applicable Product in a GLP Tox Study. 

  
 - 25 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.109 Sublicensee 

The term “Sublicensee” shall mean an entity to which Roche has licensed rights (through one or multiple tiers), other than through a Compulsory
Sublicense, pursuant to this Agreement. 
 1.110 Territory 

The term “Territory” shall mean all countries of the world. 

1.111 Third Party 
 The term “Third Party” shall
mean a person or entity other than (i) 4DMT or any of its Affiliates or (ii) a member of the Roche Group. 
 1.112 Third Party Supplier 

The term “Third Party Supplier” shall mean a Third Party (such as a CMO/CRO) that provides services and/or materials on behalf of 4DMT under a
Project Plan. 
 1.113 US 
 The term “US” shall
mean the United States of America and its territories and possessions. 
 1.114 US$ 

The term “US$” shall mean US dollars. 
 1.115 Valid
Claim 
 The term “Valid Claim” shall mean a claim in (a) any unexpired and issued Licensed 4DMT Patent Right (or Project Product Patent
Right where used in connection with an Enabled Product) that has not been disclaimed, revoked or held invalid by a final nonappealable decision of a court of competent jurisdiction or government agency, or (b) pending patent application within
the Licensed 4DMT Patent Rights in any country that (i) is on file with the applicable patent office and has shown evidence of reasonably consistent activity to advance to issuance of a patent and (ii) which application has been on file
with the applicable patent office for no more than [***] ([***]) years from the date to which the patent application claims its earliest priority. 

1.116 Variant 
 The term “Variant” shall mean any
adeno-associated virus capsid variant (regardless of whether or not the variant is naturally occurring). 
 1.117 XLRP 

The term “XLRP” shall mean a Product Class comprising the set of Products where the Payload is (i) [***] or (ii) [***]. For clarity,
[***]. 
 1.118 Additional Definitions 
 Each of the
following definitions is set forth in the Section of this Agreement indicated below: 

  
 - 26 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

			
	 Definition
	  	Section
	 4DMT Activities
	  	3.3
	 4DMT Claims
	  	20.1
	 4DMT [***] Year Anniversary
	  	5.4.2
	 4DMT Indemnitees
	  	20.1
	 4DMT Losses
	  	20.1
	 4DMT-Originated Transfer Activities
	  	22.3.4.3(e)
	 4DMT Product Class
	  	2.1
	 4DMT [***] Year Anniversary
	  	5.4.2
	 Accounting Period
	  	14.1
	 Alliance Director
	  	10.8
	 Available Product Class
	  	2.1
	 Bankruptcy Code
	  	23
	 Breaching Party
	  	22.2.1
	 Broad Range 4DMT Patent Right
	  	1.49
	 Chairperson
	  	10.2
	 [***]
	  	1.4
	 Claim
	  	20.3
	 Clinical Stage Roche Product Class Conversion Notice
	  	2.3.3
	 Compulsory Profit Share Percentage
	  	12.6.6
	 Decision Period
	  	18.6
	 Disclosing Party
	  	1.30
	 Early Roche Product Class Conversion Notice
	  	2.3.2
	 Endpoints
	  	1.27
	 Excluded Patent Rights
	  	1.103
	 Expert Committee
	  	12.6.7
	 Extraneous Genetic Material
	  	4.1
	 Fees
	  	11.4
	 [***]
	  	1.4
	 Indemnified Party
	  	20.3
	 Indemnifying Party
	  	20.3
	 Initiating Party
	  	18.6
	 Key Primary Patent Right
	  	18.6
	 Licensed 4DMT Patent Right
	  	1.49
	 Members
	  	10.2
	 Memo
	  	1.40
	 Mid Range 4DMT Patent Right
	  	1.49
	 Minimum Program Transfer
	  	6.2
	 Minimum Transfer Payment
	  	22.3.4.3(e)
	 Non-Breaching Party
	  	22.2.1
	 Option Exercise Fee
	  	2.3.3
	 Option Period
	  	2.3.3
	 Optionable Primary Patent Right
	  	18.4.1

  
 - 27 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

			
	 Definition
	  	Section
	 Optionable Product Dependent Claim
	  	18.4.1
	 Optioned Product Class
	  	2.3.3
	 Patent Term Extensions
	  	18.9
	 Payment Currency
	  	14.2
	 Peremptory Notice Period
	  	22.2.1
	 Primary Patent Right
	  	18.4.2
	 Product Dependent Claim
	  	18.4.2
	 Project Plan
	  	3.1
	 Receiving Party
	  	1.30
	 Relative Commercial Value
	  	12.6.3
	 Roche Claims
	  	20.2
	 Roche [***] Year Anniversary
	  	5.4.1
	 Roche Indemnitees
	  	20.2
	 Roche Losses
	  	20.2
	 Roche Product Class
	  	2.1
	 Roche Product Class Initiation Payment
	  	12.2
	 Roche Transfer Activities
	  	22.3.4.3(e)
	 Samples
	  	22.3.4.3(b)
	 Sensitive Information
	  	24(d)(v)
	 Settlement
	  	18.6
	 Significant Change
	  	3.3
	 SPCs
	  	18.9
	 Status
	  	2.1
	 Suit Notice
	  	18.6
	 Third Party Expenses
	  	11.1
	 Third Party Supplier Contract
	  	11.2
	 Unviable
	  	3.5.1(b)
	 XLRP 4DMT Product Class
	  	2.3.1
	 XLRP 4DMT Product Class Work Plan
	  	2.3.1

 2. Product Classes 
 2.1
High-Level Overview 
 At any point in time during the Agreement Term, a given Product Class will have the status (“Status”) of one
of the three following subcategories of Product Classes: 
  

	(a)	 a “Roche Product Class” (for which the Roche Group generally has diligence obligations);

  

	(b)	 a “4DMT Product Class” (for which 4DMT generally has diligence obligations); and

  

	(c)	 an “Available Product Class” (for which neither Party has diligence obligations).

 The Status of a given Product Class may change over time, in accordance with the provisions of this Agreement (as described in
this Article 2). On the Effective Date, Choroideremia is a Roche Product Class, XLRP is a 4DMT Product Class (and specifically, the XLRP 4DMT Product Class) and all other Product Classes are Available Product Classes. 

  
 - 28 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 2.1.1 Roche Product Class Subcategories 

As further described and defined in this Agreement, in general the Roche Product Class may be further classified in two subcategory sets (that may
overlap). 
 2.1.1.1 Subcategories generally applicable pre-Phase I/IIa Study 

A Roche Product Class that has not yet entered into a clinical trial (or, as applicable, not yet Completed the applicable first Phase I/IIa Study)
may be subcategorized as a Collaboration Product Class (where 4DMT is conducting work under an active Project Plan) or a Roche Solo Product Class (where there is not yet entry into a clinical trial and Roche is pursuing work independently). However
for clarity, once a Collaboration Product Class has no active Project Plan and a Roche Solo Product Class has entered into the first clinical trial, the applicable subcategory no longer applies. 

2.1.1.2 Financial subcategories 
 Particularly for purposes of
development event, sales event and royalty payments under Article 12, the Roche Product Class has three subcategories: 
  

	(i)	 Choroideremia (designated as a Roche Product Class as of the Effective Date), 

 

	(ii)	 an Other Product Class, and 

 

	(iii)	 an Optioned Product Class, which is a former 4DMT Product Class (specifically with the subcategory of
Optionable 4DMT Product Class) whose Status was converted by Roche to a Roche Product Class upon Completion of the first associated Phase I/IIa Study. 

2.1.2 4DMT Product Class Subcategories 
 As further described
and defined in this Agreement, in general a 4DMT Product Class is subcategorized first as an Optionable 4DMT Product Class under which Roche has the right upon Completion of Phase I/IIa to convert the Status to a Roche Product Class.
If Roche exercises such right, then the Status becomes a Roche Product Class, and is no longer a 4DMT Product Class. If Roche does not exercise such right, then the Status remains as a 4DMT Product Class, but is
sub-categorized as a Non-Optionable 4DMT Product Class, unless and until the Status once again becomes an Available Product Class. (A
Non-Optionable 4DMT Product Class may also be created by 4DMT’s submission of a Continuation Election Notice for a terminated Roche Product Class.) 

In addition, as described in this Agreement, one Optionable 4DMT Product Class is designated as the XLRP 4DMT Product Class (for such time as its Status
is an Optionable 4DMT Product Class). 
 2.2 Roche Product Class 

2.2.1 Choroideremia 
 As of the Effective Date, Choroideremia is
hereby designated as a Roche Product Class (and is further a Collaboration Product Class in accordance with Section 3.2.1). 

  
 - 29 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 2.2.2 Prior to Initiation of the first Phase I/IIa Study 

Prior to Initiation of the first Phase I/IIa Study to occur for the first Product associated with any Product Class, Roche may change the Status of any of
up to [***] Available Product Classes to a Roche Product Class by providing written notice to 4DMT, and such Roche Product Class will then also be designated as a Collaboration Product Class in accordance with Section 3.2.2(i).

 2.2.3 After Initiation of the first Phase I/IIa Study 
 After
Initiation of such first Phase I/IIa Study and at any time thereafter during the Agreement Term, Roche may change the Status of any Available Product Class to a Roche Product Class (without the restrictions applicable under
Section 2.2.2) by providing written notice to 4DMT. 
  

	(a)	 Collaboration Product Class 

Roche may designate any such Roche Product Class as a Collaboration Product Class in accordance with Section 3.2.2(ii)(b). 

 

	(b)	 Roche Solo Product Class 

Roche will not be required to designate such a Roche Product Class as a Collaboration Product Class. However prior to designating a Roche
Solo Product Class that would place Roche in a High Volume Roche Solo Scenario, Roche shall provide 4DMT with written notice and a summary of all pre-clinical development conducted for the previous [***]
Calendar Quarters on all Products associated with the current Roche Solo Product Classes. If at least one such Roche Solo Product Class did not have bona fide substantive development work during such previous [***] Calendar Quarter(s) in
which it was a Roche Solo Product Class (which may include reasonable internal review periods not to extend beyond one such Calendar Quarter), then within [***] ([***]) days of 4DMT’s receipt of such written notice and development summaries,
4DMT may disallow Roche from designating such new Roche Solo Product Class (however in such case no Roche Product Class Initiation Payment will be due and 4DMT may not issue an invoice for such Roche Product Initiation Payment). 

2.2.4 Additional Ways to Change Product Class Status to Roche Product Class 

Roche may create a Roche Product Class in accordance with the Early Roche Product Class Conversion Notice described under Section 2.3.2 and the
Clinical Stage Roche Product Class Conversion Notice described under Section 2.3.3. 
 2.2.5 Requesting the Other Program Transfer 

Roche may request the Other Program Transfer set forth in Section 6.2 for any Roche Product Class. 

2.2.6 HSR 
 As Roche may exercise rights under this Agreement to
designate a new Roche Product Class, if needed each Party shall (i) cooperate with the other Party in the preparation, execution and filing of all documents that that may be required pursuant to the Hart-Scott-Rodino Antitrust Improvements Act
or any other Applicable Law, and (ii) observe all applicable waiting periods before changing the Status of a Product Class to a Roche Product Class. Each Party shall bear its own costs (including counsel or other expert fees) with respect
to preparing, executing and filing such documents. Subject to the terms and conditions of this Agreement, each Party shall use all reasonable efforts to take, or cause to be taken, all reasonable actions and to do, or cause to be done, all things
necessary and appropriate to consummate the change of Status contemplated by this Section 2.2. 

  
 - 30 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 2.3 4DMT Product Class 

2.3.1 XLRP 4DMT Product Class 
 As of the Effective Date, XLRP is
designated as a 4DMT Product Class, with a further designation as the “XLRP 4DMT Product Class”. 4DMT will develop at its own expense a Product associated with the XLRP 4DMT Product Class to the first Completion of a
Phase I/IIa Study under a work plan (the “XLRP 4DMT Product Class Work Plan”). The initial XLRP 4DMT Product Class Work Plan is attached as Appendix 2.3.1. 

4DMT will not modify the Pre-Clinical Success Criteria or the Endpoints without a consensus decision from the JSC. It
is expected that updates and revisions may be needed over time to the XLRP 4DMT Product Class Work Plan. Without limiting 4DMT’s rights under Section 10.7.3(iii), the Parties shall work together in good faith to seek to mutually agree
via the JSC in writing an update to such plan, and both Parties shall approach such discussions in good faith. 4DMT will in good faith seek to incorporate Roche’s input concerning such changes, including (i) a target product profile that
accommodates Roche’s reasonable wishes, including Endpoints that Roche reasonably deems as functional readouts of treatment efficacy taking into account FDA guidelines as they evolve and (ii) resource investment by 4DMT and timelines
reflective of Highest Priority Efforts. Without limiting 4DMT’s rights under Section 10.7.3(iii), so long as the Parties unanimously agree (including through the JSC) to such changes to the XLRP 4DMT Product Class Work Plan (without
4DMT exercising final decision-making authority regarding a dispute about changes to the XLRP 4DMT Product Class Work Plan) and the XLRP 4DMT Product Class Work Plan reflects 4DMT’s Highest Priority Efforts, then 4DMT will be
considered to have devoted Highest Priority Efforts if it conducts its activities in accordance with the XLRP 4DMT Product Class Work Plan. 
 2.3.2
4DMT Product Class with Roche Early Conversion Right 
 In addition to the XLRP 4DMT Product Class under Section 2.3.1, during the Agreement
Term but after Initiation of the first Phase I/IIa Study for the first Product for which this happens, and only when no 4DMT Product Class (including no XLRP 4DMT Product Class) has been designated in the previous [***] ([***]) month period,
4DMT may initiate a change of the Status of an Available Product Class to a 4DMT Product Class by providing a 4DMT Product Class Status Notice to Roche, including a proposed work plan that at a minimum describes the timelines, a
target product profile, Pre-Clinical Success Criteria and Endpoints. However, Roche will then have the option to convert the Status of such Product Class to a Roche Product Class by providing written
notice to 4DMT (“Early Roche Product Class Conversion Notice”) within [***] ([***]) weeks following the 4DMT Product Class Status Notice (which option Roche may also earlier waive in writing prior to
expiration of the [***] ([***]) week period). Roche’s provision of the Early Roche Product Class Conversion Notice (i) will change the Status of the given Product Class from Available Product Class to Roche Product Class (so
4DMT’s submission of the 4DMT Product Class Status Notice will not count against 4DMT’s eligibility to submit a new 4DMT Product Class Status Notice for another Product Class in the same [***] ([***]) months) and
(ii) any such Roche Product Class will also be designated as a Collaboration Product Class in accordance with Section 3.2.2(ii)(a). Except where Roche timely provides the Early Roche Product Class Conversion Notice, the
Product Class Status will be deemed changed from Available Product Class to 4DMT Product Class (subject to Roche’s Option to Convert set forth in Section 2.3.3). 

  
 - 31 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 2.3.3 Option to Convert to Roche Product Class at Phase I/IIa Study Completion 

For a given 4DMT Product Class (including the XLRP 4DMT Product Class), commencing upon the later of (i) the first Completion of the first
Phase I/IIa Study for such 4DMT Product Class and (ii) 4DMT’s written notice to Roche of the Completion and provision of all relevant study reports related to such Phase I/IIa Study (and any earlier work) for such Product
Class and ending [***] ([***]) days thereafter (the “Option Period”), Roche shall have the right to send a written notice to 4DMT (“Clinical Stage Roche Product Class Conversion Notice”) to
convert the Status of the 4DMT Product Class to a Roche Product Class. During the Option Period, Roche shall have the right to perform reasonable due diligence by asking questions of and receiving answers from representatives of 4DMT pertinent
to Roche’s decision to convert the Status. 4DMT shall respond to Roche’s inquiries in a reasonable and timely fashion and without delay and shall not withhold from Roche, in response to Roche’s inquiries, any material information in
4DMT’s possession and control related to Products associated with the Product Class. If requested by Roche as part of this due diligence, 4DMT shall provide the raw clinical trial data for Roche to conduct an independent reanalysis.
Roche’s provision of the timely Clinical Stage Roche Product Class Conversion Notice (i) will change the Status of the given Product Class from 4DMT Product Class to Roche Product Class, and for so long as such Product
Class is a Roche Product Class, will also be deemed as an “Optioned Product Class” and (ii) a fee set forth in Section 12.3 (“Option Exercise Fee”) will be due. If Roche does not provide a timely
Clinical Stage Roche Product Class Conversion Notice, then the Status of the Product Class will remain as a 4DMT Product Class but will be deemed as a Non-Optionable 4DMT Product Class, and
Roche shall have no further rights with respect to such Product Class (unless the Status returns to Available Product Class in accordance with Section 2.4). 

2.3.4 Status Change through Termination 
 The Status of a Roche
Product Class may be changed to a 4DMT Product Class as a consequence of certain termination provisions set forth in Section 22.3.1. 
 2.4
Available Product Class 
 At any time during the Agreement Term, Roche may change the Status of a Roche Product Class to an Available Product
Class by providing notice of termination in accordance with Section 22.2.2 (unless 4DMT thereafter provides a Continuation Election Notice under Section 22.3.1). 

At any time during the Agreement Term, 4DMT may change the Status of a 4DMT Product Class to an Available Product Class by providing written notice
to Roche. 
 The Status of a Roche Product Class or a 4DMT Product Class may also be changed to an Available Product Class in accordance with
Article 5 and/or Section 22.3.1. 

  
 - 32 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 3. Research and Development Collaboration 

3.1 Overview 
 Under the Collaboration, 4DMT and Roche will
collaborate on at least one Collaboration Project associated with a Collaboration Product Class in the Field (and specifically in the Retina Field unless otherwise agreed to by the Parties) from
pre-clinical research (or development as the case may be) through Completion of a Phase I/IIa Study according to an agreed project plan for each Collaboration Project (each, a “Project
Plan”) executed by authorized representatives of both Parties (except for the initial Project Plan for the first Collaboration Project attached to this Agreement as per Section 3.2.1). The activities conducted in connection with the
Collaboration will be overseen by the JSC. Each Party will use Commercially Reasonable Efforts to conduct their activities under a given Project Plan. 

3.2 Collaboration Product Class 
 3.2.1 First Collaboration
Product Class 
 Choroideremia is hereby designated as the first Collaboration Product Class. The initial Project Plan for Choroideremia is attached as
Appendix 3.2.1. 
 3.2.2 Additional Collaboration Product Classes 

In addition to the first Collaboration Product Class, and subject to any applicable Roche Product Class Initiation Payments set forth in
Section 12.2, 
  

	(i)	 prior to Initiation of the first Phase I/IIa Study to occur for the first Product associated with any
Product Class, any Product Class designated as a Roche Product Class in accordance with Section 2.2.2 will also be designated as Collaboration Product Class; 

 

	(ii)	 after Initiation of such first Phase I/IIa Study, 

 

	 	(a)	 any Roche Product Class created by Roche’s submission of an Early Roche Product Class Conversion
Notice will be designated as a Collaboration Product Class as of the date of such notice, and 

  

	 	(b)	 Roche will have the right (but not the obligation) to designate any other Roche Product Class as a
Collaboration Product Class by providing written notice to 4DMT. 

 After the designation of any such additional Collaboration
Product Class, the Parties will promptly work together in good faith to create a Project Plan in accordance with Section 3.3 for such Collaboration Product Class. 

3.3 Project Plans 
 Each Project Plan will set forth
(i) the scope of the Collaboration with respect to the applicable Collaboration Product Class and the resources that will be dedicated to the activities contemplated within the scope of the Collaboration Project, including the
responsibilities of each Party (in addition to those set forth in this Agreement) and particularly the responsibilities and activities to be performed by or on behalf of 4DMT (the “4DMT Activities”) (ii) specific objectives for
each year, which objectives will be updated or amended, as appropriate, by the JSC as research and development progresses, 

  
 - 33 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
(iii) applicable deliverables and milestones and (iv) budgets for such activities (subject to Section 11.1). Each Project Plan shall be deemed to be incorporated into this
Agreement by this reference and governed by the terms herein. If any provision in a Project Plan conflicts with the terms and conditions contained in the body of this Agreement, the language in the body of this Agreement shall prevail.
Notwithstanding the foregoing, the Parties may agree to modify the terms and conditions of this Agreement with respect to a given Project Plan by setting forth such modifications in a Project Plan under a section entitled “Modifications to
Agreement Terms and Conditions.” Except for the initial Project Plan for Choroideremia, each Project Plan shall conform in format substantially to the form of the Project Plan attached hereto as Appendix 3.3 and shall be executed by
authorized representatives of both Parties. 
 The JSC shall review the Project Plans on an ongoing basis and may amend the Project Plans. Any such change
with a significant budgetary or timeline impact (a “Significant Change”) shall be reflected in a written amendment to the Project Plans executed by authorized representatives of both Parties. For clarity, an increase or decrease of
over [***] percent ([***]%) of the total cost of a given Project Plan under Section 11.1 will be deemed a Significant Change. 
 For purposes of
executing or amending a Project Plan, Roche Basel will be authorized to execute on behalf of Roche (without need for execution by Roche US). 
 3.4 4DMT
Reporting 
 4DMT shall provide a written progress report to Roche at the end of each [***] on the status of each Collaboration Project, including
results achieved during the previous [***], associated data obtained and associated project intellectual property developed by 4DMT (but for clarity, written reports about project intellectual property will be activity-focused and not contain
opinions or information that might be deemed privileged). Such reports shall be in the form mutually agreed between the Parties, but Roche may request, at a minimum, the following topics: (i) goals, (ii) achievements since last report
including data generated, (iii) key issue(s), (iv) plans to solve key issue(s), (v) budget updates and (vi) next steps. 4DMT shall also keep Roche apprised through JSC meetings of significant developments with respect to the
items above. 
 4DMT shall, upon Roche’s reasonable request, use reasonable efforts to make its management and scientists available at the premises of
4DMT to discuss scientific achievements relating to 4DMT (subject to the signature of non-disclosure agreements on customary terms). 

3.5 Project Plan Termination 
 3.5.1 General 

A Project Plan may be terminated as a result of a termination of the Agreement under Section 22.2. In addition: 

 

	(a)	 Roche will have the right to terminate a Project Plan without cause upon ninety (90) days prior written
notice to 4DMT. 

  
 - 34 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(b)	 Either Party will have the right to terminate a Project Plan effective immediately upon written notice to the
other Party in the event a Party reasonably determines that continuation of the Project Plan would be scientifically unviable, illegal, unethical or impossible (collectively, “Unviable”). 

 

	(c)	 Roche may terminate a Project Plan effective immediately upon written notice to 4DMT in the event 4DMT has a
Change of Control in accordance with Article 24. 

  

	(d)	 Roche may terminate a Project Plan in the event of material breach by 4DMT with respect to such Project Plan
with ninety (90) days’ notice (unless 4DMT cures such breach during such period). 

 3.5.2 Financial Consequences of Project Plan
Termination 
 If a Project Plan is terminated, then Roche will be released from any obligation to make any payments which would otherwise have accrued after
the effective date of termination for such Project Plan other than as set forth below. 
 If the Project Plan is terminated by termination of the Agreement
by 4DMT for breach by Roche, or by termination of the Agreement as a whole or a given Project Plan by Roche either for being Unviable or without a cause, then Roche will: 
  

	(i)	 reimburse 4DMT for up to [***] days of FTEs budgeted by 4DMT to the Collaboration Project to the extent that
these employees – after good faith discussions between the Parties- cannot be reasonably allocated to other Product Classes (or other 4DMT projects outside the scope of this Agreement); 

 

	(ii)	 provide funding to 4DMT for any non-cancellable commitments to outside
Third Party Suppliers to the extent that such would have been otherwise reimbursable as Third Party Expenses under Sections 11.1 and 11.2; and 

  

	(iii)	 reimburse 4DMT for a Collaboration Product Class that is Choroideremia, [***] percent ([***]%) of

  

	 	(x)	 the costs previously incurred by 4DMT and 

 

	 	(y)	 4DMT’s non-cancellable costs 

associated with process and formulation development and manufacture of Licensed Product used under the Project Plan (including the
Choroideremia GMP Lot) under Section 8(a) (but for clarity, such payment will not be due or payable if prior to the date of termination the GMP Package Approval development event under Section 12.4 occurs and the corresponding payment is
triggered). 
 3.5.3 Change of Status after Project Plan Termination 
  

	(a)	 If Roche terminates a Project Plan for material breach by 4DMT, then Roche may convert such associated Roche
Product Class to either a Roche Product Class that is not a Collaboration Product Class or an Available Project in conjunction with the written notice of breach. 

 

	(b)	 If Roche terminates a Project Plan for Change of Control, then Article 24 will apply. 

  
 - 35 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(c)	 If either Party terminates a Project Plan as Unviable, then the Status of such Collaboration Product
Class will convert to an Available Product Class. If Roche is the Party that so terminates, Roche will thereafter have no rights to convert such Product Class to a Roche Product Class. If 4DMT is the Party that so terminates, then 4DMT may
not again propose such Product Class as a 4DMT Product Class. 

  

	(d)	 If Roche terminates a Project Plan without cause, then 4DMT shall have the right to change the Status of such
Product Class to either a Non-Optionable 4DMT Product Class or an Available Product Class, and if the latter, then Roche will have no right to thereafter change the Status to a Roche Product Class.

 3.6 Roche Materials 
 Roche
Materials will not be provided under the Collaboration unless specifically set forth in a given Project Plan. If so provided, 4DMT shall only use such Roche Materials as set forth in the Project Plan. Except as contemplated in the Project Plan, 4DMT
shall not chemically or biologically modify, or take any actions to determine the chemical structure of, Roche’s Materials, without Roche’s prior written consent. 4DMT shall not transfer Roche Materials to a third party without
Roche’s prior written consent. Upon completion of a given Project Plan, 4DMT shall either destroy or, at Roche’s written request, return all Roche Materials remaining in 4DMT’s possession, including any replications, progeny,
derivatives, analogs or clones thereof. 
 4. Grant of License 

4.1 License 
 4DMT hereby grants to Roche an exclusive
(even as to 4DMT) right and license, including the right to sublicense, under 4DMT’s interest in any Mid Range 4DMT Patent Right and 4DMT Know-How to research, have researched, develop, have developed,
register, have registered, make, have made, use, have used, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold Products associated with a Product Class that has the Status of an
Available Product Class (subject to Section 4.1.1) or a Roche Product Class in the Field in the Territory, as well as the Constructs associated with such Products. For clarity, the license includes testing of Products outside the Field if
needed (and only to the extent needed) for registration of Products within the Field. 
 For clarity, the licenses to Roche under the Agreement do not
include Patent Rights and Know-How of any member of the Change of Control Group that is excluded from being an Affiliate of 4DMT pursuant to Section 1.4. 

If Roche elects to use a Variant (other than an Excluded Variant) Covered by a Regents Patent Right, then the exclusive license grant shall as of the date of
such election include a sublicense of the Regents License Agreement under the Regents Patent Right. 
 For clarity, to the extent a Product contains any
genetic material other than a Construct (“Extraneous Genetic Material”), such as in the case that the other active pharmaceutical ingredient in a Combination Product consists of or contains genetic materials other than a Construct,
then 

  
 - 36 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(a)	 the 4DMT Know-How does not include
Know-How related to the Extraneous Genetic Material, so long as 4DMT does not provide Roche with such Know-How, and 

 

	(b)	 the Mid Range 4DMT Patent Rights (and, if applicable Regents Patent Rights) do not include Patent Rights that
would be infringed by the making, using or selling of the Extraneous Genetic Material in the absence of the Construct. 

 4.1.1 Requirement
for Roche Product Class Status 
 The Roche Group is granted no rights under 4DMT’s interest in any Mid Range 4DMT Patent Right and 4DMT Know-How to achieve any development event described in Section 12.4 or commercialize a Product associated with a Product Class that does not have the Status of a Roche Product Class at the time of the
Roche Group’s achievement of such development event or commercialization (unless the license grant is fully paid up, irrevocable and royalty free in accordance with Section 12.6.1). 

4.1.2 Covenant not to License 
 During the Agreement Term, 4DMT
may not grant a license for Products in the Field to any Third Party under any Patent Right Controlled by 4DMT except for Products associated with a Non-Optionable 4DMT Product Class. 

4.2 Sublicenses 
 Roche shall have the right to sublicense
or subcontract (through multiple tiers) as follows: 
 4.2.1 Right to Sublicense to its Affiliates 

Roche shall have the right to grant sublicenses to its Affiliates, and to [***] if [***] are, respectively, not an Affiliate under this Agreement, under its
rights granted under Section 4.1, without prior approval of 4DMT or notice thereto. If Roche grants such a sublicense, Roche shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the Affiliate to the same
extent as they apply to Roche for all purposes. Roche assumes full responsibility for the performance of all obligations and observance of all terms so imposed on such Affiliate and shall itself account to 4DMT for all payments due under this
Agreement by reason of such sublicense. 
 4.2.2 Right to Sublicense to Third Parties 

Roche and its Affiliates shall have the right to grant written sublicenses to non-Affiliate entities under its rights
granted under Section 4.1 without prior approval of 4DMT. Roche shall give prompt written notice to 4DMT of each sublicense that Roche grants under this Section 4.2.2. Roche shall provide 4DMT if 4DMT so requests in response to such notice
a copy of the sublicense agreement; provided that it may be redacted to remove commercially sensitive information that is not required to be known in order to confirm consistency and compliance with this Agreement. 

4.3 Research Cross License 
 While a given Project Plan is
active, each Party grants to the other Party a non-exclusive right and license under Know-How and Patent Rights Controlled by such Party solely to enable the other Party
to perform the activities contemplated under the Project Plan under this Agreement. 

  
 - 37 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 4.4 Grant-Back License 

Roche hereby grants to 4DMT an exclusive, worldwide right and license under Roche’s interest in any Project Product Patent Right to research, have
researched, develop, have developed, register, have registered, make, have made, use, have used, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold Enabled Products outside the Field
(including inside what was originally the Field for any Product Classes or countries no longer subject to the license under Section 4.1). Such right and license shall be exclusive even as to Roche, except the Roche Group shall retain a non-exclusive right to test Products outside the Field if needed for registration of Products within the Field. Such right and license shall include the right to sublicense, however any such sublicense may not
include the right for such sublicensee to be consulted concerning the Handling of any Project Product Patent Right. 
 5. Diligence 

5.1 Collaboration 
 Each Party will use Commercially
Reasonable Efforts to conduct their respective activities under a given Project Plan. 
 5.2 Roche Commercially Reasonable Efforts 

Roche agrees to use Commercially Reasonable Efforts to pursue development and commercialization of Licensed Products in the Field in the Territory. Roche shall
be deemed to use Commercially Reasonable Efforts if it pursues development or commercialization of at least one Licensed Product at any given time during the term of the agreement; however subject to Section 5.4.1 and 5.5. 

5.3 4DMT Commercially Reasonable Efforts 
 5.3.1 4DMT
Product Class other than XLRP 4DMT Product Class 
 While a 4DMT Product Class is an Optionable 4DMT Product Class, 4DMT will use Commercially
Reasonable Efforts to advance a Product associated with such 4DMT Product Class to Completion of Phase I/IIa. 
 5.3.2 XLRP 4DMT Product Class 

While the XLRP 4DMT Product Class is an Optionable 4DMT Product Class, 4DMT will use Highest Priority Efforts to advance a Product associated with such
XLRP 4DMT Product Class to Completion of Phase I/IIa. 
 If 4DMT fails to use such Highest Priority Efforts, then Roche may immediately send a
notice to 4DMT and the following will occur: 
  

	(a)	 the Status of the XLRP 4DMT Product Class will be changed to a Roche Product Class (however without the
right for Roche to unilaterally designate such a Roche Product Class as a Collaboration Product Class); 

  
 - 38 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(b)	 the obligations of diligence in Article 5 for Roche Product Classes shall not apply to such Roche Product
Class; 

  

	(c)	 such Roche Product Class will be deemed as an Other Product Class, subject to the corresponding payment
obligations in Sections 12.4 (but excluding Development Events 1 and 2), 12.5 and 12.6, and for clarity no further payments for an Optioned Product Class payment stream shall be due for such Roche Product Class; and 

 

	(d)	 notwithstanding anything to the contrary in this Agreement, Roche may immediately request the Program Transfer
set forth in Article 6. 

 5.4 Progression to IND Filing 

5.4.1 Roche Progression 
 If Roche has not advanced a Licensed
Product for a given Roche Solo Product Class to Filing of an IND within [***] ([***]) years after the date that such Product Class is designated as a Roche Product Class (the “Roche [***] Year Anniversary”), then the
Status for such Roche Product Class will change to an Available Product Class effective on the applicable Roche [***] Year Anniversary. 
 Within
[***] ([***]) days of a given Roche [***] Year Anniversary, Roche shall provide written notice to 4DMT indicating if the Status of the applicable Product Class has changed to an Available Product Class or remains as a Roche Product Class,
and if the Status has changed, Roche will provide a notice of termination for such Product Class in accordance with Section 22.2.2. 
 5.4.2 4DMT
Progression 
 In addition to 4DMT’s obligations under Section 5.3, if 4DMT has not advanced a Product for a given 4DMT Product Class to
(i) Filing of an IND within [***] ([***]) years after the date that such Product Class is designated as a 4DMT Product Class (the “4DMT [***] Year Anniversary”) or (ii) Completion of a Phase I/IIa Study within
[***] ([***]) years after the date that such Product Class is designated as a 4DMT Product Class (the “4DMT [***] Year Anniversary”), then the Status for such 4DMT Product Class will change to an Available Product
Class effective on the applicable 4DMT [***] Year Anniversary or 4DMT [***] Year Anniversary. 
 Within [***] ([***]) days of a given 4DMT [***] Year
Anniversary and 4DMT [***] Year Anniversary, 4DMT shall provide written notice to Roche indicating if the Status of the applicable Product Class has changed to an Available Product Class or remains as a 4DMT Product Class. 

5.5 Additional Development Progression 
 5.5.1 Roche
Progression 
 No more than [***] each Calendar Year, for Roche Product Classes that have not yet had a First Commercial Sale of an associated Product and
are not the subject of an active Project Plan, if the high-level summary provided by Roche for such Product Class under Section 7.2(b) indicates that no bona fide substantive development work has occurred on a Product associated
with such Roche Product Class in the previous [***], then 4DMT may request that Roche provide a notice of termination for such Product Class in accordance with Section 22.2.2, and unless Roche has a bona fide dispute about
4DMT’s conclusion, Roche will provide such termination notice. 

  
 - 39 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 In any given [***] where there is a High Volume Roche Solo Scenario, Roche will provide for each Roche Solo
Product Class a summary of all development work conducted. If at least one such Roche Solo Product Class has not had bona fide substantive development work during such [***] (which may include reasonable internal review periods not
to extend beyond one such [***]), 4DMT may request that Roche provide a notice of termination of up to a maximum of the number such Roche Solo Product Classes for which Roche has not been diligent (however for clarity no more than the number that
will take Roche out of the High Volume Roche Solo Scenario), and unless Roche has a bona fide dispute about 4DMT’s conclusion (which may include whether 4DMT in bad faith accepted a Roche Product Class Initiation Payment for the
designation of a new Roche Product Class in a High Volume Roche Solo Scenario, rather than disallowing at the time of designation based on a similar standard of what constitutes substantive development work), Roche will provide such termination
notice(s). 
 5.5.2 4DMT Progression 
 No more than [***] each
Calendar Year, for 4DMT Product Classes that have not yet had a first commercial sale of an associated Product (but excluding Optionable 4DMT Product Classes if Roche is receiving regular progress updates through the JSC), Roche may provide written
notice to 4DMT requesting an update of the Status of the applicable 4DMT Product Class. If 4DMT or its sublicensees have conducted no bona fide substantive development work on a Product associated with such 4DMT Product Class in the
previous [***], then Roche may request that 4DMT provide a notice of change of Status for such Product Class, and unless 4DMT has a bona fide dispute about Roche’s conclusion, 4DMT will provide Roche with written notice of the change of
the Status of such 4DMT Product Class to an Available Product Class. 
 5.5.3 Commercial Progression 

For clarity, 
  

	(a)	 upon the First Commercial Sale anywhere in the world by the Roche Group of a Licensed Product, Roche will have
no further diligence obligations to 4DMT for Products specifically associated with the associated Roche Product Class and 4DMT may not request that Roche convert such Product Class to an Available Product Class, with the proviso
that until the license associated with such Licensed Product is fully paid-up and irrevocable, then Roche must exercise Commercially Reasonable Efforts with respect to such Licensed Product unless Roche is
using Commercially Reasonable Efforts to pursue development and commercialization of at least one other Licensed Product under Section 5.2, and 

  

	(b)	 upon the first commercial sale anywhere in the world by 4DMT of a Product associated with a Non-Optionable 4DMT Product Class following the receipt of any applicable regulatory approval required by such sale, 4DMT will have no further diligence obligations to Roche for such Product Class and
Roche may not request that 4DMT convert such Product Class to an Available Product Class. 

  
 - 40 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 6. Program Transfer 

6.1 IND and Regulatory 
 Except as otherwise agreed to by
the Parties, for a given Roche Product Class and upon Roche’s request after 
  

	(i)	 Completion of the Phase I/IIa work under a Project Plan for a Collaboration Product Class or

  

	(ii)	 Roche’s provision of a Clinical Stage Roche Product Class Conversion Notice, 

4DMT shall promptly transfer sponsorship of any IND for the Licensed Product(s) associated with the given Roche Product Class to the Roche Affiliate
designated by Roche and the Parties will cooperate to draft and execute the necessary documents required to effect such transfer. Prior to the transfer, 4DMT shall provide to Roche copies of all material correspondence with the Regulatory
Authorities. 
 In addition, at a date defined by Roche, 4DMT shall transfer and assign to Roche any regulatory dossiers containing information necessary or
useful to Roche in connection with its regulatory filings for all Products, including, but not limited to clinical trial dossiers, regulatory correspondence, Regulatory Authority meeting minutes and study reports from completed non-clinical and clinical studies. For all completed study reports, 4DMT shall provide necessary documentation to confirm data reliability, as required by Article 43 of the Japanese Pharmaceutical Affairs Law
Enforcement Regulations and related notifications, including, but not limited to original author signatures, raw data lists, GLP and GCP compliance information. All documentation is to be provided in English. 

Also at a date defined by Roche, 4DMT shall transfer to Roche all relevant historical clinical safety data. Safety information on serious adverse events shall
be provided in CIOMS format and safety information on non-serious adverse events shall be provided in English Line Listing format. 

6.2 Other Program Transfer 
 In addition to
Section 6.1, upon Roche’s request, the Parties will work together to effect the transfer to Roche (or Roche’s designee) of the 4DMT Know-How, Licensed Constructs and Licensed Products applicable
to a given Roche Product Class. 4DMT shall make its personnel (or cause its third party CMO/CRO to be) available as reasonably requested by Roche to complete such transfer. The transfer activities set forth in Appendix 6.2 (the “Minimum
Program Transfer”) shall be provided [***]. If more than the Minimum Program Transfer is required, then 4DMT shall seek to reasonably accommodate Roche’s needs and Roche shall reimburse 4DMT the expenses of providing assistance to
Roche, [***]. 
 If instead of a transfer, Roche (at its discretion) elects to continue utilizing the services of a given 4MDT CMO/CRO under separate
contract between a member of the Roche Group and such CMO/CRO, then 4DMT will cooperate with Roche to put in place such documents as are needed to (i) release the CMO/CRO of its obligations to 4DMT such that Roche may contract with the CMO/CRO
for the relevant services and (i) confirm with the given CMO/CRO the license of rights to Roche and such transfer of title/rights of the relevant applicable Know-How and materials at a given CMO/CRO as
appropriate under this Agreement. Such documents may include an assignment or novation of the relevant contract between 4DMT and such CMO/CRO, if agreed to by 4DMT, the CMO/CRO and Roche. 

  
 - 41 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 7. Development and Regulatory Affairs 

7.1 By 4DMT 
 Except as otherwise agreed by the Parties:

  

	(i)	 4DMT shall be responsible for pursuing clinical development of Products associated with a Collaboration Product
Class that is the subject of an active Project Plan in the Collaboration in accordance with the Project Plan. 

  

	(ii)	 4DMT at its sole cost and discretion (but subject to the diligence obligations set forth in this Agreement),
shall be responsible for pursuing clinical development of Products associated with a 4DMT Product Class (other than the XLRP 4DMT Product Class) that is an Optionable Product Class. 

 

	(iii)	 Subject to the diligence and other obligations set forth in this Agreement, 4DMT shall be responsible for
pursuing clinical development of Products associated with the XLRP 4DMT Product Class that is an Optionable Product Class, with such activities to be conducted in accordance with the XLRP 4DMT Product Class Work Plan.

  

	(iv)	 4DMT at its sole cost and discretion, shall as between the Parties have the sole right to pursue the clinical
development of Products associated with a 4DMT Product Class that is a Non-Optionable 4DMT Product Class (but subject to Section 5.4.2 and 5.5.2). 

Notwithstanding the foregoing, in each case above other than a 4DMT Product Class that is a Non-Optionable 4DMT
Product Class, unless Roche requests otherwise, Roche will have the right to (a) receive copies of minutes and any other communications with applicable Regulatory Authorities concerning Products associated with such Collaboration Product
Class and 4DMT Product Class, (ii) provide input into information to be submitted to a Regulatory Authority concerning such Products (which input 4DMT must reasonably implement for a Collaboration Product Class and must reasonably
consider for the XLRP 4DMT Product Class) and (iii) participate in any meetings with an applicable Regulatory Authority concerning such Products. 

7.2 By Roche 
 Except to the extent that Licensed Products
are the subject of an active Project Plan in the Collaboration or as otherwise agreed to by the Parties: 
  

	(a)	 Roche, at its sole cost and discretion, shall be responsible for pursuing clinical development of Licensed
Products, including all regulatory matters connected therewith, and shall devote Commercially Reasonable Efforts to the foregoing. 

  

	(b)	 Prior to the First Commercial Sale of a given Licensed Product, Roche shall provide an annual written report to
4DMT to update 4DMT with a high-level summary as to development progress for such Licensed Product, including all preclinical and clinical development activities. Thereafter, Roche will have no further obligation to provide development progress
reports with respect to such Licensed Product. 

  
 - 42 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 7.3 Shared Product 

7.3.1 Dossier Sharing 
 Notwithstanding anything express or
implied, if there are regulatory dossiers or documentation that are used for Shared Products, the Parties shall reasonably cooperate with each other to share such dossiers or documents. 

7.3.2 Pharmacovigilance Agreement 
 Where advisable or legally
required, the Parties (or their applicable Affiliates and/or licensees) shall execute a separate Pharmacovigilance Agreement specifying the procedure for the information exchange of the adverse events that may occur with respect to Shared Products.

 8. Manufacturing 
 Except as otherwise agreed to by
the Parties: 
  

	(a)	 4DMT shall be responsible for having clinical supplies of Licensed Products associated with a Collaboration
Product Class manufactured by a Third Party CMO through Completion of the first Phase I/IIa Study in accordance with the Project Plan. Such Third Party CMO will be a Preferred CMO, unless otherwise agreed to by the Parties. For Choroideremia,
Roche will [***], however upon 4DMT’s achievement of [***], 4DMT will be entitled to receive the applicable development event payment under Section 12.4. 

 

	(b)	 Roche shall be responsible for all other manufacturing of all Licensed Products associated with a given Roche
Product Class (e.g. for a Roche Solo Product Class, Pivotal Trials and commercial supplies). For Licensed Products associated with a Collaboration Product Class, prior to Completion of the Phase I/IIa Study, Roche will have the right (but not the
obligation) to conduct manufacturing activities at Roche’s expense in preparation for the Pivotal Study, including contracting with any 4DMT CMO working on the manufacture and testing of Licensed Product for the Phase I/IIa Study.

  

	(c)	 4DMT shall be responsible for manufacturing of Products associated with a given 4DMT Product Class, however
subject to what right Roche may have under this Agreement to provide input for Products associated with an Optionable 4DMT Product Class, particularly the XLRP 4DMT Product Class while it is an Optionable 4DMT Product Class. While a 4DMT
Product Class is an Optionable 4DMT Product Class: 

  

	 	(i)	 4DMT may not use a CMO other than a Preferred CMO to conduct work under the XLRP 4DMT Product Class Work
Plan or a work plan for a 4DMT Product Class that is not the XLRP 4DMT Product Class without Roche’s consent. 

  

	 	(ii)	 For the Product associated with an Optionable 4DMT Product Class, if Roche requests, the Parties will work
together to enter into such side agreements as will allow Roche to conduct manufacturing activities [***] in preparation for a Pivotal Study, including contracting with any 4DMT CMO working on the manufacture and testing of the applicable Product
for the Phase I/IIa Study. If and when such Optionable 4DMT Product Class becomes a Non-Optionable 4DMT Product Class, (x) 4DMT will receive the benefit of and ownership in

  
 - 43 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	 	
Roche’s rights in any intellectual property for such testing and manufacturing, and (y) at 4DMT’s option, any Product made in preparation for the potential Pivotal Study will
either be destroyed by Roche or the CMO in possession, or 4DMT may elect to acquire title to such Product if [***]. 

 9. Commercialization

 Roche, at its own expense, shall have sole responsibility and decision making authority for the marketing, promotion, sale and distribution of
Licensed Products in the Field in the Territory. 4DMT, at its own expense, shall have sole responsibility and decision making authority for the marketing, promotion, sale and distribution of Products associated with a
Non-Optionable 4DMT Product Class or Enabled Products in the Territory. 
 10. Governance 

10.1 Joint Steering Committee 
 Within [***] ([***]) days
after the Effective Date of this Agreement, the Parties shall establish a JSC to 
  

	(i)	 oversee the Collaboration activities under this Agreement, 

 

	(ii)	 provide input for the XLRP 4DMT Product Class, and 

 

	(iii)	 monitor development progress of any Optionable 4DMT Product Classes. 

10.2 Members 
 Except as otherwise agreed by the JSC, the
JSC shall be composed of six (6) persons (“Members”). Roche and 4DMT each shall be entitled to appoint three (3) Members with appropriate seniority and functional expertise. Each Party may replace any of its Members and
appoint a person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least [***] days prior to the next scheduled meeting of the JSC (to the extent practicable). Both Parties shall
use reasonable efforts to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part or the whole JSC meeting with prior notification to the JSC.
Members may be represented at any meeting by another person designated by the absent Member. The JSC shall be chaired by a [***] Member (“Chairperson”). 

10.3 Responsibilities of the JSC 
 The JSC shall have the
responsibility and authority to: 
  

	(a)	 review and recommend for execution proposed Project Plans (and budgets); 

 

	(b)	 review Project Plans (and budget) on an ongoing basis and amend Project Plans (with any Significant Change
reflected in a written amendment to the Project Plan executed in accordance with Section 3.3); 

  

	(c)	 create, oversee or disband JOTs, as appropriate; 

 

	(d)	 approve amendments to the XLRP 4DMT Product Class Work Plan; 

  
 - 44 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(e)	 review proposed work plans provided with a 4DMT Product Class Status Notice; 

 

	(f)	 review changes to the work plans for any Optionable 4DMT Product Class that is not the XLRP 4DMT Product
Class; 

  

	(g)	 monitor the development of Optionable 4DMT Product Classes through regular progress report updates by 4DMT;

  

	(h)	 approve plans for a program transfer in accordance with Article 6; and 

 

	(i)	 attempt to resolve any disputes on an informal basis by unanimous consensus on the JSC (with the JSC having no
authority to resolve contractual disputes). 

 The JSC shall have no responsibility and authority other than that expressly set forth in
this Section. 
 10.4 Meetings 
 The Chairperson or
his/her delegate will be responsible for sending invitations and agendas for all JSC meetings to all Members at least [***] days before the next scheduled meeting of the JSC (or as soon as practicable). The venue for the meetings shall be agreed by
the JSC. The JSC shall hold meetings at least [***] per calendar year, either in person or by tele-/video-conference, and in any case as frequently as the Members of the JSC may agree shall be necessary, but not more than [***] times a year. 

10.5 Minutes 
 The Chairperson will be responsible for
designating a Member to record in reasonable detail and circulate draft minutes of JSC meetings to all members of the JSC for comment and review within [***] days after the relevant meeting. The Members of the JSC shall have [***] days to provide
comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the JSC within [***] days of the relevant meeting. The Chairperson will approve the final version of the minutes
before its distribution. 
 10.6 Progress Reports 
 4DMT
shall prepare and provide Roche [***] written reports as outlined in Section 3.4. Promptly upon completion of any Project Plan, 4DMT shall provide a final written report summarizing its activities under the Project Plan and the results thereof.
Upon the written request of Roche and not more than [***] in each Calendar Year, 4DMT shall permit Roche, [***], to have access during normal business hours to those records of 4DMT that may be necessary to verify the basis for any payments
hereunder. 
 4DMT will also prepare and provide Roche on a [***] basis (or as otherwise agreed to by the Parties) written progress reports for any
Optionable 4DMT Product Class, including the XLRP 4DMT Product Class. 

  
 - 45 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 10.7 Decisions 

10.7.1 Decision Making Authority 
 The JSC shall decide matters
within its responsibilities set forth in Section 10.3 with each Party having one vote, irrespective of the number of participants present. 
 10.7.2
Consensus; Good Faith 
 The Members of the JSC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided
by the JSC. The Parties shall endeavor to make decisions by consensus. 
 10.7.3 Escalation 

If the JSC is unable to decide a matter by consensus, then such matter shall be referred to [***] for 4DMT and [***] Roche pRED (or their designee), who
together shall use reasonable and good faith efforts to reach a decision by consensus within [***] days after the date such matter is referred to them. If the Parties still fail to reach a decision within such [***] days, then 

 

	(i)	 Roche shall have the final decision authority on any matter [***], 

 

	(ii)	 Notwithstanding the above, with regards to Choroideremia, 4DMT shall have the final decision authority on
[***], 

  

	(iii)	 4DMT shall have the final decision making authority for [***], 

which final decisions shall be exercised in good faith. No final decision may be exercised in conflict with the terms and conditions of this Agreement. No
final decision shall amend or contradict this Agreement. No final decision shall resolve any dispute as to the interpretation or application of this Agreement. Any final decision in accordance with this Section 10.7 shall constitute a decision
of the JSC. 
 10.8 Alliance Director 
 Each Party shall
appoint one person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall be permanent participants of the JSC
meetings and may attend JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JSC to reach consensus and avert escalation of such issues or potential
disputes. 
 10.9 Limitations of Authority 
 The JSC
shall have no authority to amend or waive any terms of this Agreement nor to resolve contractual disputes. 
 10.10 Expenses 

Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the JSC. 

  
 - 46 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 10.11 Lifetime 

The JSC shall exist while at least one Project Plan is active. 

11. Project Plan Payments to 4DMT 
 11.1 Collaboration
Costs 
 Unless otherwise agreed to by the Parties, Roche shall (i) pay 4DMT at the FTE Rate for work performed by or on behalf of 4DMT under a
given Project Plan and (ii) reimburse 4DMT for the expenses of a Third Party Supplier (“Third Party Expenses”) that 4DMT incurred under a given Project Plan as set forth in Section 11.2. Notwithstanding the foregoing,
[***]. The number of FTEs per month that may not be exceeded without mutual agreement of the Parties will be included in each corresponding Project Plan. If the Parties mutually agree to conduct work in under a Project Plan in areas of the Field
other than the [***] (for example in a Field [***]), it is expected that costs under the Project Plan will be [***]. 
 11.2 Third Party Supplier and
Third Party Expenses 
 For those Third Party Suppliers for which Roche will be responsible for reimbursing to 4DMT Third Party Expenses under a Project
Plan, Roche will have the right (but not the obligation) to approve any proposed Third Party Suppliers performing under a Project Plan, and 4DMT will not use Third Party Suppliers to provide services or materials under a Project Plan if Roche has a
reasonable basis to object to such Third Party Supplier. Contracts between 4DMT and a given Third Party Supplier for work to be performed under a given Project Plan (“Third Party Supplier Contract”) will contain appropriate clauses
that apply responsibilities and obligations applicable to 4DMT under this Agreement, and Roche will have the right to receive a copy of the Third Party Supplier Contract. Roche may provide input into draft Third Party Supplier Contracts, which input
4DMT must reasonably consider. 
  
 The reimbursement made for Third Party Expenses may
not exceed the amount estimated in the most up to date version of the Budget of the respective Project Plan, as revised and approved by the JSC in accordance with Section 10.3 (and subject to Significant Change provisions of Section 3.3).

 11.3 Payment Schedule 
 Payments made for Project
Plans will be made to 4DMT within [***] ([***]) days after Roche’s receipt of an undisputed invoice from 4DMT itemizing all amounts payable in respect of the 4DMT Activities and Third Party Expenses. 4DMT will invoice Roche on a [***] basis (or
such other basis as may be set forth in the Project Plan) after the completion of 4DMT Activities for which amounts may be billed, however any individual Third Party Expenses over [***] US Dollars (US$ [***]) that 4DMT incurs within [***]
months after the previous [***] invoice may be invoiced to Roche separately (i.e. without waiting for the next [***] invoicing period). Invoices must include detail supporting the amounts that are billed, [***]. 

  
 - 47 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 11.4 Fair Market Value 

The Parties acknowledge that the compensation to 4DMT and the pass-through expenses paid to any healthcare organization or healthcare professional (hereinafter
collectively the “Fees”) set forth in a Project Plan shall be the fair market value of the 4DMT Activities provided by 4DMT and/or the healthcare organization or healthcare professional, as applicable and these Fees have not been
determined in a manner which takes into account the volume or value of any referrals, purchases or business otherwise generated between 4DMT/healthcare organization or healthcare professional and Roche or any of their respective Affiliates and shall
not obligate or influence 4DMT/healthcare organization or healthcare professional or any other person to purchase, use, recommend or arrange for the use of Roche’s products or those of any organization affiliated with Roche. Notwithstanding the
above, no healthcare organization may pass through any Fees provided hereunder, directly or indirectly, to any customer of such healthcare organization as a price concession or otherwise. 

11.5 Optionable 4DMT Product Class Work 
 For clarity,
this Article 11 applies only to work performed under a Project Plan for a Collaboration Product Class (and excluding manufacturing work for Choroideremia in accordance with Section 8(a)). Work performed by or on behalf of 4DMT for
Optionable 4DMT Product Classes will be done at 4DMT’s own expense. 
 12. Payment to 4DMT (other than Project Plan Payments) 

12.1 Initiation Payment 
 Within [***] ([***]) days after
the Effective Date and receipt of an invoice from 4DMT, Roche shall pay to 4DMT Twenty-One Million US Dollars (US$21,000,000). Such amount is non-refundable and non-creditable against any other payment due under this Agreement. 
 12.2 Roche Product Class Initiation Payment
(other than Optioned Product Class) 
 This Section 12.2 applies only to Roche Product Classes that are either Collaboration Product Classes or
Roche Solo Product Classes, i.e. is not an Optioned Product Class (in which case Section 12.3 applies). 
 The designation of the first [***] such
Roche Product Classes under Section 2.2 (including Choroideremia) is included in the Initiation Payment set forth in Section 12.1. 
 For any such
additional Roche Product Class designations beyond the first [***], Roche shall pay to 4DMT a payment (“Roche Product Class Initiation Payment”) of [***] US Dollars (US$[***]) for each such additional Roche
Product Class designation within [***] ([***]) days of: 
  

	(i)	 for a Roche Solo Product Class (that is not disallowed by 4DMT in a High Volume Roche Solo Scenario), the date
that Roche provides notice changing the Status from an Available Product Class to a Roche Product Class, or 

  

	(ii)	 for a Collaboration Product Class, the date that the associated Project Plan is executed by authorized
representatives of both Parties (unless such Roche Product Class Initiation Payment was already made under (i) above) 

 and
receipt by Roche of an invoice from 4DMT. 

  
 - 48 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 12.3 Option Exercise Fee 

Within [***] ([***]) days after Roche provides a Clinical Stage Roche Product Class Conversion Notice to 4DMT for a given 4DMT Product Class as
described in Section 2.3.3 and Roche’s receipt of an invoice from 4DMT, Roche shall pay to 4DMT [***] US Dollars (US$[***]) [***]. 
 12.4
Development Event Payments 
 Roche shall pay up to a total of 
  

	(i)	 [***] US Dollars (US$ [***]) in relation to the achievements of development events by the first Licensed
Product in Choroideremia to achieve the applicable event, 

  

	(ii)	 [***] US Dollars (US$ [***]) in relation to the achievements of development events by the first Licensed
Product in each Other Product Class to achieve the applicable event, and 

  

	(iii)	 [***] US Dollars (US$ [***]) in relation to the achievements of development events by the first Licensed
Product in each Optioned Product Class to achieve the applicable event. 

 The development event payments under this Section 12.4
shall be paid by Roche according to the following schedule of Development Events achieved by the Roche Group (or by 4DMT in accordance with an active Project Plan). 
  

													
	 Development Event
	  	Payments in Million US Dollars	 
	  	Choroideremia	 	  	Other Product
Class	 	  	Optioned
Product Class	 
	 1. [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 2. [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 3. [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 4. [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 5. [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 6. [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 7. [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 8. [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 

 Each development event payment for a given Licensed Product shall be paid only once for a given Product Class, the first time
a Licensed Product in a given Product Class reaches such Development Event, regardless of the number of times such events are reached for the given Licensed Product or other Licensed Products in the same Product Class. 

  
 - 49 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 If any of the payment-resulting Development Events 3-8 are achieved
for a given Licensed Product prior to any lower-numbered Development Event(s) for that Product Class having been achieved and paid for such Product Class, then Roche shall pay such earlier unpaid Development Event milestone(s) at the same time
as the later achieved Development Event payment is due for such Licensed Product. Notwithstanding the foregoing, the Development Event 2 payment will only be due if achieved by 4DMT or on behalf of 4DMT by a Third Party. 

For such development events listed in this Section 12.4 that are achieved by Roche or by a Third Party on behalf of Roche, Roche shall timely notify 4DMT
(in any event within [***] ([***]) days). The development payments listed in this Section 12.4 shall be paid by Roche to 4DMT within [***] ([***]) days from occurrence of the applicable event and receipt of an invoice from 4DMT. 

12.5 Sales Based Events 
 Roche shall pay up to a total of

  

	(i)	 [***] US Dollars (US$ [***]) based on Calendar Year Net Sales of Licensed Product(s) in Choroideremia in the
Territory, and 

  

	(ii)	 [***] Million US Dollars (US$ [***]) based on Calendar Year Net Sales of Licensed Product(s) in each Other
Product Class in the Territory, and 

  

	(iii)	 [***] Million US Dollars (US$ [***]) based on Calendar Year Net Sales of Licensed Product(s) in each Optioned
Product Class in the Territory, 

 in accordance with the following Net Sales Thresholds: 

 

													
	 Net Sales Threshold
	  	Payments in Million US Dollars	 
	  	Choroideremia	 	  	Other Product
Class	 	  	Optioned
Product Class	 
	 Calendar Year Net Sales in the Territory of a Licensed Product exceed US$ [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Calendar Year Net Sales in the Territory of a Licensed Product exceed US$ [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Calendar Year Net Sales in the Territory of a Licensed Product exceed US$ [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Calendar Year Net Sales in the Territory of a Licensed Product exceed US$ [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 TOTAL
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  
 - 50 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Each of the sales based event payments shall be paid no more than once per each Product
Class during the Agreement Term, at first occurrence of the event for the first Licensed Product in a given Product Class reaching the respective Net Sales Threshold, irrespective of whether or not the previous sales based event payment
was triggered by the given Licensed Product or other Licensed Products in the same Product Class, and shall be non-refundable. Each sales based event payment shall be payable within [***] ([***]) days after
the end of the Calendar Year in which the applicable Net Sales threshold was achieved and the receipt of an invoice from 4DMT. 
 12.6 Royalty Payments

 12.6.1 General 
 Royalties shall be payable by Roche on
Net Sales of Licensed Products on a Licensed Product-by Licensed Product basis until the expiry of the Royalty Term. Thereafter, the licenses granted to Roche shall be fully paid up, irrevocable and royalty
free as to the particular Licensed Product in the particular country. 
 12.6.2 Royalty Rates 

The following royalty rates shall apply to the respective tiers of aggregate Calendar Year Net Sales of a Licensed Product in the Territory, on an incremental
basis, based on the indicated Product Class, as follows: 
  

													
	 Tier of Calendar Year

Net Sales in million US$
	  	Choroideremia
Percent (%) of
Net Sales	 	 	Other Product
Class Percent
(%) of Net Sales	 	 	Optioned
Product Class
Percent (%) of
Net Sales	 
	 [***]
	  	 	[***]	% 	 	 	[***]	% 	 	 	[***]	% 
	 [***]
	  	 	[***]	% 	 	 	[***]	% 	 	 	[***]	% 
	 [***]
	  	 	[***]	% 	 	 	[***]	% 	 	 	[***]	% 
	 [***]
	  	 	[***]	% 	 	 	[***]	% 	 	 	[***]	% 

  
 - 51 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 For example, if Net Sales of a Licensed Product in Choroideremia for a given Calendar Year are US$ [***],
then royalties owed to 4DMT on such Net Sales of such Licensed Product for that Calendar Year shall equal [***] US Dollars (US$ [***]) calculated as follows: 

[***] 
 For the purpose of calculating royalties of a Licensed
Product, Calendar Year Net Sales and the royalty rates shall be subject to the following adjustments, as applicable: 
 12.6.3 Licensed Combination Product

 If Roche or its Affiliates intend to sell a Licensed Product that is a Licensed Combination Product, then the Parties shall meet approximately [***] prior
to the anticipated First Commercial Sale of such Licensed Combination Product in the Territory to negotiate in good faith and agree to an appropriate adjustment to Net Sales to reflect the relative commercial value contributed by the components of
the Licensed Combination Product (the “Relative Commercial Value”). If, after such good faith negotiations not to exceed [***] ([***]) days, the Parties cannot agree to an appropriate adjustment, the dispute shall be initially
referred to the executive officers of the Parties in accordance with Section 25.2. Should the Parties fail to agree within [***] ([***]) days of such referral, then the Relative Commercial Value shall be determined by an Expert Committee under
the procedures of Section 12.6.7. 
 12.6.4 No Valid Claim/Regulatory Exclusivity; Excluded Variant Competition; Generic Competition 

For a given Licensed Product, if in a given country within the Territory there is: 
  

	(a)	 no Valid Claim that Covers such Licensed Product and no applicable regulatory exclusivity for such Licensed
Product remaining in such country; 

  

	(b)	 entry of a Like-Substance Product has occurred; or 

 

	(c)	 entry of a Third Party Excluded Product (other than a Like-Substance Product) containing an Excluded Construct
that has an Excluded Variant carrying the same Payload as contained within the Licensed Product, 

 then the royalty payments due to 4DMT
for such Licensed Product in such country shall be reduced by [***] percent ([***]%). If [***] have occurred, then the Royalty Term for such Licensed Product in such country shall end (unless the Royalty Term had expired prior to such time for a
given Licensed Product in a given country), royalties shall no more be due by Roche in such country for such Licensed Product, and the license in that country for such Licensed Product shall be fully paid-up
and irrevocable. 
 12.6.5 Third Party Payments 
 With the
exception of any Regents Patent Rights, Roche shall be responsible for and pay or have paid any consideration owed to any Third Party in relation to Third Party intellectual property rights. Roche shall have the right to deduct a maximum of [***]
percent ([***]%) of such consideration actually paid to a Third Party in respect of Patent Rights Covering a given Licensed Product from royalty payments otherwise due and payable by Roche to 4DMT under this Agreement with respect to such Licensed
Product; provided that the royalty to 4DMT on such Licensed Product is not reduced in any [***] to less than [***] the royalty that would otherwise have been due but for this Section 12.6.5, 

  
 - 52 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
however for clarity, Roche may carry forward any amounts not utilized as a result of the maximum deduction cap in this Section 12.6.5 to future accounting periods until any amounts not
utilized are fully deducted. Any such deduction shall be permitted on a Licensed Product-by-Licensed Product and country-by-country basis only. 
 12.6.6 Apportionment of Compulsory Sublicensee Consideration 

Consideration, if any, paid by a Compulsory Sublicensee of the Licensed Product shall be shared between the Parties based on an equivalent profit share
percentage (the “Compulsory Profit Share Percentage”). The Compulsory Profit Share Percentage shall be calculated for the respective Calendar Year to which the Compulsory Sublicensee payment relates to as follows: 

 

	 	(a)	 royalties payable for the Licensed Product in the applicable Territory, divided by 

 

	 	(b)	 the corresponding Net Sales related to the royalties payable for the Licensed Product in the applicable
Territory, less all corresponding expenses that are allocable to the Licensed Product (e.g. cost of goods sold, royalty expenses, profit-share expenses, marketing and distribution expenses, general and administration expenses etc.), and which are in
accordance with the then-currently used IFRS for such period. 

 The Parties shall negotiate in good faith and agree upon the Compulsory
Profit Share Percentage to be used on a consistent basis to fairly share Compulsory Sublicensee payments between the Parties. For the purpose of clarity, any sales or payments by Compulsory Sublicensees under a Compulsory Sublicense shall not be
considered as Net Sales and shall not give rise to any royalty payment under Section 12.6.2 of this Agreement. 
 12.6.7 Expert Committee 

If the Parties are unable to agree on the Relative Commercial Value under Section 12.6.3 or the Compulsory Profit Share Percentage under
Section 12.6.6, then Roche will select one (1) individual who would qualify as an Expert, 4DMT will select (1) individual who would qualify as an Expert, and those two (2) individuals shall select one (1) individual who
would qualify as an Expert and who shall be chairman of a committee of the three Experts (the “Expert Committee”), each with a single deciding vote. The Expert Committee will promptly hold a meeting to review the issue under review,
at which it will consider memoranda submitted by each Party at least [***] ([***]) days before the meeting, as well as reasonable presentations that each Party may present at the meeting. The determination of the Expert Committee as to the
issue under review will be binding on both Parties. The Parties will [***] the costs of the Expert Committee. Unless otherwise agreed to by the Parties in writing, the Expert Committee may not decide on issues outside the scope mandated under terms
of this Agreement. Neither Party shall engage in ex parte communications with the Expert Committee. 
 13. General Payment Provisions 

13.1 Invoices 
 All invoices that are required or permitted
under Articles 11 and 12 shall be in writing and sent by 4DMT to Roche at the following address or other address as Roche may later provide: 

  
 - 53 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 F. Hoffmann-La Roche Ltd 

Kreditorenbuchhaltung 

Grenzacherstrasse 124 
 4070 Basel

 Switzerland 
 Attn: [***]

 13.2 Late Payment 
 Any payment under this Agreement
that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at [***] ([***]) percentage points above the average one-month Euro Interbank Offered
Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such payment is overdue. 
 13.3 Disclosure of Payments

 4DMT acknowledges that Roche may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as may be
advisable or required under Applicable Law, including the US Sunshine Act. 
 14. Royalty accounting and reporting 

14.1 Timing of Payments 
 Roche shall calculate royalties
on Net Sales quarterly as of March 31, June 30, September 30 and December 31 (each being the last day of an “Accounting Period”) and shall pay royalties on Net Sales within the [***] ([***]) days after the end of
each Accounting Period in which such Net Sales occur. 
 14.2 Method of Payment 

Royalties on Net Sales and all other amounts payable by Roche hereunder shall be paid by Roche in US Dollars (the “Payment Currency”) to
account(s) designated by 4DMT. 4DMT shall be entitled to require payment from Roche’s choice of either a U.S. or Swiss account. 
 14.3 Currency
Conversion 
 When calculating the Sales of any royalty-bearing Licensed Product that occur in currencies other than the Payment Currency, Roche shall
convert the amount of such sales [***] into the Payment Currency using Roche’s then-current internal foreign currency translation actually used on a consistent basis in preparing its audited financial statements (at the Effective Date, YTD
average rate as reported by Reuters). 
 14.4 Reporting 

With each payment Roche shall provide 4DMT in writing for the relevant Calendar Quarter on a Licensed Product-by-Licensed Product basis the following information: 
 (a) Sales in [***]; 

  
 - 54 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(b)	 Net Sales in [***]; 

  

	(c)	 adjustments made pursuant to Sections 12.6.3-12.6.5;

  

	(d)	 Net Sales in [***] after adjustments made pursuant to Sections
12.6.3-12.6.5 in [***]; 

  

	(e)	 exchange rate used for the conversion of Net Sales from [***] to the Payment Currency pursuant to
Section 14.3 

  

	(f)	 Net Sales after adjustments made pursuant to Sections 12.6.3-12.6.5 in
the Payment Currency; 

  

	(g)	 royalty rate pursuant to Section 12.6.2; and 

 

	(h)	 total royalty payable in the Payment Currency. 

For illustrative purposes only, a sample royalty report template is attached as Appendix 14.4. 

15. Taxes 
 4DMT shall pay all sales, turnover, income,
revenue, value added, and other taxes levied on account of any payments accruing or made to 4DMT under this Agreement. 
 If provision is made in law or
regulation of any country for withholding of taxes of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to 4DMT, then Roche shall promptly pay such tax, levy or charge for and on behalf of
4DMT to the proper governmental authority, and shall promptly furnish 4DMT with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due 4DMT or be promptly reimbursed by 4DMT
if no further payments are due to 4DMT. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in
minimizing the amount required to be so withheld or deducted. 
 16. Royalty Auditing 

16.1 4DMT Right to Audit 
 Roche shall keep, and shall
require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all royalties payable under this Agreement. Such books of accounts shall be
kept at their principal place of business. At the expense of 4DMT, 4DMT shall have the right to engage an independent public accountant reasonably acceptable to Roche to perform, on behalf of 4DMT an audit of such books and records of Roche and its
Affiliates, its licensees and Sublicensees, that are deemed necessary by Roche’s independent public accountant to report on Net Sales of Licensed Product for the period or periods requested by 4DMT and the correctness of any financial report or
payments made under this Agreement. 
 Upon timely request and at least [***] ([***]) working days’ prior written notice from 4DMT, such audit shall be
conducted in the countries specifically requested by 4DMT, during regular business hours in such a manner as to not unnecessarily interfere with Roche’s normal business activities, and shall be limited to results in the [***] ([***]) calendar
years prior to audit notification. 

  
 - 55 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Such audit shall not be performed more frequently than [***] per Calendar Year nor more frequently than [***]
with respect to records covering any specific period of time. 
 All information, data documents and abstracts herein referred to shall be used only for the
purpose of verifying royalty statements, shall be treated as Roche’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than [***] after completion of an audit hereof, if an audit has been
requested; nor more than [***] from the end of the Calendar Year to which each shall pertain; nor more than [***] after the date of termination of this Agreement. 

16.2 Audit Reports 
 The auditors shall only state factual
findings in the audit reports and shall not interpret the agreement. The auditors shall share all draft audit reports with Roche before the draft report is shared with 4DMT and before the final document is issued. The final audit report shall be
shared with Roche at the same time it is shared with 4DMT. 
 16.3 Over-or Underpayment 

If the audit reveals an overpayment, Roche shall be entitled to credit the amount of the overpayment against subsequent royalty payments due hereunder until
exhausted, or if no further royalty payments are owed by Roche, 4DMT shall reimburse Roche for the amount of the overpayment within [***] ([***]) days. If the audit reveals an underpayment, Roche shall make up such underpayment with the next royalty
payment or, if no further royalty payments are owed by Roche, Roche shall reimburse 4DMT for the amount of the underpayment within [***] ([***]) days. Roche shall pay for the audit costs if the underpayment of Roche exceeds [***]% of the aggregate
amount of royalty payments owed with regard to the royalty statements subject of the audit. Section 13.2 shall apply to this Section 16.3. 

16.4 Duration of Audit Rights 
 The failure of 4DMT to
request verification of any royalty calculation within the period during which corresponding records must be maintained under this Article 16 will be deemed to be acceptance of the royalty payments and reports absent non-de minimis fraud
uncovered on a subsequent audit of another period. 
 17. Payments to Roche 

For Enabled Products, 4DMT shall pay Roche a royalty on all net sales of such Product(s) by 4DMT, its Affiliates or licensees, with the royalty rate based on
the stage of the Product effective date of such termination as follows: 
  

					
	 Stage of Product at effective date of termination
	  	Royalty rate	 
	 [***]
	  	 	[***]	% 
	 [***]
	  	 	[***]	% 
	 [***]
	  	 	[***]	% 
	 [***]
	  	 	[***]	% 

  
 - 56 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 subject to the following: 
  

	(i)	 net sales for this purpose shall have the same meaning given such term in this Agreement for Licensed Products
applied mutatis mutandis to sales by 4DMT and its Affiliates and Sublicensees for Enabled Products; 

  

	(ii)	 the life of the royalty obligation shall be the later of (x) [***] years from the First Commercial Sale (either
by the Roche Group or First Commercial Sale applied for mutatis mutandis for sales by 4DMT and its Affiliates and Sublicensees) and (y) the life of the Valid Claims of the any Project Product Patent Right, each determined country-by-country and Enabled Product-by-Enabled Product; and 

 

	(iii)	 such royalty shall be subject to adjustments equivalent to those in Sections 12.6.3, 12.6.4 (other than
Excluded Variant Competition under 12.6.4(c)), 12.6.5 and 12.6.6 in this Agreement. 

 For clarity, the royalties in this Article 17
apply only to Products that do not require Initiation of a new Phase I/IIa Study. 
 Payments shall be made in a timely fashion as applicable to Roche.
Article 16 for Licensed Products shall be applied for mutatis mutandis to Roche’s right to audit 4DMT for Enabled Products. 
 17.1 Enabled
Products under the RFO Agreement 
 If an Enabled Product as defined under the RFO Agreement is a Licensed Product under this Agreement, then 4DMT will
not owe payments to Roche under Section 3.4 of the RFO Agreement based on monies paid by Roche to 4DMT under Article 12 of this Agreement. 

18. Intellectual Property 
 18.1 Inventorship 

The determination of inventorship for inventions (i) conceived or reduced to practice in the performance of a Collaboration Project or (ii) conceived
or reduced to practice by or on behalf of 4DMT for Optionable Project Work shall be in accordance with United States inventorship laws. 
 18.2 Ownership

 Except as otherwise set forth in this Agreement, as between the Parties: 
  

	(i)	 4DMT shall own any Optionable Variant Patent Right and Project Variant Patent Right at all times.

  

	(ii)	 4DMT and Roche shall jointly own any Project Product Patent Right at all times. 

 

	(iii)	 4DMT shall own any Optionable Product Patent Right until the applicable 4DMT Product Class is no longer an
Optionable Product Class, at which time 

  

	 	(a)	 if the 4DMT Product Class is a Non-Optionable 4DMT Product
Class or the Status of the 4DMT Product Class changes to an Available Product Class, then 4DMT’s ownership in such continue indefinitely, or 

  

	 	(b)	 if the 4DMT Product Class changes to a Roche Product Class, then as between the Parties, 4DMT and Roche
shall jointly own such Patent Right, and 4DMT shall, upon Roche’s expense and at Roche’s request, sign all such documentation as to effect the assignment of such Patent Right as a jointly-owned Patent Right. 

  
 - 57 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(iv)	 Ownership of any other Project Patent Right and Optionable Patent Right shall follow inventorship.

 Each Party hereby assigns to the other Party the assigning Party’s interest in such Project Patent Right as necessary to result in
the Project Patent Right being owned as provided in this Section. 
 18.3 Patent Coordination Team 

Where the Parties need to consult with each other on the Handling of Patent Rights, the Parties shall establish a patent coordination team and shall adopt
procedures for interacting on patent matters. 
 18.4 Prosecution 

18.4.1 Optionable Variant Patent Rights and Optionable Project Product Patent Rights 

This Section 18.4.1 shall apply only until such time as an Optionable Variant Patent Right or an Optionable Project Product Patent Right becomes either an
Optioned Patent Right or a Non-Optionable Patent Right (or Roche waives its right to be consulted for a given Patent Right). The Parties will consult with each other on the Handling of any Optionable Variant
Patent Right and Optionable Product Patent Right through the patent coordination team. The Parties will attempt to use mutually-acceptable outside counsel (whether patent attorneys or patent agents) for the prosecution of the Optionable Variant
Patent Right and Optionable Product Patent Right (i.e., they will discuss and attempt to reach consensus on the outside attorney or agent that will Handle the filings; each Party shall reasonably consider the other’s views, and seek in good
faith to reach consensus, although the ultimate decision as to choice of counsel to represent each Party is reserved to that Party). Decisions that cannot be resolved by consensus of the patent coordination team shall, upon request of either party,
be promptly escalated to the [***] (in the case of 4DMT) or to the [***] (in the case of Roche) or their designee. Prior to the first filings of the applicable Optionable Product Patent Right and Optionable Variant Patent Right, the patent
coordination team, together with the Parties’ respective patent practitioners, shall discuss in good faith whether it is in the best interest of obtaining the best coverage to file dependent claims in the Optionable Variant Patent Right that
explicitly claims the combination of Optionable Variants with specific Optionable Payloads (instead of merely generically encompassing the foregoing) (each an “Optionable Product Dependent Claim”) in an otherwise-Optionable Variant
Patent Right (provided that the Parties would also discuss and agree on whether the Optionable Product Dependent Claim should be segregated through use of a divisional filing). Both Parties shall approach such discussion in good faith. Handling of
an Optionable Variant Patent Right and Optionable Product Dependent Claim shall be [***], and Handling of an Optionable Product Patent Right other than a Product Dependent Claim shall be [***]. After consultation with Roche, decisions on the
Handling of an Optionable Variant Patent Right shall be at the sole discretion of 4DMT, however reasonable consideration shall be given to Roche’s input if such Optionable Variant Patent Right is likely to be subject to Roche’s right to
convert to an Optioned Product Class or the Handling could impact the validity or patentability of an Optionable Product Patent Right. If 4DMT’s Handling of an Optionable Variant Patent Right is contrary to Roche’s input (for instance
if Roche does not give consent to file a Product Dependent Claim, but 4DMT chooses to file it anyway, as it is entitled to do in accordance with this Section) and the validity, 

  
 - 58 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
scope or enforceability of the Optionable Product Patent Right is weakened as a result in comparison to the Optionable Variant Patent Right, or if the Product cannot be claimed in a separate
Optionable Product Patent Right, then the Optionable Variant Patent Right Covering Products shall be deemed as an “Optionable Primary Patent Right”. Roche’s input into the Handling of an Optionable Primary Patent Right must be
reasonably implemented. After consultation between the Parties, decisions on the Handling of an Optionable Product Patent Right shall be at the discretion of 4DMT with reasonable consideration to Roche’s input. 

For clarity, at such time as an Optionable Variant Patent Right or an Optionable Project Product Patent Right becomes an Optioned Patent Right, then the
applicable Optionable Variant Patent Right, Optionable Project Product Patent Right, Optionable Product Dependent Claim and Optionable Primary Patent Right shall be treated as, respectively, a Variant Patent Right, Project Product Patent Right,
Product Dependent Claim and Primary Patent Right. 
 Also for clarity, at such time as an Optionable Variant Patent Right or an Optionable Project Product
Patent Right becomes a Non-Optionable Patent Right, then Roche will have no further right to be consulted on the Handling or the applicable Optionable Variant Patent Right, Optionable Project Product Patent
Right, Optionable Product Dependent Claim or Optionable Primary Patent Right. 
 18.4.2 Priority Filings for Variant Patent Rights and Project Product Patent
Rights 
 This Section 18.4.2 applies to the Handling of a Variant Patent Right and Project Product Patent Right where the Handling is limited to the
filing of priority patent applications. The Parties will consult with each other on such Handling of any Project Variant Patent Right and Project Product Patent Right through the patent coordination team. The Parties will attempt to use
mutually-acceptable outside counsel (whether patent attorneys or patent agents) for the Handling of the Project Variant Patent Right and Project Product Patent Right (i.e., they will discuss and attempt to reach consensus on the outside attorney or
agent that will Handle the filings; each Party shall reasonably consider the other’s views, and seek in good faith to reach consensus, although the ultimate decision as to choice of counsel to represent each Party is reserved to that Party).
Decisions that cannot be resolved by consensus of the patent coordination team shall, upon request of either party, be promptly escalated to the [***] (in the case of 4DMT) or to the [***] (in the case of Roche) or their designee. Prior to the first
filing of the applicable Project Product Patent Right and Project Variant Patent Right, the patent coordination team, together with the Parties’ respective patent practitioners, shall discuss in good faith whether it is in the best interest of
obtaining the best coverage to file dependent claims in the Project Variant Patent Right that explicitly claim the combination of Project Variants with specific Project Payloads (instead of merely generically encompassing the foregoing) (each a
“Product Dependent Claim”) in an otherwise-Project Variant Patent Right (provided that the Parties would also discuss and agree on whether the Product Dependent Claim should be segregated through use of a divisional filing). (For
clarity, an Optionable Product Dependent Claim shall also be deemed as a Product Dependent Claim at such time, if any, as such Optionable Project Variant Patent Right becomes a Project Variant Patent Right). Both Parties shall approach such
discussion in good faith. Handling of any Project Variant Patent Right and Product Dependent Claim shall be [***], and Handling of any Project Product Patent Right other than a Product Dependent Claim shall be [***]. After consultation with Roche,
decisions on the Handling of a Project Variant Patent Right shall be at the sole discretion of 4DMT, however reasonable consideration shall be given to Roche’s input. If 

  
 - 59 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
4DMT’s Handling of a Project Variant Patent Right is contrary to Roche’s input (for instance if Roche does not give consent to file a Product Dependent Claim, but 4DMT chooses to file
it anyway, as it is entitled to do in accordance with this Section) and the validity, scope or enforceability of the Project Product Patent Right is weakened as a result in comparison to the Project Variant Patent Right, or if the Product cannot be
claimed in a separate Project Product Patent Right, then the Project Variant Patent Right Covering Products shall be deemed as a “Primary Patent Right” (and for clarity, an Optionable Primary Patent Right shall also be deemed as a
Primary Patent Right at such time, if any, as such Optionable Project Variant Patent Right becomes a Project Variant Patent Right). Roche’s input into the Handling of a Primary Patent Right must be reasonably implemented. After consultation
with 4DMT, decisions on the Handling of any Project Product Patent Right shall be at the discretion of Roche with reasonable consideration to 4DMT’s input. 

18.4.3 Project Product Patent Rights 
 After the filing of
priority applications, Roche shall, at its own expense and discretion, (i) Handle any Project Product Patent Right (other than a Product Dependent Claim) that are at least jointly owned by Roche, (ii) consult with 4DMT as to the Handling
of such a Patent Right, and (iii) furnish 4DMT copies of all documents relevant to any such Handling. Roche shall furnish such documents and consult with 4DMT in sufficient time before any action by Roche is due to allow 4DMT to provide
comments thereon, which comments Roche shall consider if applicable to the Field. At Roche’s reasonable request, 4DMT shall cooperate in all reasonable ways with the Handling of any such Patent Right. If Roche elects not to Handle a such a
given Patent Right in a given country, Roche shall give sufficient notice to 4DMT to allow 4DMT to assume, if it so desires, the Handling of such Patent Right at 4DMT’s expense and discretion. 

4DMT shall, at its own expense but in coordination with Roche, Handle any Product Dependent Claim that is at least jointly owned by Roche. 

4DMT shall, at its own expense and discretion, Handle any Project Product Patent Right that is not owned (even jointly) by Roche (for example after
application of Section 22.3.1(d)). 
 18.4.4 Other 4DMT Patent Rights 

This Section 18.4.4 applies only where not otherwise set forth in this Article 18 (for an Optionable Patent Right and for a Project Product Patent
Right). 
 4DMT shall, at its own expense and discretion, (i) Handle any Full Range 4DMT Patent Right, (ii) consult with Roche as to the Handling
of any Broad Range 4DMT Patent Right, and (iii) furnish Roche copies of all documents relevant to any such Handling of a Broad Range 4DMT Patent Right. 4DMT shall furnish such documents and consult with Roche in sufficient time before any
action by Roche is due to allow Roche to provide comments thereon, which comments 4DMT shall consider. At 4DMT’s reasonable request, Roche shall cooperate in all reasonable ways with the Handling of any 4DMT Patent Right. 

Notwithstanding anything to the contrary, Roche’s input into the Handling of any Primary Patent Right (if any) must be considered. 

  
 - 60 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 If Roche requests 4DMT file and prosecute a Broad Scope 4DMT Patent Right in countries where 4DMT does not
want to file, then Roche shall reimburse 4DMT for the costs of the Handling in such countries, and if 4DMT thereafter grants a license under such Patent Rights to Third Parties, then 4DMT shall assume responsibility for the expense of Handling such
rights in the future. 
 If the Party responsible for the cost of Handling of a given Broad Scope 4DMT Patent Right in a given country no longer desires to
pay for such Handling, it shall notify the other Party. The other Party may reply within [***] ([***]) days that it is willing to assume responsibility going forward for the costs associated with such Handling, or else the Party responsible for the
Handling may allow the Patent Right to become abandoned. 
 18.5 List of Licensed 4DMT Patent Rights 

Upon the written request of Roche (no more than [***] a year), 4DMT shall provide Roche an updated list (including anticipated or actual expiration dates) of
any Licensed 4DMT Patent Right that Roche does not Handle. 4DMT shall prepare such lists in good faith but shall not be liable for any omissions provided that such omissions shall not deprive Roche of its license to the applicable Licensed 4DMT
Patent Right in Section 4.1. Roche shall not be liable to 4DMT for any consequences resulting from Roche making over- or under-payment errors under Section 12 caused by reliance upon the information contained in such lists. 

18.6 Infringement 
 Each Party shall promptly provide
written notice to the other Party during the Agreement Term of any known infringement or suspected infringement by a Third Party of any Broad Range 4DMT Patent Right, and shall provide the other Party with all evidence in its possession supporting
such infringement or unauthorized use or misappropriation. 
 Within [***] ([***]) days after Roche provides or receives such written notice
(“Decision Period”), if the infringement is of a 
  

	a)	 Project Product Patent Right, or 

 

	b)	 a Primary Patent Right in a given country where either 

 

	 	1)	 with respect to a given Primary Patent Right in a given country, there is no other product Covered by such
Primary Patent Right that is on sale or in active clinical development by or on behalf of 4DMT, its Affiliates or their Third Party licensees or 

  

	 	2)	 there are no Roche Patent Rights that Covers a Product 

(such a Primary Patent Right, a “Key Primary Patent Right”), 

then Roche, in its sole discretion, shall decide whether or not to initiate such suit or action and shall notify 4DMT in writing of its decision in writing
(“Suit Notice”). 
 If Roche decides to bring a suit or take action on the infringement of a Project Product Patent Right or Key Primary
Patent Right, once Roche provides Suit Notice, Roche may immediately commence such suit or take such action. In the event that Roche (i) does not in writing advise 4DMT within the Decision Period that Roche will commence suit or take action, or
(ii) fails to commence suit or take action within a reasonable time after providing Suit Notice, 4DMT shall thereafter have the right (subject to Roche’s written consent, not to be unreasonably withheld) to commence suit or take action and
shall provide written notice to Roche of any such suit commenced or action taken by 4DMT. 

  
 - 61 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Other than any Project Product Patent Rights and Key Primary Patent Rights, 4DMT shall have the right to
enforce all other Full Range 4DMT Patent Rights against infringement, provided that for any Broad Range 4DMT Patent Right (a) 4DMT shall not do so against infringement in the Field without Roche’s advance written consent and (b) for
any Licensed 4DMT Patent Right, 4DMT shall reasonably consider allowing Roche to bring the enforcement action if there is no Project Product Patent Right, Key Primary Patent Right or other Roche Group-controlled Patent Right that can be asserted
against the infringement in the Field. 
 With respect to any Broad Range 4DMT Patent Right, upon written request, the Party bringing suit or taking action
(“Initiating Party”) shall keep the other Party informed of the status of any such suit or action and shall provide the other Party with copies, to the extent the Initiating Party is lawfully permitted to do so, of all substantive
documents or communications filed in such suit or action. In addition, (i) if the Project Product Patent Right or Key Primary Patent Right being asserted claims priority to any other Full Range 4DMT Patent Right that is not a Project Product
Patent Right, then Roche must confer with 4DMT as to strategy in advance (through counsel in such a manner as to maintain privilege) and reasonably consider 4DMT’s comments, and (ii) if the Broad Range 4DMT Patent Right (other than the
Project Product Patent Right or Key Primary Patent Right) claims priority to any Project Product Patent Right or Primary Patent Right, then 4DMT must confer with Roche as to strategy in advance (through counsel in such a manner as to maintain
privilege) and reasonably consider Roche’s comments. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or action. 

The Initiating Party shall, except as provided below, pay all expenses of the suit or action, including the Initiating Party’s attorneys’ fees and
court costs and the other Party’s reasonable costs associated with any assistance that they provide in the case. Any damages, settlement fees or other consideration received as a result of such suit or action shall be allocated as follows: 

 

	(a)	 First, to reimburse the Initiating Party for its costs and, if any remains, to the other Party for any advisory
counsel fees and costs that were not previously required to be reimbursed by the Initiating Party as provided for above in this Section; and 

  

	(b)	 Second, the balance, if any, shall be allocated as follows: 

 

	 	(i)	 where 4DMT is the Initiating Party by virtue of Roche declining to bring a suit or take action, [***] percent
([***]%) to 4DMT, and [***] percent ([***]%) to Roche, otherwise 

  

	 	(ii)	 [***] percent ([***]%) to Roche, and [***] percent ([***]%) to 4DMT. 

If the Initiating Party believes it is reasonably necessary or desirable to obtain an effective remedy, upon written request the other Party agrees to be
joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to the suit or action. At the Initiating Party’s written
request, the other Party shall offer reasonable assistance to the Initiating Party in connection therewith [***] to the Initiating Party except for [***]. The other Party shall have the right to participate and be represented in any such suit or
action by its own counsel [***]. All expenses of the non-Initiating Party under this paragraph shall be [***]. 

  
 - 62 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 The Initiating Party may settle, consent judgment or otherwise voluntarily dispose of the suit or action
(“Settlement”) without the written consent of the other Party but only if such Settlement can be achieved without adversely affecting the other Party (including any of its Patent Rights). If a Settlement could adversely affect the
other Party, then the written consent of the other Party would be required, which consent shall not be unreasonably withheld. 
 18.7 Defense 

If an action for infringement is commenced against either Party, its licensees or its sublicensees related to the discovery, development, manufacture, use or
sale of a Product, then Roche shall have the right (but not the obligation) to defend such action at its own expense, and 4DMT shall assist and cooperate with Roche, at Roche’s expense, to the extent necessary in the defense of such suit. Roche
shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion, so long as such settlement or adverse judgment does not adversely affect the rights of 4DMT and its Affiliates (including any patent rights
Controlled by any of them). Roche shall assume full responsibility for the payment of any award for damages, or any amount due pursuant to any settlement entered into by it with such Third Party. 

If the manufacture, use, importation, offer for sale or sale of any Product pursuant to this Agreement results in any claim, suit or proceeding alleging
patent infringement or trade secret misappropriation against 4DMT or a member of the Roche Group, then such Party shall promptly notify the other Party hereto. The Parties shall cooperate with each other in connection with any such claim, suit or
proceeding and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding. 
 If a Third
Party asserts that a Patent Right owned by or licensed to it is infringed by the development, manufacture, use, importation, offer for sale or sale of Products by a member of the Roche Group, or that its trade secrets were misappropriated in
connection with such activity, then Roche shall have the exclusive right and responsibility to resolve any such claim, whether by obtaining a license from such Third Party, by defending against such Third Party’s claims or otherwise, and shall
be solely responsible for the defense of any such action, any and all costs incurred in connection with such action (including, without limitation, attorneys’ and expert fees) and all liabilities incurred in connection therewith.
Notwithstanding the above, Roche shall not enter into any settlement of any such claim without the prior written consent of 4DMT if such settlement would require 4DMT to be subject to an injunction or to make any monetary payment to Roche or any
Third Party, or admit any wrongful conduct by 4DMT or its Affiliates, or would limit or restrict the claims of or admit any invalidity and/or unenforceability of any Patent Right Controlled by 4DMT, or have any impact on activities outside the
Field. 
 18.8 Common Interest Disclosures 
 With regard
to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that 

  
 - 63 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
they have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect Products, and have a further common legal interest in defending
against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to Products. Accordingly, the Parties agree that all such information and materials obtained by 4DMT and
Roche from each other will be used solely for purposes of the Parties’ common legal interests with respect to the conduct of the Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work
product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and
materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one
Party be deemed to apply against any other Party. 
 18.9 Patent Term Extensions 

The Parties shall use Commercially Reasonable Efforts to obtain all available patent term extensions, adjustments or restorations, or supplementary protection
certificates (“SPCs”, and together with patent term extensions, adjustments and restorations, “Patent Term Extensions”) with regards to any Project Product Patent Right (or, as may be applicable, any Primary Patent
Right). 4DMT shall execute such authorizations and other documents and take such other actions as may be reasonably requested by Roche to obtain such Patent Term Extensions, including designating Roche as its agent for such purpose as provided in 35
USC § 156. All filings for such Patent Term Extensions shall be made by [***]; provided, that in the event that [***] elects not to file for a Patent Term Extension, [***] shall (a) promptly inform [***] of its intention not to file
and (b) grant [***] the right to file for such Patent Term Extension. Each Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such extensions. The
Parties shall cooperate with each other in gaining patent term restorations, extensions and/or SPCs wherever applicable to such Project Product Patent Right and Primary Patent Right. Notwithstanding the foregoing, if the applicable Project Product
Patent Right claims priority to a Project Variant Patent, then 4DMT shall not be required to allow such Project Product Patent Right to be extended, but only if (a) Roche provides its consent or (b) the length of commercial exclusivity for
the applicable Product is not reduced. 
 19. Representations and Warranties 

19.1 By both Parties 
 19.1.1 Authorization 

Each Party hereby warrants and represents to the other that: 
  

	(a)	 it has full legal power and corporate authority to enter into this Agreement and perform its obligations
hereunder and has taken all corporate action required to authorize the execution, delivery and performance of this Agreement and the transactions contemplated hereby; 

  
 - 64 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(b)	 the execution, delivery and performance of this Agreement shall, upon the Effective Date, constitute a valid,
legal and binding agreement of such Party (assuming it constitutes a legal, valid and binding agreement of each other Party), enforceable against it in accordance with its terms; 

 

	(c)	 it is not a party to any contract, commitment or agreement, nor any of its properties and assets subject to or
bound or affected by any charter, by-law or other corporate restriction, or any order, judgment, decree, law, statute, ordinance, rule, regulation or other restriction of any kind or character, which would
prevent it from entering into this Agreement or from consummating the transactions contemplated hereby, and it shall not enter into any agreement with a Third Party that it knows will prevent or materially impede it from performing its obligations
hereunder; and 

  

	(d)	 the execution and delivery of this Agreement by it and the consummation of the transactions contemplated hereby
will not, currently or with the passage of time, (i) violate, or result in a default under any note, agreement, contract, understanding, arrangement, restriction or other instrument or obligation to which it is a party or by which it may be
bound; (ii) violate any order, award, injunction, judgment or decree to which it is subject; or (iii) infringe the contractual rights of any Third Party or cause it to be in breach of any undertakings to a Third Party.

 19.2 By 4DMT 
 19.2.1 Work Performed

 All work conducted pursuant to a Project Plan or the XLRP 4DMT Product Class Work Plan shall be performed by qualified personnel and in compliance
with applicable law. 
 19.2.2 Safety Data 
 With respect to
Products tested in the course of the Collaboration, Products associated with an Optionable 4DMT Product Class or Product associated with a Roche Product Class under development by Roche (to the extent known by 4DMT), 4DMT has disclosed to
Roche and will continue to disclose to Roche (i) the results of all preclinical testing and human clinical testing in its possession or control and (ii) all information in its possession or control concerning side effects, injury, toxicity
or sensitivity reaction and incidents or severity thereof with respect to such Products. 
 19.2.3 Grants 

To the best of 4DMT’s knowledge and belief as of the Effective Date, 4DMT has the lawful right to grant Roche and its Affiliates the rights and licenses
described in this Agreement, and no Third Party has any rights that would interfere with, conflict or limit 4DMT’s performance of any Collaboration Project. 

19.2.4 Ownership and Validity of Know-How 

The 4DMT Know-How is legitimately in the possession of 4DMT and has not been misappropriated from any Third Party. 4DMT
has taken reasonable measures to protect the confidentiality of the 4DMT Know-How. For any know-how or materials originating outside of 4DMT that 4DMT utilizes in
performance of a Project Plan or the XLRP 4DMT Product Class Work Plan, 4DMT has full rights to so utilize. 

  
 - 65 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 19.2.5 No Claims 

As of the Effective Date, there are no claims or investigations, pending or to 4DMT’s knowledge threatened against 4DMT or any of its Affiliates, at law
or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement. 
 19.2.6 No Conflict 

Neither 4DMT nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of this
Agreement or that would impede the fulfillment of 4DMT’s obligations hereunder. As of the Effective Date, 4DMT has granted no rights to any Third Party (i) in the Field for Products or (i) to treat the conditions known as
choroideremia or X-linked retinitis pigmentosa, and shall not do so except for 4DMT Product Classes that are Non-Optionable 4DMT Product Classes. 

19.2.7 Excluded Variant Availability 
 4DMT will not grant any new
rights or options (except as such rights and options exist on the Effective Date) to any person, contractual or otherwise, to Excluded Constructs and Excluded Products in the Field. Any Excluded Variant and the associated Excluded Construct and
Excluded Product that becomes no longer subject to Third Party rights or obligations in the Field after the Effective Date will be included in the rights and licenses as for Constructs and Products under this Agreement. 

19.3 Disclaimer 
 ROCHE AND 4DMT SPECIFICALLY DISCLAIM ANY
GUARANTEE THAT A COLLABORATION PROJECT OR WORK CONDUCTED UNDER THE XLRP 4DMT PRODUCT CLASS WORK PLAN WILL BE SUCCESSFUL, IN WHOLE OR IN PART. THE FAILURE OF THE PARTIES TO SUCCESSFULLY COMPLETE THE OBJECTIVES AND MILESTONES OF THE COLLABORATION
PROJECTS OTHER THAN IN BREACH OF THE TERMS HEREOF WILL NOT CONSTITUTE A BREACH OF ANY REPRESENTATION OR WARRANTY OR OTHER OBLIGATION UNDER THIS AGREEMENT. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, ROCHE AND THE COMPANY MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE PRODUCTS OR INFORMATION DISCLOSED HEREUNDER, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, VALIDITY OF PATENTED OR UNPATENTED RIGHTS, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 20. Indemnification and
Liability 
 20.1 Indemnification by Roche 
 Roche
shall indemnify, hold harmless and defend 4DMT and its directors, officers, employees and agents (“4DMT Indemnitees”) from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees,
witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts 4DMT or any 4DMT Indemnitee becomes legally obligated to pay (“4DMT Losses”) because of any action, actions, demand, demands, judgment,
judgments, claim or claims against it by a Third Party or Third Parties (“4DMT Claims”) to the extent that such 4DMT Claim(s) arise out of (a) Roche’s breach of this Agreement; and/or (b) activities related to the

  
 - 66 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
Licensed Products (for non-limiting examples, product liability claims and claims for liability arising out of clinical trials) conducted by or on behalf
of the Roche Group, including the research, development, manufacture, use, storage, shipment, distribution, marketing, promotion, or sale of Construct or Product by the Roche Group; except to the extent such 4DMT Losses are due to the gross
negligence, willful misconduct, failure to act or breach by 4DMT of this Agreement, or to the extent such Losses relate to the research, development, manufacture, use, storage, shipment, distribution, marketing, promotion, or sale of Construct or
Product by 4DMT, its Affiliates and sublicensees. 
 20.2 Indemnification by 4DMT 

4DMT shall indemnify, hold harmless and defend the Roche Group and their directors, officers, employees and agents (“Roche Indemnitees”) from
and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Roche or any Roche Indemnitee becomes legally
obligated to pay (‘Roche Losses”) because of any action, actions, demand, demands, judgment, judgments, claim or claims against it by a Third Party or Third Parties (“Roche Claims”) to the extent that such Roche
Claim(s) arise out of (a) the breach by 4DMT of this Agreement (including any breach of a representation or warranty), (b) activities related to Products for work conducted by or on behalf of 4DMT under a Project Plan while such Product
was associated with a Collaboration Product Class or for work conducted by 4DMT while such a Product was associated with an Optionable 4DMT Product Class, (c) activities related to Products in
Non-Optionable 4DMT Product Classes (for non-limiting examples, product liability claims and claims for liability arising out of clinical trials) conducted by or on
behalf of 4DMT or (d) the research, development, manufacture, use, storage, shipment, distribution, marketing, promotion, or sale of Construct or Product outside the Field by 4DMT or its collaborators or sublicensees, except to the extent such
Roche Losses are due to the gross negligence or willful misconduct or failure to act of Roche or the breach by Roche of this Agreement or to the extent such Losses relate to the research, development, manufacture, use, storage, shipment,
distribution, marketing, promotion, or sale of Construct or Product by Roche, its Affiliates and sublicensees. 
 20.3 Procedure 

In the event of a 4DMT Claim or a Roche Claim (each a “Claim”) against a Party (or its related Indemnitee) entitled to indemnification under
this Agreement (“Indemnified Party”), the Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the Claim and the Indemnifying Party shall undertake and solely manage and
control, at its sole expense, the defense of the Claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its choice
at its own expense. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party (or its related Indemnitee) without the Indemnifying Party’s written consent. The Indemnifying Party shall not
settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto (or the Indemnifying Party pays the liability not released), unless the Indemnified Party otherwise agrees in
writing. 

  
 - 67 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 20.4 Insurance 

For as long as there is a Collaboration Product Class or an Optionable 4DMT Product Class, and for [***] thereafter, 4DMT will secure and maintain
insurance of commercial general liability with limits of at least [***] U.S. dollars ($[***]) per occurrence and [***] U.S. dollars ($[***]) in the aggregate, plus an umbrella policy for [***] U.S. dollars ($[***]) per occurrence and in the
aggregate, workers’ compensation insurance as required by law, and employers’ liability insurance with limits of at least [***] U.S. dollars ($[***]) per accident and a [***] U.S. dollars ($[***]) disease policy limit, and shall provide a
certificate evidencing such insurance upon the request of Roche (which may not be made more than [***] per year). 
 20.5 Disclaimer 

EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED WITH RESPECT TO THIS
AGREEMENT. NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER. 

21. Obligation Not to Disclose Confidential Information 

21.1 Non-Use and Non-Disclosure 

During the Agreement Term and for [***] ([***]) years thereafter, a Receiving Party shall (i) treat Confidential Information provided by Disclosing Party
as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third Parties, without the Disclosing Party’s prior written consent, and (iii) not use
such Confidential Information other than for fulfilling its obligations under this Agreement. 
 21.2 Permitted Disclosure 

Notwithstanding the obligation of non-use and non-disclosure set forth in
Section 21.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations. 

21.3 Press Releases 
 Prior to the first Initiation of a
Phase I/IIa Study, neither Party shall issue a press release announcing the existence of this Agreement without written consent of the other Party. Thereafter: 
  

	(a)	 Roche shall issue press releases in accordance with its internal policy that typically does not issue a press
release until [***]. Roche shall provide 4DMT with a copy of any draft press release related to the activities contemplated by this Agreement at least [***] ([***]) weeks prior to its intended publication for 4DMT’s review. 4DMT may provide
Roche with suggested modification to the draft press release. Roche shall consider 4DMT’s suggestions in issuing its press release, and if requested by 4DMT, shall remove any 4DMT Confidential Information. 

  
 - 68 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(b)	 4DMT shall only issue press releases related to the activities contemplated by this Agreement that have either
(i) been approved by Roche or (ii) are required to be issued by 4DMT as a matter of law and 4DMT has a competent legal opinion to that effect. In all circumstances, 4DMT shall provide Roche with a draft press release at least [***] ([***])
weeks prior to its intended publication for Roche’s review. During such period, Roche shall (i) approve the draft press release and permit 4DMT to issue the press release, (ii) contact 4DMT to discuss modification to the draft press
release, or (iii) contact 4DMT and disapprove the press release. If Roche asks for modification, then 4DMT shall either make such modification or work with Roche to arrive at a press release that Roche approves. If 4DMT issues a press release
without Roche’s approval, then 4DMT must obtain a competent legal opinion that the release was required to be issued by 4DMT as a matter of law. 

21.4 Commercial Considerations 
 Nothing in this Agreement
shall prevent Roche or its Affiliates from disclosing Confidential Information of 4DMT to (i) governmental agencies to the extent required or desirable to secure government approval for the development, manufacture or sale of Licensed Products
in the Field, (ii) Third Parties acting on behalf of Roche, to the extent reasonably necessary for the development, manufacture or sale of Licensed Products in the Field, (iii) Third Parties requesting clinical trial data information (in
accordance with Roche’s then-current data sharing policy) or (iv) Third Parties to the extent reasonably necessary to market Licensed Products in the Field or by 4DMT to Third Parties in furtherance of 4DMT’s activities and retained
rights outside the Field and retained rights for Non-Optionable 4DMT Product Classes within the Field. The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such
Confidential Information is required to be disclosed by the Receiving Party to comply with Applicable Law, to defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice
of such disclosure to the Disclosing Party and, to the extent practicable, takes reasonable and lawful actions to minimize the degree of such disclosure. 

4DMT may disclose the results of the Collaboration as follows: 
  

	(a)	 subject to Roche’s prior written approval which shall not unreasonably be withheld, in presentations
prepared for investors and/or prospective investors, 4DMT may disclose de-identified data (including de-identified results generated under the Collaboration with regard to Variants identified or tested under
the Collaboration), and 

  

	(b)	 to Third Parties in furtherance of 4DMT’s activities and retained rights outside the Field and retained
rights for Non-Optionable 4DMT Product Classes within the Field. 

 21.5 4D Materials 

The Roche Group shall use any and all biological materials received from 4DMT under the RFO Agreement or this Agreement, and any progeny and derivatives
thereof, solely within the scope of its licenses in Article 4, and shall only transfer them to Third Parties as necessary for the research, development, manufacture, and commercialization of Licensed Constructs and Licensed Products for the
Field and subject to reasonable obligations of confidentiality and limited use (limited to Licensed Constructs and Licensed Products for the Field). 

  
 - 69 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 22. Term and Termination 

22.1 Commencement and Term 
 This Agreement shall commence
upon the Effective Date and continue for the Agreement Term. 
 22.2 Termination 

22.2.1 Termination for Breach 
 A Party (“Non-Breaching Party”) shall have the right to terminate this Agreement in its entirety or on a country-by-country basis in the
event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement. The non-Breaching Party shall provide written notice to the Breaching Party,
which notice shall identify the breach and the countries in which the Non-Breaching Party intends to have this Agreement terminate. The Breaching Party shall have a period of ninety (90) days after such
written notice is provided (“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a bona fide dispute as to whether such breach occurred or has been cured, it will so notify the Non-Breaching Party, and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section 25.2. Upon a determination of breach or failure to cure, the Breaching
Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching Party’s
request for termination, this Agreement shall terminate in its entirety or such identified countries effective as of the expiration of the Peremptory Notice Period. 

22.2.2 Termination by Roche without a Cause 
 Roche shall have the
right to terminate this Agreement at any time, in whole or on a Licensed Product-by-Licensed Product, Product Class-by-Product Class or country-by-country basis upon ninety (90) days prior written notice. The effective date of
termination under this Section 22.2.2 shall be the date the date ninety (90) days after Roche provides such written notice to 4DMT. 
 22.3
Consequences of Termination 
 22.3.1 Termination by 4DMT for Breach by Roche, by Roche without a Cause or under Sections 5.4 or 5.5 

Upon any termination by 4DMT for breach by Roche, by Roche without a cause, or in accordance with Sections 5.4 or 5.5, the rights and licenses granted by
4DMT to Roche under this Agreement (except any that are fully paid-up and royalty free) shall terminate in their entirety or on a
country-by-country, Licensed Product-by-Licensed Product or Product Class-by-Product Class basis, as applicable, on the effective date of termination. If the Agreement is being terminated as a whole, then Status of any Roche Product Class
(except where licenses are fully paid-up and royalty free) will change to a 4DMT Product Class and 4DMT will have no diligence obligations to Roche for Products associated with a 4DMT Product Class. If
the Agreement is being terminated on a Product Class-by-Product Class basis, then the Status of the Product Class associated with such Product Class will
be deemed as an Available Product Class, however subject to additional change of Status in the case of a Continuation Election Notice in accordance with (f) below. If the Agreement is being terminated

  
 - 70 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
on a country-by-country or Licensed
Product-by-Licensed Product basis, then the Parties will work in good faith to agree how to equitably apportion the Status of any applicable Product
Class associated with the Continuation Election Notice as between a Roche Product Class and Available Product Class, subject to additional change of Status in the case of a Continuation Election Notice in accordance with (f) below.

 If 4DMT desires to continue development and/or commercialization of such terminated (or
soon-to-be terminated, as applicable) Licensed Product(s), 4DMT shall give a Continuation Election Notice to Roche within [***] ([***]) days of 4DMT’s notice of
termination for breach by Roche, within [***] ([***]) days of receipt of Roche’s notice of termination for Cause, or within [***] ([***]) days of the effective date of termination of rights under Sections 5.4 or 5.5. If Roche receives such
a timely Continuation Election Notice, and (i) subject to the payments under Article 17 and (ii) to the extent reasonably requested by 4DMT for Product(s) no longer subject to the license grant under Section 4.1: 

 

	(a)	 After the effective date of termination Roche shall, to the extent Roche has the right to do so, and 4DMT does
not decline — after being queried and allowed a reasonable opportunity to review the future obligations associated with the following items — to accept in writing the assignment or transfer: assign and transfer to 4DMT all regulatory
filings and approvals, all final pre-clinical and clinical study reports and clinical study protocols, and all test data, including clinical data, in Roche’s possession and control for such Product(s) in
the country necessary for 4DMT to continue to develop and commercialize the Product(s). All data shall be transferred in the form and format in which it is maintained by Roche. Original paper copies shall only be transferred if legally required.
Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to 4DMT. 

  

	(b)	 With respect to a given clinical trial agreement that has not been cancelled and is assignable without Roche
paying any consideration or commencing litigation in order to effect an assignment thereof, 4DMT may request (within [***] ([***]) days after receipt of a copy thereof) that such agreement be assigned to 4DMT and Roche shall take such actions
necessary to effect such assignment. To the extent not assignable, Roche shall be under no obligation to continue ongoing clinical trials unless 4DMT agrees in writing to reimburse Roche’s expenses for such; and irrespective of the foregoing,
Roche shall be under no obligation to continue ongoing clinical trials if Roche deems they should be discontinued for safety or efficacy reasons, and Roche shall be under no obligation to recruit or enroll new patients after the effective date of
termination. 

  

	(c)	 4DMT shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental
agencies of the country to the extent required or desirable to secure government approval for the development, manufacturing or sale of Product(s) in the country, (ii) Third Parties acting on behalf of 4DMT, its Affiliates or licensees, to the
extent reasonably necessary for the development, manufacture, or sale of Product(s) in the country, and (iii) Third Parties to the extent reasonably necessary to market Product(s) in the country. 

  
 - 71 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(d)	 4DMT shall own, and Roche shall assign ([***]), and effective upon the applicable termination hereby assigns,
its ownership rights in and under, any Project Product Patent Right that no longer Covers Product Classes that are still subject to the license grant under Section 4.1, except that Roche shall be under no obligation to make such assignment if
the Project Product Patent Right shares priority with a Project Product Patent Right that Covers Product Classes still subject to the license grant under Section 4.1 (however Section 4.4 shall apply). For such assignment, Roche agrees to
execute and deliver all documents and instruments reasonably requested 4DMT to evidence or record such assignment or to file, prosecute, enforce, or extend the assigned rights, and appoints 4DMT as attorney-in-fact to execute and deliver the foregoing if 4DMT is unable to obtain the foregoing after making reasonable inquiry. 

 

	(e)	 Roche shall grant 4DMT a non-exclusive, sublicensable, royalty-bearing
license under any Roche Patent Right and such Know-How as Roche provides, under this Section 22.3.1 solely to the extent necessary to allow 4DMT, its Affiliates or licensees to develop, manufacture, have
manufactured, use, offer to sell, sell, promote, export and import the applicable Product(s) in the Field in the applicable country(ies). For clarity, the license under this Section 22.3.1(e) shall not include any licenses that Roche has with a
Third Party for which such grant would be prohibited or under which a member of the Roche Group would incur financial or legal liability obligations to such Third Party. 

 

	(f)	 If the Agreement is being terminated on a Product Class-by-Product Class basis, then the Status of the Product Class associated with the Continuation Election Notice will be deemed as a 4DMT Product Class that is a Non-Optionable 4DMT Product Class. If the Agreement is being terminated on a country-by-country or Licensed Product-by-Licensed Product basis, then the Parties will work in good faith to agree how to equitably apportion the Status of the applicable Product Class associated with
the Continuation Election Notice. 

 22.3.2 Termination by Roche for Breach by 4DMT 

Upon any termination by Roche for breach by 4DMT, Roche and its Affiliates may upon notice retain all rights and licenses granted to Roche by 4DMT under this
Agreement; provided that Roche’s payment obligations shall survive, and Roche’s diligence obligations within the scope of the termination shall not survive, and the Parties will agree upon an appropriate reduction (if any) in payments
otherwise due under Article 12 commensurate with the scope and nature of the breach. 
 22.3.3 Direct License 

Irrespective of anything to the contrary in this Agreement, any existing, permitted sublicense granted by Roche under Section 4.2 of this Agreement (and
any further sublicenses thereunder) shall, upon the written request of Roche, remain in full force and effect, provided that (i) such Sublicensee is not then in breach of its sublicense agreement (and, in the case of termination by 4DMT for
breach by Roche, that such Sublicensee and any further sublicensees did not cause the breach that gave rise to the termination by 4DMT); and (ii) and such Sublicensee agrees to be bound to 4DMT under the terms and conditions of such sublicense
agreement; and (iii) such terms and conditions of such sublicense agreement impose no greater obligation on 4DMT than this Agreement. 

  
 - 72 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 22.3.4 Other Obligations 

22.3.4.1 Obligations Related to Ongoing Activities 
 After the
effective date of termination, Roche shall have the right to complete any on-going studies that are non-cancellable for contractual or patient safety reasons. 

22.3.4.2 Obligations Related to Manufacturing 
 In the case of
termination by 4DMT for breach by Roche or by Roche without a cause, if 4DMT elects to develop the applicable terminated (or soon-to-be terminated) Licensed Product(s)
inside the Field, the following shall apply with respect to the applicable Product(s): 
  

	a)	 Clinical Supplies 

If requested by 4DMT prior to [***] after the effective date of termination, Roche will notify 4DMT of the amount of all existing and available
clinical material under its Control and Roche’s fully burdened manufacturing cost for such material. If 4DMT notifies Roche within [***] thereafter that it is willing to reimburse Roche for such costs, then Roche shall transfer such materials
to 4DMT and 4DMT shall assume all liability for the use of such material. Roche shall have no obligation to perform any additional activities concerning the clinical supplies (e.g. retesting, analyses). 

 

	b)	 Commercial Supplies 

If a Product is marketed by Roche or Roche’s Affiliates in any country on the date of the notice of termination of this Agreement, upon
the request of 4DMT, Roche shall manufacture and supply such Product to 4DMT for a period that shall not exceed [***] from the effective date of the termination of this Agreement at a price to be agreed by the Parties in good faith. 4DMT shall use
Commercially Reasonable Efforts to take over the manufacturing as soon as possible after the effective date of termination. 
 If, however,
Roche elects not to provide the Know-How described in Section 22.3.4.3(c) and such Know-How is critical to the manufacture of commercialized Product(s), then Roche
shall continue to supply 4DMT (i) indefinitely (on terms to be negotiated) or (ii) until such time as Roche can transfer the process to a third party CMO acceptable to both Parties. 

22.3.4.3 Limitations on Grant-Backs; Transfer Expenses 
 For
purposes of clarity, irrespective of anything to the contrary in this Agreement: 
  

	(a)	 All transfers and licenses from Roche to 4DMT or other obligations of Roche under Section 22.3 are solely
with respect to Product(s) that are not Licensed Combination Product(s), and are solely for the use in the Field. Such transfers, licenses and obligations do not extend to other therapeutically active ingredients or products, even if physically
mixed, combined or packaged together with a Product, and even if a Product is intended (according to the investigation plan, proposed labeling or actual labeling, as applicable) for use with such other therapeutically active ingredients or products.

  
 - 73 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	(b)	 In connection with research studies or clinical trials, Roche may have collected human samples and related
clinical information for additional limited research and development programs (“Samples”). Legal and contractual restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. 4DMT
acknowledges and accepts that notwithstanding anything herein, Roche shall not be obliged to transfer any such Samples to 4DMT. 

  

	(c)	 With respect to Product(s) that are biologics, Roche shall be under no obligation to provide proprietary cell
lines, growth media, culture media, or disclose proprietary technical development/manufacturing know-how; provided that if such Know-How is necessary to continue the
development or commercialization of the applicable Product, then Roche shall provide such services for 4DMT on reasonable terms to be negotiated between the Parties (not to exceed Roche’s fully burdened manufacturing costs (calculated on a
basis consistent with how the Roche was determining these fully burdened manufacturing costs prior to provision of the notice of termination) for the Product plus [***] percent ([***]%) plus any incremental costs incurred which are not reflected in
the fully burdened manufacturing costs for changing to 4DMT specifications) or shall enable a third party contracting organization acceptable to both Parties to perform such activities. 

 

	(d)	 Nothing in this Agreement shall be construed as granting 4DMT any license under the Excluded Patent Rights.

  

	(e)	 Except if the termination results from a Roche uncured material breach of this Agreement: [***] for transfer
activities from Roche to 4DMT under Sections 22.3.1 and 22.3.4 (“Roche Transfer Activities”); however transfer activities corresponding to the return of material remains, data, reports, records, documents, Regulatory Filings and
Regulatory Approvals originally provided by 4DMT to Roche no less than [***] from the effective date of termination (“4DMT-Originated Transfer Activities”) shall be [***]. If 4DMT desires Roche Transfer Activities other than
4DMT-Originated Transfer Activities, 4DMT shall make a payment to Roche of [***] US Dollars (US$ [***]) (“Minimum Transfer Payment”). The Minimum Transfer Payment shall be non-refundable, but shall be fully creditable against
4DMT’s reimbursement for the Roche Transfer Activities. Roche shall be under no obligation to provide Roche Transfer Activities (beyond than 4DMT-Originated Transfer Activities) prior to receipt of the Minimum Transfer Payment or if the Minimum
Transfer Payment is received later than [***] ([***]) days after the effective date of the termination. 

 22.3.4.4 Royalty and Payment
Obligations (including early termination of a Project Plan) 
 Termination of this Agreement by a Party, for any reason, shall not release Roche from any
obligation to pay royalties or make any payments to 4DMT that are payable prior to the effective date of termination. Termination of this Agreement by a Party, for any reason, will release Roche from any obligation to pay royalties or make any
payments to 4DMT that would otherwise become payable on or after the effective date of termination. Notwithstanding the foregoing, if termination of this Agreement results in early termination of an ongoing Project Plan, then Section 3.4
applies. 

  
 - 74 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 22.4 Survival 

Article 17 (Payments to Roche), Article 20 (Indemnification and Liability), Article 21 (Obligation Not to Disclose Confidential Information),
Article 22 (Term and Termination), Section 25.1 (Governing Law) and Section 25.3 (Arbitration) shall survive any expiration or termination of this Agreement for any reason. 

23. Bankruptcy 
 All licenses (and to the extent applicable
rights) granted under or pursuant to this Agreement by 4DMT to Roche are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to
“intellectual property” as defined under Section 101(60) of the Bankruptcy Code. Unless Roche elects to terminate this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall
retain and may fully exercise all of its rights and elections under the Bankruptcy Code, subject to the continued performance of its obligations under this Agreement. 

24. Change of Control 
 In the event that there is a Change
of Control then the following provisions shall apply and be in full force and effect. 
  

	(a)	 4DMT shall provide written notice to Roche at least [***] ([***]) days prior to the completion of such Change
of Control, subject to any confidentiality obligations of 4DMT then in effect (but in such even shall so notify Roche within [***] ([***]) days after completion of such Change of Control). 

 

	(b)	 The Change of Control Group in connection with such Change of Control (for clarity, other than 4DMT and its
Affiliates in existence prior to the effectuation of such Change of Control) shall agree in writing with Roche that it will not utilize any 4DMT Know-How or Patent Rights during the Agreement Term for the
research, development or commercialization of any Product in the Field. 

  

	(c)	 If the Change of Control Group had collective worldwide sales of pharmaceutical products in the Calendar Year
that preceded the year in which the Change of Control was completed of [***] US Dollars (US$ [***]) or more, 4DMT may not designate a Product Class as a 4DMT Product Class without the written consent of Roche. 

 

	(d)	 Roche shall have the right in its sole discretion, at Roche’s election exercised within [***] ([***])
months following the Change of Control to unilaterally implement some or all of the following: 

  

	 	(i)	 terminate any or all Collaboration Projects effective immediately without obligation to pay 4DMT for FTEs
budgeted by 4DMT, or non-cancellable commitments to outside vendors, that become due after the termination date (and if the Collaboration Project is Choroideremia, without the requirement to reimburse 4DMT for
costs associated with process and formulation development and manufacture of Licensed Product used under the Project Plan (including the Choroideremia GMP Lot) under Section 8(a)), and either change the Status of such associated Collaboration
Product Class to a Roche Product Class that is not a Collaboration Product Class or to an Available Product Class. 

  

	 	(ii)	 change the Status of any Optionable 4DMT Product Class to a Roche Product Class that is not a
Collaboration Product Class effective immediately upon written notice; 

  

	 	(iii)	 terminate and/or restrict 4DMT’s participation on the JSC, including any rights 4DMT may have in future
decision making with respect thereto; 

  
 - 75 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

	 	(iv)	 limit 4DMT’s and/or the Change of Control Group’s rights to receive any Roche information with
respect to the development or commercialization of Licensed Products under this Agreement, including royalty reports, to period high level summary reports that may only be shared at a senior level within 4DMT or such Change of Control Group, and

  

	 	(v)	 require 4DMT and the Change of Control Group, following consummation of such Change of Control transaction, to
adopt reasonable procedures to be agreed upon in writing with Roche to prevent the disclosure of all Confidential Information disclosed by Roche including information about the development or commercialization of Licensed Products by Roche
(“Sensitive Information”) beyond 4DMT personnel having access to and knowledge of Sensitive Information prior to the Change of Control and to control the dissemination of Sensitive Information disclosed after the Change of Control
within the Change of Control Group. The purposes of such procedures shall be to strictly limit such disclosures to only those personnel having a need to know Sensitive Information in order for 4DMT (and the Change of Control Group) to perform its
obligations under the Agreement and to prohibit the use of Sensitive Information for competitive reasons that would be detrimental to Roche’s interests under the Agreement and/or Licensed Products, including without limitation, the use of
Sensitive Information for the development or commercialization of products in the Field by the Change of Control Group. 

 25.
Miscellaneous 
 25.1 Governing Law 
 This Agreement
shall be governed by and construed in accordance with the laws of the state of California, without reference to its conflict of laws principles. 
 25.2
Disputes 
 Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred
to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows: 

For 4DMT: [***] 
 For Roche:
[***] 
 25.3 Arbitration 
 Should the Parties fail to
agree within [***] after such dispute has first arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association (AAA) as in force at the time when initiating the arbitration. The tribunal shall
consist of three arbitrators. The place of arbitration shall be San Francisco, California. The language to be used shall be English. 
 25.4 Assignment

 Neither Party may assign its rights or obligations under this Agreement absent the prior written consent of the other Party, except to any of its
Affiliates or in the context of a merger, acquisition, sale or other transaction involving all or substantially all of the assets of the Party seeking to assign, 

  
 - 76 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
in which case such Party in its sole discretion may assign its rights and obligations under this Agreement. In addition, 4DMT may assign its rights to receive payments under Article 12 of
this Agreement in whole or in part to another entity, provided that 4DMT provides Roche a copy of such assignment and remains responsible and liable for all obligations under this Agreement. Any permitted assignment shall be binding on the
successors of the assigning Party. 
 25.5 Debarment 

4DMT represents and warrants that neither 4DMT nor 4DMT’s employees have ever been debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R.
§312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or
debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event 4DMT or an employee of 4DMT receives notice of debarment, suspension, sanction, exclusion, ineligibility or
disqualification under the above-referenced statutes, 4DMT shall immediately notify Roche in writing and Roche shall have the right, but not the obligation, to terminate this Agreement for breach, effective, at Roche’s option, immediately or at
a specified future date. 
 25.6 Anti-Bribery 
 4DMT
shall procure that its officers, workers, agents and any other persons who perform activities for or on behalf of it in connection with this Agreement shall: 
  

	(a)	 not commit any act or omission which causes or could cause it or Roche or any member of the Roche Group to
breach, or commit an offence under, any laws relating to anti-bribery and/or anti-corruption; 

  

	(b)	 keep accurate and up to date records showing all payments made and received and all other advantages given and
received by it in connection with this Agreement and the steps it takes to comply with this Section and permit Roche or any member of the Roche Group to inspect those records as required; 

 

	(c)	 promptly notify Roche of: (i) any request or demand for any financial or other advantage received by it;
and (ii) any financial or other advantage it gives or intends to give whether directly or indirectly in connection with this Agreement; and (iii) promptly notify Roche of any breach of this clause. 

Roche may terminate this Agreement immediately by giving written notice to that effect to the 4DMT if the 4DMT is in breach of this Section. 

25.7 Product Class 
 Expect as specifically indicated to
the contrary, wherever this Agreement refers to conditions applicable to a Product Class with a given Status (i.e. Roche Product Class, 4DMT Product Class and Available Product Class) and a further subcategory of a Status (e.g. Optionable
4DMT Product Class, Collaboration Product Class, Optioned Product Class), such conditions apply only while such Product Class maintains such Status or the subcategory of a Status. 

  
 - 77 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 25.8 Independent Contractor 

No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner
whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and not- withstanding any other provision of this
Agreement to the contrary, 4DMT legal relationship to Roche under this Agreement shall be that of independent contractor. 
 25.9 Unenforceable Provisions
and Severability 
 If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be
replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement will remain in full force and effect, provided that the material interests of
the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 
 25.10 Waiver

 The failure by either Party to require strict performance and/or observance of any obligation, term, provision or condition under this Agreement will
neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not
constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
 25.11 Interpretation 

As used in this Agreement, “include,” “includes,” “including,” and all other conjugations of the verb “to include”
shall be deemed followed by “without limitation.” 
 25.12 Appendices 

All Appendices to this Agreement shall form an integral part to this Agreement. 

25.13 Entire Understanding 
 This Agreement, the Memo and
the RFO Agreement contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral. Any payments potentially
due from 4DMT to Roche under the RFO Agreement (for example, for Enabled Products as such term is defined therein) are no longer required and will not be made. 

25.14 Amendments 
 No amendments of the terms and
conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both Parties. 

  
 - 78 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 25.15 Notice 

All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (to Roche) or by email (to
4DMT) (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as
follows: 
  

			
	 if to 4DMT, to:
	  	 4D Molecular Therapeutics Inc.
 5980 Horton
Street, Suite 460
 Emeryville, California 94608
 USA

Attn: [***]
 Email: [***]

		
	 if to Roche, to:
	  	 F. Hoffmann-La Roche Ltd

Grenzacherstrasse 124
 4070 Basel

Switzerland
 Attn: Legal Department

Facsimile No.: [***]

		
	 and:
	  	 Hoffmann-La Roche Inc.

150 Clove Road
 Suite 8

Little Falls, New Jersey 07424
 U.S.A.

Attn. Corporate Secretary
 Facsimile No.: [***]

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 
 [Signature Page Follows] 

  
 - 79 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

	
	4D Molecular Therapeutics Inc.
	
	/s/ David Kirn
	Name: David Kirn
	Title: CEO

  

					
	F. Hoffmann-La Roche Ltd	 		 	
			
	 /s/ Dr. Andreas Hohn
	 		 	 /s/ Dr. Melanie Wick

	Name: Dr. Andreas Hohn	 		 	Name: Dr. Melanie Wick
	Title: Vice Director	 		 	Title: Authorized Signatory

  

	
	Hoffmann-La Roche Inc.
	
	/s/ John P. Parise
	Name: John P. Parise
	Title: Authorized Signatory

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Appendix 1.103 

Excluded Patent Rights 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Appendix 2.3.1 

Initial XLRP 4DMT Product Class Work Plan 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Appendix 3.2.1 

Initial Project Plan for Choroideremia 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Appendix 3.3 

Project Plan Template 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Project Plan Attachment 1 

Collaboration Project Activities 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Project Plan Attachment 2 

Timelines 
 Omitted pursuant
to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Project Plan Attachment 3 

Budget 
 Omitted pursuant to
Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Appendix 6.2 

Minimum Program Transfer 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Appendix 14.4 

Sample Royalty Report Template 

Omitted pursuant to Regulation S-K, Item 601(a)(5).EX-10.6

 Exhibit 10.6 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not
material and would likely cause competitive harm to the registrant if publicly disclosed. 
 Execution Copy 

8-6-2019 

CONFIDENTIAL 
 AMENDED AND
RESTATED 
 COLLABORATION AND LICENSE AGREEMENT 

BY AND BETWEEN 
 4D
MOLECULAR THERAPEUTICS, INC 
 AND 

UNIQURE BIOPHARMA B.V. 

August 6, 2019 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

AMENDED AND RESTATED 

COLLABORATION AND LICENSE AGREEMENT 

This Amended and Restated Collaboration and License Agreement (this “Agreement”) is entered into on and has an effective date
of August 6, 2019, (the “Amended CLA Effective Date”) and amends and restates the original Collaboration and License Agreement (the “Original Agreement”), dated January 17, 2014 (the “Original CLA
Effective Date” or “Effective Date”), by and between 4D Molecular Therapeutics, Inc, a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 5858 Horton St,
Emerystation North, Suite 460, Emeryville, CA 94608 (“4DMT”) (the original 4DMT party to the Agreement was 4D Molecular Therapeutics, LLC, a Delaware limited liability corporation that is now the entity defined as 4DMT in the
foregoing), and uniQure biopharma B.V., a corporation organized and existing under the laws of The Netherlands and having a principal office located at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands (“uniQure”). The Original
Agreement shall govern the rights between the parties for the period from the Original CLA Effective Date to, but excluding, the Amended CLA Effective Date, subject to any releases or other retrospective rights or obligations expressly provided in
this Agreement. 
 INTRODUCTION 

1. 4DMT is a biopharmaceutical company focused on research, development, manufacturing and marketing of novel adeno-associated viral vectors
for delivery of nucleic acids to target cells. 
 2. uniQure is a biopharmaceutical company focused on the research, development,
manufacturing and marketing of gene therapy based biopharmaceutical products. 
 3. 4DMT and uniQure desire to conduct a research
collaboration to identify improved AAV Capsid Variants (as defined below). 
 4. 4DMT and uniQure now desire to amend, modify and restate the
Original Agreement in its entirety via this Agreement, and 4DMT and uniQure are entering into a new Collaboration and License Agreement to be effective of even date herewith (the “New CLA”), pursuant to which, 4DMT and uniQure will pursue
a new collaboration in which 4D will take the lead for the identification of novel AAV Capsid Variants for development and commercialization as therapeutic products in the Field and pursuant to the terms and conditions thereunder, and, through the
execution of this Agreement and the New CLA, the Parties have resolved the matters that were referred to and described in correspondence between the Parties dated February 28, 2019 with respect to the Original Agreement. 

5. uniQure desires to receive from 4DMT exclusive rights under 4DMT’s intellectual property rights to research (subject to 4DMT’s
retained rights to conduct research under the Research Program), Develop, manufacture and Commercialize Selected Capsid Variants, Royalty Bearing Compounds and Royalty Bearing Products in the Field (each as defined below) pursuant to this Agreement,
subject to 4D’s non-exclusive rights with respect thereto as described next. 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 6. 4DMT desires to receive from uniQure non-exclusive
rights under uniQure’s intellectual property rights (including uniQure’s rights in intellectual property generated by 4D under this Agreement) to research, Develop, manufacture and Commercialize 4DMT Proposed Products as Royalty Bearing
Compounds and Royalty Bearing Products in the Field (each as defined below) pursuant to this Agreement. 
 NOW, THEREFORE, in consideration
of the mutual covenants contained herein, and other good and valuable consideration, the receipt of which is hereby acknowledged, 4DMT and uniQure agree as follows effective as of the Effective Date: 

ARTICLE I 

DEFINITIONS 

Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective
meanings set forth below: 
 1.1 “4DMT AAV Capsid Variant”. 4DMT Capsid Variant means any AAV Capsid Variant that does not
carry a Gene Therapy Construct contained in a Royalty Bearing Compound or Royalty Bearing Product. 
 1.2 “4DMT AAV Capsid Variant
Library”. 4DMT AAV Capsid Variant Library means any AAV Capsid Variant Library constructed by or licensed to 4DMT, including all AAV Capsid Variant Libraries provided to 4DMT pursuant to the UCB Agreements. 

1.3 “4DMT Intellectual Property”. 4DMT Intellectual Property means the 4DMT Know-How
and the 4DMT Patent Rights. 
 1.4 “4DMT Know-How”. 4DMT Know-How means Know-How that is (a) Controlled by 4DMT or its Affiliates as of the Effective Date or during the Research Term, and (b) necessary or useful to conduct
the Research Program or to research, Develop, make and have made, use or Commercialize the relevant Selected Capsid Variant, or a Royalty Bearing Compound or Royalty Bearing Product due to the presence of such Selected Capsid Variant therein. 4DMT Know-How includes Core 4DMT Know-How but does not include Joint Know-How. 

1.5 “4DMT Patent Right”. 4DMT Patent Right means any Patent Right Controlled by 4DMT or its Affiliates as of the Effective
Date or during the Term that Covers 4DMT Know-How. Schedule 1.5 lists the 4DMT Patent Rights existing as of the Effective Date. 4DMT Patent Rights include Core 4DMT Patent Rights but do not include
Joint Patent Rights. 
 1.6 “AAV”. AAV means adeno-associated virus. 

1.7 “AAV Capsid Variant”. AAV Capsid Variant means an AAV capsid that is modified as compared to the wild type sequence. 

  
 - 2 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.8 “AAV Capsid Variant Library”. AAV Capsid Variant Library means a
collection of variant AAV capsid open reading frames inserted into an AAV genome in a manner that renders such variants genome replication-competent with the appropriate helper virus functions and capable of being selected and evolved to optimize
their ability to deliver nucleic acid sequences to human or animal cells. 
 1.9 “Accounting Standards”. Accounting
Standards means, with respect to uniQure and its Affiliates, International Financial Reporting Standards (“IFRS”) or, to the extent applicable, generally accepted accounting principles as practiced in the United States
(“GAAP”), and with respect to 4DMT and its Affiliates, GAAP, in each case as they exist from time to time, consistently applied. 

1.10 “Affiliate”. Affiliate means, with respect to a Party, any entity that directly or indirectly controls, is controlled by,
or is under common control with such Party. As used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity,
whether through ownership of voting securities, by contract or otherwise. For purposes of this definition, “control” shall be presumed to exist if one of the following conditions are met: (a) in the case of corporate entities, direct
or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate entities, direct or indirect
ownership of more than fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. 

1.11 “Animal POC”. Animal POC means gene expression and/or gene function, in an animal model, of the transgene cassette that
defines the relevant potential Product. 
 1.12 “Business Day”. Business Day means a day that is not a Saturday, Sunday or a
day on which banking institutions in New York, New York, USA or Amsterdam, The Netherlands are authorized by Law to remain closed. 
 1.13
“Calendar Quarter”. Calendar Quarter means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, however, that
the first Calendar Quarter hereunder shall commence on the Effective Date and the final Calendar Quarter hereunder shall end on the effective date of termination or expiration of this Agreement. 

1.14 “Calendar Year”. Calendar Year means each successive period of twelve (12) months commencing on
January 1 and ending on December 31; provided, however, that the first Calendar Year hereunder shall commence on the Effective Date and the final Calendar Quarter hereunder shall end on the effective date of termination or
expiration of this Agreement. 
 1.15 “Candidate Success Criteria”. Candidate Success Criteria means the criteria that an
AAV Capsid Variant identified through a Research Selection Process (or any Research Compound containing such AAV Capsid Variant) must meet before it progresses to the next stage of the Research Program, as determined and approved by the JRSC, and as
further described in Section 3.3(a). 

  
 - 3 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.16 “CEO”. CEO means the Chief Executive Officer of a Party or, if there is
no Chief Executive Officer of a Party, the Board Chairperson or senior-most executive officer or equivalent of such Party. 
 1.17
“Clinical Trial(s)”. Clinical Trial(s) means a Phase I Study, a Phase II clinical study, a Pivotal Study or a Phase III Study. 

1.18 “Clinical POC”. Clinical POC means demonstration of safety and a Pre-agreed level
of therapeutic efficacy, including a change in the levels of a Pre-agreed disease relevant biomarker in some cases as a substitute for therapeutic efficacy, in a
Pre-agreed number of human patients. 
 1.19 “Commercially Reasonable Efforts”.
Commercially Reasonable Efforts means, with respect to a Party, the efforts required in order to carry out a task in a diligent and sustained manner without undue interruption or delay, which level is at least commensurate with the level of effort
that a similarly situated Third Party would devote to a product of similar market potential and having similar commercial and scientific advantages and disadvantages resulting from its own research efforts or to which it has rights, taking into
account its safety and efficacy, regulatory status, the competitiveness of the marketplace, its proprietary position, pricing, reimbursement, launching strategy and other market-specific factors, and all other relevant factors. 

1.20 “Commercialization” or “Commercialize”. Commercialization or Commercialize means any activity directed
to obtaining pricing or reimbursement approvals, marketing, promoting, distributing, importing, exporting, offering to sell or selling a product, or to have any such activity performed. When used as a verb, “Commercialize” means to engage
in Commercialization. 
 1.21 “Compound”. Compound means an AAV Capsid Variant carrying a Gene Therapy Construct. 

1.22 “Confidential Information”. Confidential Information means any and all information and data, including all uniQure
Know-How, 4DMT Know-How and Joint Know-How, and all other scientific, pre-clinical,
clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection with this Agreement or
the Prior Confidentiality Agreement. All Core uniQure Know-How shall be considered the Confidential Information of uniQure, with respect to which: (a) uniQure shall be considered the disclosing Party, (b)
4DMT shall be considered the receiving Party, and (c) clauses (b) and (e) of Section 8.2 shall not apply. All Core 4DMT Know-How shall be considered the Confidential Information of 4DMT, with
respect to which: (i) 4DMT shall be considered the disclosing Party, (ii) uniQure shall be considered the receiving Party, and (iii) clauses (b) and (e) of Section 8.2 shall not apply. 

1.23 “Control”. Control means, with respect to any item of or right under Patent Rights or
Know-How, the possession (whether by ownership or license, other than a license pursuant to this Agreement) of the ability of a Party or, as applicable, its Affiliate (subject to Section 12.7), to grant
access to, or a license or sublicense of, such items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the
other Party such access or license or sublicense. 

  
 - 4 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.24 “Core 4DMT Intellectual Property”. Core 4DMT Intellectual Property
means Core 4DMT Know-How and Core 4DMT Patent Rights. 
 1.25 “Core 4DMT Know-How”. Core 4DMT Know-How means [***]. 
 1.26
“Core 4DMT Patent Right”. Core 4DMT Patent Right means any Patent Right that Covers the Core 4DMT Know-How. 

1.27 “Core uniQure Intellectual Property”. Core uniQure Intellectual Property means Core uniQure Know-How and Core uniQure Patent Rights. 
 1.28 “Core uniQure
Know-How”. Core uniQure Know-How means [***]. 

1.29 “Core uniQure Patent Right”. Core uniQure Patent Right means any Patent Right that Covers the Core uniQure Know-How. 
 1.30 “Cover”, “Covering” or “Covered”.
Cover, Covering or Covered means, with respect to a product, technology, process or method that, in the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or
the practice of such technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue). 

1.31 “Default”. Default means with respect to a Party that (a) any representation or warranty of such Party set forth
herein shall have been untrue in any material respect when made or (b) such Party shall have failed to perform any material obligation set forth in this Agreement. 

1.32 “Delivery Success Criteria”. Delivery Success Criteria means the following criteria that determines whether an AAV Capsid
Variant demonstrates improved delivery or function of a Gene Therapy Construct: [***]. 
 1.33 “Development” or
“Develop”. Development or Develop means pre-clinical and clinical drug development activities, including: test method development and stability testing, toxicology, formulation, process
development, manufacturing scale-up, development-stage manufacturing, quality assurance/quality control procedure development and performance with respect to clinical materials, statistical analysis and report
writing and clinical studies, regulatory affairs, and all other pre-Regulatory Approval activities. When used as a verb, “Develop” means to engage in Development. 

1.34 “EMA”. EMA means the European Medicines Agency, or any successor agency. 

  
 - 5 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.35 “European Union” or “EU”. European Union or EU means
the countries that are members of the European Union, as redefined from time to time. 
 1.36 “FDA” or “Food and
Drug Administration”. FDA or Food and Drug Administration means the United States Food and Drug Administration, or any successor agency. 

1.37 “Field”. Field means the delivery of Gene Therapy Constructs to cells in (a) the central nervous system
(“CNS”) or (b) the liver, in each case where such delivery is for the purpose of effecting expression of the applicable RNA or amino acid sequence in the targeted cells and is potentially useful for the diagnosis, treatment,
palliation or prevention of a disease or medical condition in humans or animals, irrespective of the administration site or mode of administration (e.g., intravenous, direct injection, subcutaneous or intrathecal) of the Compound used to
effect delivery. For clarity, intravenous administration of any Compound targeted to cells in other organs (i.e., not specifically targeted to liver or CNS tissues), including for treatment of neoplastic and eye disorders, is excluded from
the Field. 
 1.38 “First Commercial Sale”. First Commercial Sale means, with respect to any Royalty Bearing Product and a
country, the first sale for end use or consumption of such Royalty Bearing Product in such country after all required approvals, including Regulatory Approval, have been granted by the Regulatory Authority of such country. For clarity, sales for
test marketing, sampling and promotional uses, clinical trials purposes or compassionate use shall not constitute a First Commercial Sale. 

1.39 “FTE”. FTE means [***] ([***]) hours of work devoted to or in support directly of the Research Program that is carried
out by one or more qualified scientific or technical employees of 4DMT or its Affiliates, measured in accordance with 4DMT’s normal time allocation practices from time to time. Overtime, and work on weekends, holidays and the like, shall not be
counted with any multiplier (e.g., time-and-a-half or double time) toward the number of hours that are used to calculate
the FTE contribution. The portion of an FTE billable for one (1) individual during a Calendar Quarter shall be determined by dividing the number of hours worked directly by said individual on the Research Program during such Calendar Quarter by
[***] ([***]) hours. 
 1.40 “FTE Costs”. FTE Costs means, for any Calendar Quarter, the number of FTEs multiplied by the
FTE Rate. 
 1.41 “FTE Rate”. FTE Rate means the amount for each FTE as set forth in Schedule 1.41. 

1.42 “Fully Burdened Manufacturing Cost”. Fully Burdened Manufacturing Cost means, as applicable to a Royalty Bearing Product,
the cost of manufacturing such Royalty Bearing Product, which is equal to the sum of (a) for such Royalty Bearing Product (or components thereof), the costs of all direct material, direct labor and allocable manufacturing overhead consumed,
provided, or procured by a Party, in each case for the manufacture of such Royalty Bearing Product, and (b) for such Royalty Bearing Product (or components thereof) made by a Third Party, the out-of-pocket costs paid to such Third Party by a Party; in each case (a) and (b) to the extent such costs are incurred by a Party or its Affiliates and to the extent such costs are reasonably allocable
to the manufacture of such Royalty Bearing Product. For clarity, Fully Burdened Manufacturing Cost excludes costs of excess capacity. Fully Burdened Manufacturing Cost shall be calculated in a manner consistent with Accounting Standards. 

  
 - 6 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.43 “Gene Therapy Construct”. Gene Therapy Construct means any nucleic acid
sequence that encodes an RNA or an amino acid sequence that is intended to be delivered to a targeted tissue to treat, prevent or ameliorate a disease or condition. 

1.44 “GLP Tox Compound”. GLP Tox Compound means a Research Compound that uniQure, in its sole discretion, elects to progress
to GLP Tox Studies to be conducted by or on behalf of uniQure in accordance with Section 3.3(a). 
 1.45 “GLP Tox
Study”. GLP Tox Study means a formal toxicology study of a Research Compound conducted under Good Laboratory Practices that is required to obtain approval from a regulatory authority, whether the FDA or otherwise, to begin conducting
Clinical Trials. 
 1.46 “Good Laboratory Practices”. Good Laboratory Practices means the then-current good laboratory
practice standards promulgated or endorsed by the FDA, as defined in 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S. to the extent applicable to the relevant study, as they may be updated from time
to time). 
 1.47 “Governmental Authority”. Governmental Authority means any United States federal, state or local or any
foreign government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing
authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. 

1.48 “Grant Letter”. Grant Letter means each of the Option Agreements, dated as of even date herewith, by and between
uniQure’s Affiliate, uniQure B.V., and (a) in the first case, Dr. David Schaffer and (b) in the second case, Dr. David Kirn. 

1.49 “IGT”. IGT means Integrative Gene Therapeutics, Inc., a California corporation, which jointly owns with UC certain of the
UC Patent Rights. 
 1.50 “Indication”. Indication means any disease, condition or syndrome. 

1.51 “Initial Research Term”. Initial Research Term means the period commencing on the Effective Date and ending on [***].

 1.52 “Initiation”. Initiation means, with respect to a Clinical Trial, the first dosing of a participant in such Clinical
Trial. 
 1.53 “Invention”. Invention means any new and useful process, article of manufacture, compound, composition of
matter, formulation or apparatus, or any improvement thereof, discovery or finding, which is patentable. 

  
 - 7 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.54 “Invoice”. Invoice means an original invoice sent by 4DMT to uniQure
with respect to any payment due hereunder substantially in the form attached hereto as Schedule 1.54. 
 1.55 “Know-How”. Know-How means (a) any scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever,
that is not in the public domain, including databases, practices, methods, techniques, specifications, formulations, formulae, protein sequences, nucleic acid sequences, AAV Capsid Variants, AAV Capsid Variant Libraries, Gene Therapy Constructs,
Compounds, knowledge, know-how, trade secrets, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical
and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data, and (b) any biological, chemical, or physical material or composition of matter that is not in the public
domain or otherwise generally available to the public. 
 1.56 “Law”. Law means all laws, statutes, rules, codes,
regulations, orders, judgments or ordinances applicable to a Party, this Agreement or the activities contemplated hereunder. 
 1.57
“Lead Optimization”. Lead Optimization means the discovery phase dedicated to the evaluation of new AAV Capsid Variants derived from an AAV Capsid Variant Library following a Research Selection Process to identify one or more
Research Compounds that meet Delivery Success Criteria. 
 1.58 “Licensed IP”. Licensed IP means the 4DMT Intellectual
Property, Core uniQure Intellectual Property, and Joint Intellectual Property. 
 1.59 “Materials”. Materials means any
tangible chemical or biological research materials that are provided or otherwise made available by one Party to the other Party under the terms of Section 3.4 for use in performance of the Research Program; provided, however,
that Materials will not include any AAV Capsid Variants or AAV Capsid Variant Libraries. 
 1.60 “NDA”. NDA means a New Drug
Application or Biologics License Application filed with the FDA or any other application required for the purpose of marketing or selling or commercially using a therapeutic or prophylactic product to be filed with a Regulatory Authority in a non-U.S. country or group of countries, including a Product License Application or Marketing Authorization Application (“MAA”) in the European Union or Japan. 

1.61 “Net Sales”. Net Sales means, with respect to a Royalty Bearing Product, the gross amount of sales of such Royalty
Bearing Product invoiced by uniQure or its Affiliates to Third Parties, less the following to the extent related to such Royalty Bearing Product and incurred by such uniQure or its Affiliates and invoiced to the Third Party: 

(a) sales returns and allowances actually paid, granted or accrued, including trade, quantity and cash discounts and any other adjustments,
including those granted on account of price adjustments or billing errors; 

  
 - 8 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (b) rejected goods, damaged or defective goods, recalls, returns; 

(c) rebates, chargeback rebates, compulsory rebates, reimbursements or similar payments granted or given to wholesalers or other distributors,
buying groups or health care insurance carriers; 
 (d) non-collectable receivables; 

(e) customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes); or 

(f) charges for packing, freight, shipping and insurance. 

Each of the foregoing deductions shall be determined as incurred in the ordinary course of business in type and amount consistent with good industry practice
and in accordance with Accounting Standards on a basis consistent with uniQure’s audited consolidated financial statements. For clarity, sales by uniQure or its Affiliates of a Royalty Bearing Product to a Third Party Distributor of such
Royalty Bearing Product in a given country shall be considered a sale to a Third Party customer. All such discounts, allowances, credits, rebates, and other deductions shall be fairly and equitably allocated to the Royalty Bearing Products and other
products of uniQure and its Affiliates such that the Royalty Bearing Product does not bear a disproportionate portion of such deductions. 

In the event any Royalty Bearing Product is sold for consideration other than cash, Net Sales for such sale shall be the average price of such
Royalty Bearing Product sold for cash during the relevant period in the relevant country. 
 In the event that any discount, reduction,
payment or rebate is offered for a Royalty Bearing Product where such Royalty Bearing Product is sold to a Third Party customer as part of a grouped set of products, the applicable discount, reduction, payment or rebate for such Royalty Bearing
Product in such arrangement shall be based on the weighted average discount, reduction, payment or rebate of such grouped set of products. 

Any Royalty Bearing Products used for promotional or advertising purposes (in reasonable and customary amounts) or used for Clinical Trials or
other research purposes shall not be included in Net Sales. Donations for charity reasons or compassionate use shall also not be included in Net Sales. 

1.62 “Net Sales by 4D” has the same meaning as given in the definition of “Net Sales,” but substituting
“4DMT” for “uniQure” in each instance where “uniQure” appears in such definition. 
 1.63
“Party” and “Parties”. Party means uniQure or 4DMT individually, and Parties means uniQure and 4DMT collectively. 

  
 - 9 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.64 “Patent Rights”. Patent Rights means patents, patent
applications or provisional patent applications, utility models and utility model applications, petty patents, innovation patents, patents of addition, divisionals, continuations,
continuation-in-part applications, continued prosecution applications, requests for continued examinations, reissues, renewals, reexaminations and extensions and
supplementary protection certificates granted in relation thereto, in any country of the world. For clarity, Patent Rights shall include any Patent Right that claims priority to or common priority with such Patent Rights. 

1.65 “Phase I Study”. A Phase I Study is a human clinical trial conducted in any country that meets the requirements of
21 CFR §312.21(a). By way of example and not limitation, a Phase I Study is usually performed as a single or multiple dose clinical study in healthy volunteers or patients to assess specific administration, distribution, metabolism, excretion
(ADME), safety and tolerability, bioavailability/bioequivalence or exploratory efficacy (in the sense of demonstrating “proof-of-principle”) of an
investigational drug, and the emphasis in Phase I is usually on safety and tolerability and it is typically used to plan patient dosing in Phase II clinical studies. For clarity, a Phase I Study may also represent the initial phase of a combined
Phase Ib/II clinical study. 
 1.66 “Phase III Study”. A Phase III Study is a human clinical trial conducted in any country
that meets the requirements of 21 CFR §312.21(c). By way of example and not limitation, a Phase III Study is a large scale clinical study (usually several hundreds of patients) performed after preliminary evidence suggesting effectiveness of
the drug has been obtained in Phase II clinical studies, and it is intended to gather the pivotal information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and, along with earlier
Clinical Trials, to provide an adequate basis for Regulatory Approval. For clarity, a Phase III Study may also represent the second part of a combined Phase II/III clinical study. 

1.67 “Pivotal Study”. A Pivotal Study is a human clinical trial conducted in any country, the principal purpose of which is to
establish safety and efficacy of a Royalty Bearing Product in patients with the applicable Indication and to gather the pivotal information about such safety and effectiveness that is needed to evaluate the overall benefit-risk relationship of the
drug and, along with earlier Clinical Trials, to provide an adequate basis for Regulatory Approval. A Pivotal Study includes any human clinical trial intended as a pivotal study of such Royalty Bearing Product regarding such Indication, such as a
phase II/III or phase IIb clinical trial, whether or not such study is a traditional Phase III Study. 
 1.68 “Pre-agreed”. Pre-agreed means on terms that are determined by the JRSC in accordance with Section 2.5. 

1.69 “Prior Confidentiality Agreement”. Prior Confidentiality Agreement means the Two Way Confidentiality Disclosure Agreement
between uniQure and 4DMT, dated August 26, 2013. 
 1.70 “Product”. Product means any preparation in final form,
either for sale by prescription, over-the-counter or any other method, or for administration to human patients in Clinical Trials, for any and all uses, and in any and
all formulations and combinations, which preparation contains a Compound. 

  
 - 10 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.71 “Project Team”. Project Team means the 4DMT and uniQure personnel
involved in the Research Program, including the Project Leaders. 
 1.72 “Prosecution and Maintenance”. Prosecution and
Maintenance means, with respect to a Patent Right, the preparation, filing, prosecution and maintenance of such Patent Right, as well as reexaminations, reissues and the like with respect to such Patent Right, together with the conduct of
interferences, the defense of oppositions and other similar proceedings with respect to the particular Patent Right; and “Prosecute and Maintain” shall have the correlative meaning. 

1.73 “Regulatory Approval”. Regulatory Approval means the technical, medical and scientific licenses, registrations,
authorizations and approvals (including approvals of NDAs and labeling approvals) of any Regulatory Authority necessary for the distribution, marketing, promotion, offer for sale, use, import, export or sale of a Royalty Bearing Product in a
regulatory jurisdiction. 
 1.74 “Regulatory Authority”. Regulatory Authority means any applicable Governmental Authority
involved in granting approvals for the manufacturing, marketing, reimbursement or pricing of a Royalty Bearing Product in the Territory or any portion thereof, including the FDA and EMA (as applicable), and any successor Governmental Authority
having substantially the same function. 
 1.75 “Research Compound”. Research Compound means a Compound containing a
Designated Capsid Variant that is the subject of activities under the Research Program. 
 1.76 “Research Plan”. Research
Plan means the research plan developed by the Parties that sets forth the activities to be undertaken during the Research Term with respect to the Research Program and the budget for such activities. The initial outline of the Research Plan is
attached as Schedule 1.76. 
 1.77 “Research Program”. Research Program means a program of collaborative research to
be undertaken by the Parties pursuant to the Research Plan to identify optimized AAV Capsid Variants for use in the Field that demonstrate improved expression of the delivered Gene Therapy Construct in the targeted tissue as compared to currently
available AAV Capsid Variants. 
 1.78 “Research Selection Process”. Research Selection Process means the iterative
evolution or isolation of lead AAV Capsid Variants from one or more 4DMT AAV Capsid Variant Libraries in cells (cultured or primary) in vitro or in animals in vivo intended to result in the identification of AAV Capsid Variants
demonstrating Pre-agreed properties suitable to proceed into Lead Optimization using a Pre-agreed evaluation methodology and that are targeted to a specified target
tissue. A given Research Selection Process is different from another Research Selection Process if such Research Selection Process was conducted to identify AAV Capsid Variants that specifically target a different tissue or are delivered by means of
a different mode of administration (e.g., such process was conducted to identify AAV Capsid Variants useful for intravenous, direct injection, subcutaneous or intrathecal delivery means). 

  
 - 11 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.79 “Research Term”. Research Term means the Initial Research Term and, if
applicable, the Extended Research Term. 
 1.80 “Research Year”. Research Year means a twelve (12) month period
beginning on the Effective Date or on any anniversary thereof. 
 1.81 “Royalty Bearing Compound”. Royalty Bearing Compound
means a Compound containing a Selected Capsid Variant. 
 1.82 “Royalty Bearing Product”. Royalty Bearing Product means a
Product containing a Royalty Bearing Compound. 
 1.83 “Royalty Term”. Royalty Term means, with respect to a Royalty Bearing
Product, on a Royalty Bearing Product-by-Royalty Bearing Product and a country-by-country
basis, the period beginning on the First Commercial Sale of such Royalty Bearing Product in such country by uniQure or any of its Affiliates or Sublicensees, and ending on latest of: (a) the expiration of the last Valid Claim within the
Licensed IP Covering such Royalty Bearing Product in such country, (b) the expiration of any applicable exclusivity, including orphan drug status or data exclusivity, and any extension thereto, granted by a Regulatory Authority in such country
with respect to such Royalty Bearing Product, or (c) the tenth (10th) anniversary of the date of the First Commercial Sale by uniQure or any of its Affiliates or Sublicensees of such Royalty
Bearing Product in such country. 
 1.84 “Selected Capsid Variant”. Selected Capsid Variant means (a) an AAV Capsid
Variant selected by uniQure in accordance with Section 3.4 (as provided in Schedule 1.83), (b) an AAV Capsid Variant resulting from a modification by uniQure or by 4DMT (or by any Third Party licensed pursuant to this Agreement) to an AAV
Capsid Variant described in subsection (a), or (c) an AAV Capsid Variant resulting from a modification by uniQure or by 4DMT (or by any Third Party licensed pursuant to this Agreement) to any AAV capsid to contain a sequence conferring the
properties that were the subject of the Research Selection Process for an AAV Capsid Variant described in subsection (a); provided that the resulting Know-How with respect to the modified AAV Capsid Variants
shall be Core uniQure Know-How. Notwithstanding anything express or implied in this Agreement: (i) uniQure and those deriving rights from uniQure shall have no right under this Agreement (but shall have
the right under the New CLA) to modify a Selected Capsid Variant of clause (a) or (b) with or to include any motif, mutation, or substitution identified under the New CLA, (ii) any such modified AAV Capsid Variant — other than an AAV
Capsid Variant of clause (a) (i.e., any of the precise AAV Capsid Variants set forth in Schedule 1.83 with no further modifications) — that includes any such motif, mutation, or substitution shall be deemed not to be a Selected Capsid
Variant under this Agreement but rather to be a New Capsid Variant under the New CLA, (iii) the activities to so modify a Selected Capsid Variant shall be deemed to have occurred under the New CLA, and (iv) the Know-How and Patent Rights related to such modifications and resulting New Capsid Variants shall be deemed to arise under the New CLA and be owned by 4DMT as New Variant Patents and the Know-How that is the subject matter of New Variant Patents. For clarity, except as stated in the preceding sentence, all AAV Capsid Variants described in clauses (b) and (c) are Selected Capsid Variants for
purposes of this Agreement, are subject to being potentially included in Proposed Products under Section 4.4, and are subject to Vector Characterization Data sharing under Section 4.3. 

  
 - 12 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.85 “Selection Process”. Selection Process means the iterative evolution or
isolation of lead AAV Capsid Variants from one or more AAV Capsid Variant Libraries in cells (cultured or primary) in vitro or in animals in vivo intended to result in the identification of AAV Capsid Variants demonstrating properties
suitable to a specified target tissue. For clarity, a Selection Process can be one that is performed by 4DMT or its Affiliate either for itself or for, with or by any Third Party under rights granted by 4DMT to such Third Party, and need not be one
that is conducted under the Research Program of this Agreement or designed for the same type of tissue in order to qualify under this definition. 

1.86 “Sublicensee”. Sublicensee means, with respect to uniQure, a Third Party to whom uniQure (or its Affiliate or another of
its Sublicensees) has granted a license or sublicense under the Licensed IP to Develop, make and have made, use or Commercialize a Royalty Bearing Product; provided, however, that a Sublicensee shall not include any Third Party
Distributor. 
 1.87 “Territory”. Territory means all countries and territories in the world. 

1.88 “Third Party”. Third Party means an entity other than uniQure, 4DMT and their respective Affiliates. 

1.89 “Third Party Distributor”. Third Party Distributor means any Third Party that provides (but does not Develop) Royalty
Bearing Products directly to customers under agreement with uniQure, its Affiliates or Sublicensees. 
 1.90 “UC AAV Capsid
Variant”. UC AAV Capsid Variant means any AAV Capsid Variant provided to 4DMT pursuant to the UCB Agreements. 
 1.91 “UC
Patent Right”. UC Patent Right means any Patent Right licensed to 4DMT pursuant to the UCB Agreements. 
 1.92 “UC
Product”. UC Product means a Royalty Bearing Product that is Covered by a UC Patent Right. 
 1.93 “UCB
Agreements”. UCB Agreements means (a) the Exclusive License and Bailment Agreement between 4DMT and the Regents of the University of California (“UC”), Agreement Control No. 2014-03-0089, dated December 19, 2013; (b) the Exclusive License and Bailment Agreement between 4DMT and UC, Agreement Control
No. 2014-03-0090, dated December 19, 2013; and (c) the Agreement for Use of Certain Biological Materials between 4DMT and UC, Agreement Control No. 2014-30-0088, dated December 19, 2013, in each case in the form provided to uniQure by 4DMT as of the Effective Date. 

1.94 “uniQure Intellectual Property”. uniQure Intellectual Property means uniQure
Know-How and uniQure Patent Rights. 

  
 - 13 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 1.95 “uniQure Know-How”. uniQure Know-How means Know-How that is (a) Controlled by uniQure or its Affiliates as of the Effective Date or during the Research Term, and (b) necessary or useful to
conduct the Research Program or to research, Develop, make and have made, use or Commercialize the relevant Selected Capsid Variant, or a Royalty Bearing Compound or Royalty Bearing Product due to the presence of such Selected Capsid Variant
therein. uniQure Know-How includes Core uniQure Know-How but does not include Joint Know-How. 

1.96 “uniQure Patent Right”. uniQure Patent Right means any Patent Right Controlled by uniQure or its Affiliates as of
the Effective Date or during the Term that Covers uniQure Know-How. uniQure Patent Rights include Core uniQure Patent Rights but do not include Joint Patent Rights. 

1.97 “Valid Claim”. Valid Claim means (a) a claim of an issued patent that has not expired or been abandoned, or been
revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within
the allowable time period), or (b) a claim within a patent application which application has not been pending for more than [***] ([***]) years from the date of its priority filing date and which claim has not been irretrievably revoked,
irretrievably cancelled, irretrievably withdrawn, held invalid or abandoned by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment
from which no appeal was taken within the allowable time period), or finally determined to be unallowable in a decision from which an appeal cannot or can no longer be taken; provided, however, that with respect to [***]. 

1.98 “Vector Characterization Data” means any and all data, results and other Know-How
that is generated either by or on behalf of a Party or its Affiliate, whether alone or together with, by or for any of its Third Party licensees, contractors or collaborators either under this Agreement or outside of this Agreement, with respect to
any Selected Capsid Variant, in regards to any of the following with respect to such Selected Capsid Variant: [***] 
 1.99 Additional
Definitions. Each of the following definitions is set forth in the section of this Agreement indicated below: 
  

			
	 Definition:
	  	Section:
	 4DMT
	  	Preamble
	 4DMT Indemnitees
	  	9.5
	 Acquiring/Acquired Party
	  	5.6(c)
	 Additional Cure Period
	  	10.2(a)
	 Agreement
	  	Preamble
	 Audited Party
	  	6.7
	 Auditing Party
	  	6.7
	 Bankruptcy Code
	  	5.5
	 CNS
	  	1.37
	 CREATE Act
	  	7.10

  
 - 14 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

			
	 Definition:
	  	Section:
	 Damages
	  	9.5
	 Defaulting Party
	  	10.2(a)
	 Designated Capsid Variant
	  	3.4(a)
	 Dispute
	  	11.1
	 Effective Date
	  	Preamble
	 Equipment Payment
	  	6.2(c)
	 Excluded Claim
	  	11.2
	 Executives
	  	2.5(b)
	 Extended Research Term
	  	3.1(c)
	 Failure to Amend
	  	4.4(d)
	 Fair Market Value
	  	6.5(b)(iii)
	 GAAP
	  	1.9
	 GLP Tox Candidate Review Period
	  	3.3(a)
	 IFRS
	  	1.9
	 Initiating Party
	  	7.6(d)
	 Joint Counsel
	  	7.5
	 Joint Intellectual Property
	  	7.2(a)
	 Joint Know-How
	  	7.2(a)
	 Joint Patent Rights
	  	7.2(a)
	 JRSC
	  	2.2(a)
	 M&A Event
	  	12.7
	 MAA
	  	1.60
	 Non-Defaulting Party
	  	10.2(a)
	 Orange Book
	  	7.9(a)
	 Paragraph IV Certification
	  	7.9(b)
	 Paragraph IV Proceeding
	  	7.9(b)(ii)
	 Project Leader
	  	2.1
	 Records
	  	3.7(a)(i)
	 SEC Filing
	  	8.5(c)
	 Sublicense Consideration
	  	6.5(b)
	 Sublicense Income Sharing Percentages
	  	6.5(a)
	 Term
	  	10.1
	 Third Party Claim
	  	9.5
	 Third Party Competitive Product
	  	4.4(a)
	 Third Party Proposal
	  	4.4(a)
	 Third Party Proposed Products
	  	4.4(a)
	 Third Party Proposer
	  	4.4(a)
	 Trade Secret Election
	  	7.3(b)
	 USPTO
	  	7.10
	 UC
	  	1.89
	 uniQure
	  	Preamble
	 uniQure Indemnitees
	  	9.6

  
 - 15 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 ARTICLE II 

GOVERNANCE 
 2.1
Project Leaders. Within [***] ([***]) Business Days after the Effective Date, each Party will appoint (and provide written notice to the other Party of the identity of) a senior representative having a general understanding of pharmaceutical
discovery and development issues to act as its project leader under this Agreement (each, a “Project Leader”). The Project Leaders will serve as the contact point between the Parties with respect to the Research Program, and will be
primarily responsible for: (a) facilitating the flow of information and otherwise promoting communication, coordination of the day-to-day work and collaboration
between the Parties; (b) providing single point communication for seeking consensus internally within the respective Party’s organization; and (c) raising cross-Party or cross-functional disputes in a timely manner. The Project
Leaders shall conduct regular telephone conferences as deemed necessary or appropriate, to exchange informal information regarding the progress of the Research Program. Each Party may change its designated Project Leaders from time to time upon
prior written notice to the other Party. Each Project Leader may designate a substitute to temporarily perform the functions of that Project Leader by prior written notice to the other Party. 

2.2 Joint Research Steering Committee. 

(a) Composition. Promptly after the Effective Date, the Parties shall establish a joint research steering committee (the
“JRSC”). The JRSC shall be comprised of at least [***] ([***]) named representatives of uniQure and at least [***] ([***]) named representatives of 4DMT, one of whom shall be [***] (unless due to his death, illness or disability),
or such other numbers as the Parties may agree in writing. As soon as practicable after the Effective Date (but in no event more than [***] ([***]) Business Days after the Effective Date), each Party shall designate by written notice to the other
Party its initial representatives on the JRSC. Each Party may replace one or more of its non-mandatory representatives, in its sole discretion, effective upon written notice to the other Party of such change.
These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research Program. The JRSC shall be disbanded upon expiration of the Research Term. 

(b) Function and Powers of the JRSC. During the Research Term, the JRSC’s responsibilities shall include: (i) approving the
initial Research Plan and any amendment thereto, including allocation of tasks and resources; (ii) developing and approving the Candidate Success Criteria; (iii) developing and approving parameters for Animal POC; (iv) developing and
approving parameters for Clinical POC; (v) determining the frequency of meetings of the Project Team, or subgroups of the Project Team, and the members of the Project Team to attend such meetings, which meetings are expected to occur at least
[***], with such meetings expected to occur in person at least [***]; (vi) reviewing, approving procedures, and making recommendations regarding Lead Optimization; (vii) determining whether a Research Compound achieves the relevant Delivery
Success Criteria; (viii) proposing Research Compounds that have achieved the Delivery Success Criteria for uniQure’s acceptance as GLP Tox Compounds; (ix) providing a forum for discussion of the Research Plan, the status of the
Research Program, and relevant data; (x) serving as a forum for informal resolution of disagreements that may arise in the relation to the 

  
 - 16 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
Parties’ activities under the Research Program, including any disagreement within any subcommittee; (xi) determining and approving the overall strategy for publications and
presentations pursuant to Section 8.4; and (xii) considering and acting upon such other matters as may be specified in this Agreement. Any decision made by the JRSC under this Section 2.2(b) shall be deemed a decision of the JRSC, as
applicable, for purposes of this Agreement. 
 2.3 Subcommittees. The JRSC may establish and disband such subcommittees as deemed
necessary by the JRSC. Each such subcommittee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written
notice to the other Party or to send a substitute representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be bound by a written agreement with confidentiality obligations
substantially the same as those set forth in ARTICLE VIII. The rules for the conduct of each subcommittee, and the scope of its responsibilities, shall be determined by the JRSC, provided that no subcommittee shall have the authority to bind
the Parties hereunder, and each subcommittee shall report to the JRSC. 
 2.4 Meetings. The JRSC shall each hold at least [***] per
Calendar Quarter. Upon necessity, either Party shall be entitled to request additional meetings of the JRSC. Meetings of the JRSC shall be effective only if at least [***] ([***]) representatives of each Party are present or participating. The
location of meetings shall be as agreed by the Parties, and may be held in person, alternating locations between the Parties, or by telephone conference call or by videoconference; provided, however, that at least [***] ([***])
meetings of the JRSC each Calendar Year are held in person. 4DMT’s costs and expenses incurred in connection with preparing for and participating in all such meetings shall be paid for by uniQure in accordance with the budget for the Research
Plan. Either Party may, from time to time, invite additional representatives or consultants to attend JRSC meetings; provided that at least [***] ([***]) Business Days’ prior written notice is given of a Party’s intention to invite
such other representatives or consultants and providing full details about the name, employer and professional background of such other representatives or consultants. Each representative and consultant participating in or attending a JRSC meeting
shall be bound by a written agreement with confidentiality obligations substantially the same as those set forth in ARTICLE VIII. The JRSC shall be co-chaired by a representative from each Party. The
chairpersons shall set the agendas for the JRSC meeting in advance. Within [***] ([***]) Business Days prior to each scheduled meeting, each Party shall, in accordance with Section 3.7(b), provide a report to the JRSC detailing its progress
with respect to the Research Program. The Parties will rotate the responsibility for recording, preparing and issuing minutes for each JRSC meeting, to be circulated within [***] ([***]) Business Days after each meeting. 

2.5 Decision-making. 
 (a)
Initial Dispute Resolution Procedures. Subject to the provisions of this Section 2.5, actions to be taken by the JRSC shall be taken only following a unanimous vote, with each Party, through its representatives, having one (1) vote.
If any subcommittee fails to reach unanimous agreement (with each Party, through its representatives, having one (1) vote) for a period in excess of [***] ([***]) Business Days, the matter shall be referred to the JRSC. 

  
 - 17 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (b) Referral of Unresolved Matters to Executives. If, in accordance with
Section 2.5(a), the JRSC does not resolve any matter considered by it within [***] ([***]) Business Days after the matter is first considered by it, the matter may be referred by either Party to the CEO of 4DMT and CEO of uniQure (the
“Executives”) to be resolved by negotiation in good faith as soon as practicable, but in no event later than [***] ([***]) Business Days after referral. Such resolution, if any, of a referred issue by the Executives shall be final
and binding on the Parties. Any decision made by the Executives under this Section 2.5(b) shall be deemed a decision of the JRSC for purposes of this Agreement. 

(c) Final Decision-Making. If a dispute referred to the Executives pursuant to Section 2.5(b) has not been resolved in accordance
with Section 2.5(b), then, subject to Section 2.5(d), uniQure shall have the final decision-making authority. Any decision made by uniQure pursuant to this Section 2.5(c) shall be deemed a decision of the JRSC for purposes of this
Agreement. 
 (d) Exceptions. Notwithstanding Section 2.5(c), uniQure shall not have the right to exercise such decision-making
authority (i) in a manner that excuses uniQure from any of its obligations specifically enumerated under this Agreement; (ii) in a manner that negates any consent rights or other rights specifically allocated to 4DMT under this Agreement;
(iii) [intentionally omitted]; (iv) in a manner that would require 4DMT to perform activities (A) for which uniQure will not reimburse 4DMT’s costs (except as expressly set forth in this Agreement), (B) that 4DMT has not agreed to perform
as set forth in this Agreement or the Research Plan, or as otherwise agreed in writing by 4DMT, or (C) that require 4DMT to use any Know-How or other technology not contemplated in the Research Plan and
that is not developed internally by 4DMT and with respect to the use of which 4DMT would owe a royalty or other payment; (v) in a manner that would change the total number of 4DMT FTEs or the allocation among the various technical disciplines
as set forth in the Research Plan; (vi) in a manner that would reduce payments committed to 4DMT pursuant to this Agreement or take away 4DMT’s right to perform activities that 4DMT has previously agreed to perform as set forth in the
Research Plan; (vii) in a manner that would require 4DMT to perform any act that it reasonably believes to be inconsistent with any Law or any approval, order, policy, guidelines of a Regulatory Authority or ethical requirements or ethical
guidelines; (viii) to determine that uniQure has fulfilled any obligation under this Agreement or that 4DMT has breached any obligation under this Agreement; or (ix) to amend the relevant Delivery Success Criteria. In the event that any
matter set forth in the preceding clauses (i)-(ix) is unresolved through the JRSC and subsequently such dispute cannot be resolved by the Executives in accordance with Section 2.5(b), then either (A) for all such matters set forth in the
preceding clauses (iv)-(vi), there shall be no change in the Research Plan or associated budget unless the Parties otherwise mutually agree in writing, (B) for all such matters set forth in the preceding clauses (i), (ii), (vii) and (viii),
either Party may require the specific issue to be referred to binding arbitration pursuant to Section 11.2, or (C) for all such matters set forth in the preceding clauses (iii) and (ix), either Party may require the specific issue to
be submitted to a panel of external scientific experts to review the dispute pursuant to the remainder of this Section 2.5(d). Each Party shall select, upon either Party’s request, one (1) external scientific expert within [***]
([***]) Business Days after such request, and the two (2) so selected shall choose a third (3rd) external scientific expert within an additional [***] ([***]) Business Days to resolve the dispute, and all three (3) shall serve as neutrals.
Each expert must be free of any conflict of interest with 

  
 - 18 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
respect to either or both Parties and their Affiliates and shall have expertise in the matters concerning the unresolved dispute. The decision of the external scientific expert panel shall be
issued within [***] ([***]) Business Days after nomination of the third external expert and shall be final and binding on the Parties. The Parties agree to share equally the cost of the proceedings, including fees of the panel members;
provided, that each Party shall bear its own attorneys’ fees and associated costs and expenses. 
 2.6 Limitations on JRSC
Authority. The JRSC and any subcommittee shall have only the powers assigned expressly to it in this ARTICLE II and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement. In
furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JRSC or any subcommittee unless such delegation or vesting
of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. 
 ARTICLE III 

RESEARCH PROGRAM 

3.1 General. 
 (a)
Objectives. The objectives of the Research Program are to (i) identify and characterize AAV Capsid Variants and Research Compounds, (ii) optimize such AAV Capsid Variants and Research Compounds and (iii) conduct other research
activities with respect to Research Compounds containing Gene Therapy Constructs of interest in place of marker or other proof-of-principle genes with which screening
and AAV Capsid Variant optimization may have been performed, in each case to identify Research Compounds that meet the Delivery Success Criteria, with the objective of having such Research Compounds accepted by uniQure for Animal POC and
subsequently as GLP Tox Compounds, consistent with the Candidate Success Criteria. 
 (b) Research Plan. The Parties shall agree to
the Research Plan and shall conduct the Research Program in accordance with the Research Plan. The JRSC shall endeavor to approve the initial Research Plan (including its associated budget) within [***] ([***]) days after the Effective Date, which
initial Research Plan shall set forth the tasks to be undertaken by the Parties (including relevant technology to be used and Materials to be provided) under the Research Program. 

(c) Extended Research Term. In the event that uniQure reasonably believes that the Parties will not complete the activities under the
Research Plan during the Initial Research Term, then uniQure, at its sole discretion, may extend the Research Term to complete the goals of such Research Plan as then in effect for an additional [***] ([***]) month period from the expiration of the
Initial Research Term (the “Extended Research Term”). uniQure may so extend the Research Term by giving written notice to 4DMT at least [***] ([***]) months prior to the expiration of the Initial Research Term. The Parties shall
mutually agree upon the number of FTEs at 4DMT needed to perform the research during the Extended Research Term, as well as out-of-pocket costs, and uniQure shall
provide funding for such FTEs and out-of-pocket costs in 

  
 - 19 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
accordance with Section 6.2(a) and, if the Parties are unable to agree on such matters prior to the expiration of the Initial Research Term, then the Research Term shall expire at the end of
the Initial Research Term. The Parties may further extend the Extended Research Term by mutual written agreement. 
 3.2 Conduct of the
Research Program. 
 (a) 4DMT and uniQure shall each use Commercially Reasonable Efforts to conduct the Research Program in accordance
with the Research Plan. In addition, uniQure shall use Commercially Reasonable Efforts to assess reasonably promptly whether each Designated Capsid Variant provided to uniQure in connection with assessing the Delivery Success Criteria can be
manufactured in insect cells. 
 (b) Either Party shall have the right to utilize the services of any Third Party to perform its obligations
under the Research Plan to the extent that such Third Party is specifically approved in the Research Plan or otherwise approved by the JRSC, provided that any permitted Third Party must have entered into a written agreement with such Party
that includes terms and conditions (i) protecting and limiting use and disclosure of Confidential Information at least to the same extent as under ARTICLE VIII, and (ii) requiring the Third Party and its personnel to assign to such Party
all right, title and interest in and to any intellectual property (and intellectual property rights) created or conceived in connection with performance of subcontracted activities. Each Party shall remain at all times fully liable for its
responsibilities under this Agreement. 
 (c) 4DMT and uniQure shall conduct the Research Program in accordance with all applicable Laws,
including, if and as applicable, Good Laboratory Practices. Each Party hereby certifies that it will not employ or otherwise use in any capacity in performing any activity hereunder the services of any person or entity known to it to be debarred
under 21 USC §335a. 
 (d) If the JRSC determines that it is desirable to transfer the AAV Capsid Variant Libraries into
baculovirus, then prior to such transfer, the Parties will negotiate in good faith an amendment to this Agreement specifying the allocation of ownership of Materials, Know-How, and Patent Rights. Except as
otherwise agreed by the Parties in writing, in no event shall 4DMT transfer the 4DMT AAV Capsid Variant Libraries to uniQure, and in no event shall uniQure transfer its baculovirus insect cell manufacturing
Know-How to 4DMT. 
 3.3 Candidate Success Criteria. 

(a) Within [***] ([***]) days following the date on which the Research Plan is approved by the JRSC, the JRSC shall determine and approve the
minimum Candidate Success Criteria applicable to each class or series of Research Compounds. For clarity, the Candidate Success Criteria shall include [***]. The objectives of the Research Program will always be to identify the best possible AAV
Capsid Variants for delivery of Gene Therapy Constructs to target cells, rather than to identify AAV Capsid Variants that merely meet the minimum Candidate Success Criteria specified in the Research Plan. Subsequently in the Research Program
(i.e., when AAV Capsid Variants have been accepted by uniQure as being ready for Animal POC testing or in parallel with the identification with lead AAV Capsid Variants for Lead 

  
 - 20 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
Optimization), the JRSC will (i) agree on disease models for testing Gene Therapy Constructs of interest for efficacy against particular target diseases, (ii) agree on procedures for
testing in these animal disease models and the Candidate Success Criteria in these models intending to result in data sufficient for submission to regulatory authorities, and (iii) recommend that Research Compounds meeting these criteria should
proceed to GLP Tox Studies. The Candidate Success Criteria shall in all of cases (i)-(iii) be expected to be able to be met only using Research Compound stocks that have been prepared by uniQure in insect cells using standard uniQure SOPs in
comparison to reference vectors also prepared by uniQure in the same way. Notwithstanding the foregoing, the Candidate Success Criteria shall be deemed to have been met for any Research Compound that uniQure advances into GLP Tox Studies. 

(b) The JRSC may, from time to time during the Research Term, nominate a Research Compound that has achieved the Candidate Success Criteria
for Animal POC (provided, however, that the JRSC may, as appropriate, nominate a Research Compound that has not achieved all the Candidate Success Criteria) for consideration as a GLP Tox Compound. uniQure will consider all data
relating to the nominated Research Compound for designation as a GLP Tox Compound, including data generated by either uniQure or 4DMT pursuant to this Agreement. Such data shall include the results from all tests and other measures included in the
Candidate Success Criteria and such other information and results as uniQure reasonably requests from 4DMT. Within [***] ([***]) days after delivery to uniQure of such data (the applicable “GLP Tox Candidate Review Period”), uniQure
shall provide 4DMT written notice whether uniQure accepts such nominated Research Compound as a GLP Tox Compound and intends to Develop and Commercialize such nominated Research Compound in accordance with the terms of this Agreement.
Notwithstanding the foregoing, uniQure shall be deemed to have accepted as a GLP Tox Compound any Research Compound that it advances into pre-clinical Development conducted under Good Laboratory Practices.

 3.4 Selection of AAV Capsid Variants. 

(a) Within [***] ([***]) days after 4DMT provides uniQure with the list of AAV Capsid Variant sequences arising from each Research Selection
Process and all other data arising from or relating to such Research Selection Process, uniQure shall submit by written notice to 4DMT a list specifying up to [***] ([***]) AAV Capsid Variants from each such Research Selection Process (the
“Designated Capsid Variants”). If uniQure has not provided such written notice to 4DMT within [***] ([***]) days, 4DMT shall provide written notice to uniQure of the date that the foregoing [***] ([***]) day period will expire, and
the Parties will have the option to agree an extension by mutual consent, not to be unreasonably withheld. 
 (b) Prior to the [***] of the
expiration of the Research Term, uniQure shall submit by written notice to 4DMT a list specifying up to [***] ([***]) AAV Capsid Variants from the list of Designated Capsid Variants for each Research Selection Process. All AAV Capsid Variants
included in such list shall be included as “Selected Capsid Variants,” subject to the terms and conditions of this Agreement. For clarity, all modifications by uniQure to the Selected Capsid Variants and other modifications set forth in
Section 1.84 shall also be deemed “Selected Capsid Variants” for purposes of the payment obligations under this Agreement. 4DMT shall provide written notice to uniQure if uniQure has not provided such list to 4DMT by the date that is
[***] ([***]) days prior to the [***] of the expiration of the Research Term. 

  
 - 21 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (c) For clarity, the subset of Designated Capsid Variants not subsequently selected as
Selected Capsid Variants may be used and licensed by 4DMT to Third Parties outside the Field, but only if they also arise from a Selection Process conducted outside the Field. Unless such subset of Designated Capsid Variants also arise from a
Selection Process conducted outside the Field, 4DMT may not conduct any research using such subset of Designated Capsid Variants unless otherwise agreed under the Research Plan. For further clarity, Selected Capsid Variants may not be used, or
licensed to Third Parties, by 4DMT or its Affiliates outside the Field. 
 3.5 Materials and
Know-How Transfer/Use of Compounds. 
 (a) In order to facilitate the Research Program, each
Party shall, as set forth in the Research Plan, provide to the other Party certain Materials and, subject to Section 3.6, Know-How Controlled by the supplying Party for use by the other Party in
furtherance of the Research Program. In addition, 4DMT shall transfer to uniQure such quantities of Designated Capsid Variants as the JRSC may reasonably request from time to time during the Research Term to exercise its rights hereunder. All
Materials and Know-How provided by one Party to the other Party remain the sole property of the supplying Party. 

(b) All Materials transferred pursuant to the Research Program shall be used (i) only for the specific purpose provided for in the
Research Plan, and (ii) solely under the control of the receiving Party. The Materials may not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying Party, and shall not be used in
research or testing involving human subjects, except as expressly contemplated in the Research Plan or in accordance with this Agreement. All Materials shall be returned to the supplying Party or destroyed (at the election of the supplying Party)
promptly after completion of the use permitted under this Agreement. 
 (c) THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY
RIGHT OF ANY THIRD PARTY. 
 (d) At the end of the Research Term, upon request by uniQure, 4DMT shall promptly provide to uniQure all
quantities of the Royalty Bearing Compounds in 4DMT’s possession and shall promptly destroy other Research Compounds. 
 3.6 Third
Party Intellectual Property. The conduct of activities under the Research Plan will use Patent Rights or Know-How licensed by 4DMT pursuant to the UCB Agreements, subject to the terms and conditions of the
UCB Agreements. 4DMT shall be solely responsible for all obligations under the UCB Agreements, including any and all payments and royalties due thereunder. In developing the Research Plan, the Parties shall discuss whether any

  
 - 22 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
Third Party Patent Rights or Know-How, other than Patent Rights or Know-How licensed by 4DMT pursuant to the UCB
Agreements, will be utilized in the conduct of activities under the Research Plan. 4DMT shall disclose to uniQure the details of any restrictions on use or payment obligations of which it is aware that would be triggered by such use of Third Party
Patent Rights or Know-How in the Research Program. If the Parties mutually agree to use any inventions claimed in any Patent Right or use any Know-How that is licensed
to or has been acquired by 4DMT other than pursuant to the UCB Agreements, and if such use would require the payment of additional consideration to the Third Party from which the Patent Rights or Know-How was
licensed or acquired, then such Patent Right or Know-How shall be deemed under the Control of 4DMT, provided that uniQure expressly agrees in writing to bear any such additional consideration actually
to be paid by 4DMT to the Third Party (which amounts uniQure may offset pursuant to Section 6.4(c)(ii)) with respect to the Development, manufacture or Commercialization of Royalty Bearing Compounds or Royalty Bearing Products. For clarity,
nothing in this Section 3.6 shall limit uniQure’s rights to obtain from a Third Party, independent of 4DMT, a license or other right with respect to such Third Party’s Patent Rights or Know-How.

 3.7 Records and Reports. 

(a) Records. 
 (i) 4DMT
shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of the Research Program by or on
behalf of 4DMT (the “Records”), including the procedures, techniques and methodologies used, the progress made, and any Invention conceived or reduced to practice or otherwise made within the scope of or in connection with the
Research Program. As part of keeping the Records, 4DMT shall ensure that all of its personnel, and all of its agents that are involved in the Research Program, will keep accurate laboratory notebooks, which laboratory notebooks: (A) shall be
duly signed, dated and witnessed; and (B) shall be created and maintained in accordance with its standard operating procedures that would be sufficient to allow for said laboratory notebooks to be used in any proceeding before the United States
Patent and Trademark Office or United States courts, in order to establish the date of invention for any Invention in accordance with the United States patent laws. During the Term, 4DMT shall, upon written request by uniQure, which shall not be
unreasonably made: (1) make all Records available for inspection and review by uniQure during normal business hours in a timely manner; and (2) provide copies of the Records or any part thereof to uniQure, as reasonably requested by
uniQure. 
 (ii) After a Research Compound has been accepted by uniQure as a GLP Tox Compound, uniQure shall have the right to request that
a copy of the relevant portions of the laboratory notebooks relating to all stages of the generation of such GLP Tox Compound be provided by 4DMT to uniQure. After such request by uniQure, 4DMT shall provide such copies of the laboratory notebooks
promptly to uniQure, which shall be maintained by uniQure as 4DMT’s Confidential Information. 

  
 - 23 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (b) Reports to the JRSC. Between [***] ([***]) and [***] ([***]) Business Days prior
to each scheduled JRSC meeting, the Parties shall provide to the JRSC a written report on the progress of the Research Program, summarizing the work performed under the Research Program and evaluating the work performed in relation to the goals of
the Research Program. Each Party shall provide such other information required by the Research Program or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of the Research Program.

 ARTICLE IV 

DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS; DILIGENCE 

4.1 Responsibility. uniQure shall have full responsibility, [***], for the worldwide research, Development, manufacturing and
Commercialization of Compounds and Products in the Field, subject to the payment obligations and other relevant terms and conditions of this Agreement. 

4.2 Diligence. The Parties will have no rights or obligations pursuant to this Section of the Original Agreement. 

4.3 Obligation to Share Vector Characterization Data for Selected Capsid Variants. 

(a) Commencing on the Amended CLA Effective Date and continuing until the termination or expiration of this Agreement, uniQure shall provide,
within [***] ([***]) days after each January 31st and July 31st of each Calendar Year, a written report to 4DMT that summarizes the Vector
Characterization Data generated by or on behalf of uniQure or its Affiliate or Sublicensee with respect to each Selected Capsid Variant for which any research or Development activities were conducted by or on behalf of uniQure or its Affiliate or
Sublicensee during the [***] ([***]) months that ended on the immediately prior [***] as applicable. 
 (b) Commencing on the Amended CLA
Effective Date and continuing until the termination or expiration of this Agreement, 4DMT shall provide, within [***] ([***]) days after each January 31st and July 31st of each Calendar Year, a written report to uniQure that summarizes the Vector Characterization Data generated by or on behalf of uniQure or its Affiliate or Sublicensee with respect to each Selected
Capsid Variant for which any research or Development activities were conducted by or on behalf of 4DMT or its Affiliate or Sublicensee during the [***] ([***]) months that ended on the immediately prior [***] as applicable. 

(c) Either Party may terminate its obligation to provide written reports pursuant to this Section 4.3 of the Agreement, if it ceases all
research, development, commercialization or other activities that would result in the generation of any further unreported Vector Characterization Data with respect to Selected Capsid Variants, and the Party provides written notice to the other
Party so stating and also certifying that all Vector Characterization Data that is required to be reported with respect to Selected Capsid Variants has been so reported and that the party provides notice that it has given up all of its rights
associated with any such Selected Capsid Variants. 

  
 - 24 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 4.4 Proposed Products in the Field. 

(a) If, at any time after the Amended CLA Effective Date, a Third Party makes a bona fide proposal to 4DMT for Developing and Commercializing
a Product in the Field based on a Selected Capsid Variant (a “Third Party Proposed Product”) using 4DMT Know-How or Joint Know-How, or the making, using
or selling of which in the absence of an appropriate license would infringe a Valid Claim under the 4DMT Patent Rights or Joint Patent Rights, then 4DMT promptly shall notify uniQure of the proposal of such Third Party (“Third Party
Proposer”) and shall provide uniQure with such information regarding such Third Party proposal, including a development plan and a plan to finance such activities (“Third Party Proposal”) as uniQure may reasonably request
to evaluate such Third Party Proposal and its potential conflict with the ongoing efforts and future plans of uniQure. At any time after the Research Term, 4DMT may make a bona fide proposal to uniQure for Developing and Commercializing a Product in
the Field based on a Selected Capsid Variant (a “4DMT Proposed Product”), including a development plan and a plan to finance such activities. Within [***] ([***]) days after receipt of a notice from 4DMT of a Third Party Proposal or
4DMT Proposed Product, uniQure shall notify 4DMT whether uniQure is conducting or is interested in conducting research or Development of such Third Party Proposed Product, 4DMT Proposed Product, or a Product that uniQure believes in good faith is or
would be competitive with such Third Party Proposed Product or 4DMT Proposed Product (a “Competitive Product”). 4DMT shall have the right to make a maximum total of [***] ([***]) proposals per calendar year on a non-exclusive basis for Developing and Commercializing a Collaboration Proposed Product (as defined below) in the Field under this Section 4.4 and under Section 4.4 of the New CLA, such calendar year total
to be determined in the aggregate under this Agreement and the New CLA, taken collectively. 4DMT shall have no other right to make a proposal for Developing or Commercializing a Product, or to otherwise develop or commercialize any product, in the
Field using a Selected Capsid Variant, except as is expressly provided herein. “Collaboration Proposed Products” means, collectively or separately, Third Party Proposed Products, 4DMT Proposed Products and New CLA Proposed Products
(as that term is defined in the New CLA). An “SCV Proposed Product” means, collectively or separately, 4DMT Proposed Products and Third Party Proposed Products. 

(b) If uniQure notifies 4DMT that uniQure is conducting or is interested in conducting research or Development of such Third Party Proposed
Product, 4DMT Proposed Product or Competitive Product, uniQure shall, within [***] ([***]) months after such notice, deliver to 4DMT a plan (including projected timelines) for the research and Development thereof on a timeline consistent with the
application of Commercially Reasonable Efforts, and, thereafter, shall use Commercially Reasonable Efforts to research, Develop, manufacture and Commercialize such Third Party Proposed Product, 4DMT Proposed Product or Competitive Product in
accordance with such plan. uniQure shall provide progress reports to 4DMT in conjunction with the reports of Vector Characterization Data under Section 4.3 from and after the date of uniQure’s notice under this Section 4.4(b), and
such reports shall contain a summary of the activities undertaken and the status of uniQure’s research and Development efforts with respect to such Third Party Proposed Product, 4DMT Proposed Product, or Competitive Product during the [***]
([***]) months that ended on the immediately prior [***] as applicable. 

  
 - 25 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (c) If uniQure notifies 4DMT that uniQure is not conducting and is not interested in
conducting research or Development of such Third Party Proposed Product, 4DMT Proposed Product, or Competitive Product: 
 (i) and the
applicable Proposed Product was a Third Party Proposed Product, then the Parties shall meet to discuss the grant of an appropriate license by uniQure to the Third Party Proposer. If 4DMT determines after such meeting and due consideration that the
grant of a license to such Third Party Proposer is necessary or appropriate, uniQure shall have [***] ([***]) months after the date of receipt of written notice of such determination (or such longer time as shall be agreed to by the Parties in
writing) to negotiate and enter into a non-exclusive sublicense under any relevant 4DMT Patent Rights and any relevant Patent Rights of uniQure (including uniQure Core Patent Rights generated under this
Agreement) that are relevant due to the presence of the applicable Selected Capsid Variant therein, to provide such Third Party Proposer with sufficient rights under such 4DMT Patent Rights and uniQure Core Patent Rights (and no other intellectual
property rights of any kind or Controlled by any person or entity), to research, Develop, manufacture and Commercialize the Third Party Proposed Product in the Field on commercially reasonable terms to be agreed by uniQure and such Third Party
Proposer (such financial terms shall be equal to or greater than the amounts as set forth in Sections 6.3(b), 6.4 and 6.5). uniQure and such Third Party Proposer shall define and agree on the uniQure Know-How
and uniQure Patent Rights that are relevant due to the presence of the applicable Selected Capsid Variant therein, to the extent necessary to Develop or Commercialize AAV Capsid Variants to be licensed in such
non-exclusive sublicense or amendment, as applicable. 
 (ii) and the applicable Proposed Product
was a 4DMT Proposed Product, then [***] uniQure hereby grants to 4DMT (who accepts such license) a non-exclusive sublicense under 4DMT Patent Rights and a non-exclusive
license under the uniQure Intellectual Property that is necessary or useful due to the presence of the applicable Selected Capsid Variant therein, and all Vector Characterization Data reported by uniQure to 4DMT under this Agreement, to research,
Develop, manufacture and Commercialize the 4DMT Proposed Product in the Field on the financial terms and conditions provided for in this Agreement. Such license shall be sublicensable through one (1) or more tiers or layers of sublicensees
without the need to obtain consent from uniQure. 
 (d) In the case of a Third Party Proposer, if uniQure fails to enter into such a non-exclusive sublicense and license agreement within such [***] ([***]) month period, uniQure shall promptly (but in any event within [***] ([***]) days after the end of such period) provide 4DMT in writing an
explanation for such failure along with the proposed terms offered by uniQure to such Third Party Proposer. If 4DMT determines in its good faith judgment based on reasonable inquiry that the terms offered by uniQure to such Third Party Proposer were
not commercially reasonable, 4DMT shall notify uniQure of such determination and provide uniQure with an additional [***] ([***]) days to enter into a sublicense with such Third Party Proposer. If uniQure fails to enter into an agreement with such
Third Party Proposer [***], then 4DMT shall be free to dispute pursuant to ARTICLE XI whether uniQure has complied with its obligations under this Section 4.4. 

  
 - 26 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 4.5 Pharmacovigilance. Within [***] ([***]) months after the Amended CLA
Effective Date, the Parties shall enter into an agreement governing the exchange of adverse event safety data (including post-marketing spontaneous reports) received by a Party and its Affiliates, including such data received from, in the case of
uniQure, its Sublicensees or, in the case of 4DMT, its licensees, relating to any AAV Capsid Variant provided to uniQure by 4DMT hereunder in order to monitor the safety of all Compounds and Products and to meet reporting requirements with any
applicable Regulatory Authority. Such data sharing agreement shall not require the sharing of data that would disclose confidential know-how or trade secrets of a Party or its Affiliates, or in the case of
uniQure, its Sublicensees or, in the case of 4DMT, its licensees, if such data may be cross-referenced, such as through a Drug Master File, to satisfy the requirements of Law and any applicable Regulatory Authority. 

4.6 Marking. Prior to the issuance in the United States of Patent Rights included in the UC Patent Rights, uniQure agrees to mark
Royalty Bearing Product(s) Covered by any UC Patent Right (or their containers or labels) sold in the United States under the licenses granted in this Agreement with the words “Patent Pending,” and following the issuance in the United
States of one or more Patent Rights included in the UC Patent Rights, with the patent numbers of the UC Patent Right(s) Covering such Royalty Bearing Product. All Royalty Bearing Products Covered by any UC Patent Right sold in other countries will
be marked in such manner as to conform with the patent Laws and practice of such countries. 
 ARTICLE V 

GRANTS OF RIGHTS 

5.1 Licenses to uniQure. 

(a) Research License to uniQure. Subject to the terms and conditions of this Agreement, 4DMT hereby grants to uniQure, and uniQure
hereby accepts, during the Research Term and any applicable GLP Tox Candidate Review Period in effect as of the end of the Research Term, an exclusive (but not as to 4DMT), worldwide, royalty-free,
non-sublicenseable license under the 4DMT Intellectual Property and 4DMT’s interest in the Joint Intellectual Property, solely to (i) conduct activities assigned to uniQure under the Research Plan,
(ii) evaluate Research Compounds, or (iii) evaluate the data developed in the conduct of activities under the Research Plan during the Research Term. 

(b) Development and Commercialization License to uniQure. Subject to the terms and conditions of this Agreement, and subject to any non-exclusive license granted to 4DMT under Section 5.2(c) with respect to any SCV Proposed Products, 4DMT hereby grants to uniQure, and uniQure hereby accepts, an exclusive (even as to 4DMT), worldwide,
milestone- and royalty-bearing license, including the right to grant sublicenses in accordance with Section 5.3, under the 4DMT Intellectual Property and 4DMT’s interest in the Joint Intellectual Property, and any Vector Characterization
Data reported by 4DMT to uniQure under this Agreement, to research (subject to 4DMT’s retained rights to conduct research under the Research Program), Develop, make and have made, use and Commercialize Selected Capsid Variants, Royalty Bearing
Compounds, and Royalty Bearing Products in the Field. 

  
 - 27 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (c) Recordation. Following the Effective Date or at any time during the Term, 4DMT at
the request and expense of uniQure shall promptly register or record the licenses granted to uniQure under this Agreement with the appropriate patent offices in all applicable countries of the Territory; provided that such registration or
recordation specifies the applicable limitations of such license, and provided further that such registration shall have no effect on the allocation of Prosecution and Maintenance rights and obligations set forth in ARTICLE VII. In the
event any of the licenses granted to uniQure under this Agreement are terminated in accordance with the terms of this Agreement, uniQure shall promptly take such actions and execute such documents as are reasonably requested by 4DMT to cancel such
registration(s) or recordation(s) in the applicable countries with respect to the terminated license grants. 
 (d) Grant-Back License to
uniQure. 4DMT hereby grants to uniQure, and uniQure hereby accepts, a non-exclusive, worldwide, royalty-free license, including the right to grant sublicenses through multiple tiers, under the 4DMT Patent
Rights and 4DMT Know-How that (i) arise from activities that are conducted under this Agreement in connection with Royalty Bearing Compounds and Royalty Bearing Products in the course of making
modifications to Selected Capsid Variants and (ii) claim or cover compositions of matter or general methods of use of Selected Capsid Variants (for clarity, including such Patent Rights and Know-How
claiming or covering compositions combining Gene Therapy Constructs in general and AAV Capsid Variants in general or general methods of making or using such combinations of Gene Therapy Constructs and AAV Capsid Variants), to research, Develop, make
and have made, use and Commercialize Selected Capsid Variants, and Products containing Selected Capsid Variants. 
 5.2 Licenses to
4DMT. 
 (a) Research License to 4DMT. Subject to the terms and conditions of this Agreement, uniQure hereby grants to 4DMT, and
4DMT hereby accepts, during the Research Term and any applicable GLP Tox Candidate Review Period in effect as of the end of the Research Term, a non-exclusive, worldwide, royalty-free, non-sublicenseable license under the uniQure Intellectual Property, solely to the extent necessary to conduct activities assigned to 4DMT under the Research Plan. 

(b) Grant-Back License to 4DMT Outside the Field. uniQure hereby grants to 4DMT, and 4DMT hereby accepts, a non-exclusive, worldwide, royalty-free license, including the right to grant sublicenses through multiple tiers, under all Vector Characterization Data reported from uniQure to 4DMT under this Agreement and the
Patent Rights and Know-How Controlled by uniQure that is relevant due to the presence of the applicable Selected Capsid Variant therein, that (i) arise from activities that are conducted under this
Agreement in connection with Royalty Bearing Compounds and Royalty Bearing Products in the course of making modifications to Selected Capsid Variants and (ii) claim or cover compositions of matter or general methods of use of Selected Capsid
Variants that are applicable outside the Field (for clarity, excluding Patent Rights and Know-How claiming or covering (A) insect cell manufacturing technology, including technology or sequence
modifications for adapting AAV Capsid Variants to insect cells or insect cell expression vectors and systems, or (B) compositions, methods of manufacture, or methods of use of Gene Therapy Constructs, but for further clarity, including such
Patent Rights and Know-How that is necessary or useful due to the presence of the applicable 

  
 - 28 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
Selected Capsid Variant therein, claiming or covering compositions combining Gene Therapy Constructs in general and AAV Capsid Variants in general or general methods of making or using such
combinations of Gene Therapy Constructs and AAV Capsid Variants), to research, Develop, make and have made, use and Commercialize 4DMT AAV Capsid Variants (excluding Selected Capsid Variants), and Products containing such 4DMT AAV Capsid Variants,
in all cases outside the Field. For the avoidance of doubt, 4DMT’s practice of the foregoing license shall be subject to its obligations set forth in Section 5.6. If any Patent Rights or Know-how
subject to the foregoing license are subject to agreements between uniQure and a Third Party that require payments to be made to the Third Party by reason of the practice of the rights granted to 4DMT under this Section 5.2(b), such Patent
Rights and Know-How shall only be deemed Controlled by uniQure if 4DMT agrees in writing to pay to uniQure the portion of the amounts due to such Third Party that is reasonably attributable to the practice of
such rights. 
 (c) Non-Exclusive License for SCV Proposed Products under
Section 4.4. uniQure grants 4DMT the sublicenses and licenses provided for in Section 4.4(c)(ii) effective upon the time set forth therein, and 4DMT accepts such sublicense and license effective as of such time. In
association with any license agreement pursuant to Section 4.4(c) with a Third Party related to a Third Party Proposed Product and subject to the terms and conditions of this Agreement, uniQure shall grant to the Third Party Proposer as
applicable, and the Third Party Proposer shall accept, a non-exclusive, worldwide, milestone- and royalty-bearing license, including the right to grant sublicenses in accordance with Section 5.3, under
the relevant uniQure Intellectual Property and uniQure’s interest in the relevant Joint Intellectual Property, in each case that is necessary or useful due to the presence of the applicable Selected Capsid Variant therein, to research, Develop,
make and have made, use and Commercialize that Third Party’s Third Party Proposed Products in the Field. 
 (d) Any licenses granted to
4DMT under the uniQure Intellectual Property (including any subset or aspect of the uniQure Intellectual Property) pursuant to this Agreement, including, without limitation, pursuant to Sections 4.4 and 5.2, are limited to only uniQure Intellectual
Property that specifically relates to Selected Capsid Variants (including patent claims specifying a Selected Capsid Variant or specifically claiming any methods of use or making any Selected Capsid Variants, and excluding all other uniQure
Intellectual Property (e.g., without limitation, compositions of matter or methods of making compositions of matter and methods of manufacturing Products (but not the Selected Capsid Variant therein) pursuant to this Agreement). 

5.3 Sublicenses. uniQure shall have the right to grant sublicenses under the license granted to it under Section 5.1(a) to
Affiliates of uniQure and Third Parties; provided that any sublicense granted to a Third Party under this Agreement shall be pursuant to a written agreement that subjects such Sublicensee to all relevant restrictions and limitations set forth
in this Agreement. uniQure shall provide 4DMT with the name and address of each Sublicensee of its rights under this ARTICLE V, the date of the grant of the sublicense and a description of the rights granted promptly after the execution and delivery
of the sublicense agreement. uniQure shall remain responsible for the performance of its Sublicensees, and shall ensure that each Sublicensee complies with the applicable terms and conditions of this Agreement.  

  
 - 29 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 5.4 Rights Retained by the Parties. Except as expressly set forth in this Agreement,
neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, in any Confidential Information of the other Party or under any Patent Right or Know-How in which
such other Party or its Affiliates has rights. Without limiting the generality of the foregoing, any of 4DMT’s rights to 4DMT Intellectual Property not specifically licensed to uniQure shall be retained by 4DMT, and any of uniQure’s rights
to uniQure Intellectual Property not specifically licensed to 4DMT shall be retained by uniQure. 
 5.5 Section 365(n)
of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as
amended or any comparable Law outside the United States (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may
fully exercise all of their respective rights and elections under the Bankruptcy Code. Each Party agrees that the other Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under
the Bankruptcy Code or any other provisions of applicable Law outside the United States that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy
proceeding by or against a Party under the Bankruptcy Code or analogous provisions of applicable Law outside the United States, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) the intellectual
property licensed to such other Party and all embodiments of such intellectual property, to the extent necessary for such other Party to practice the licenses granted to it pursuant to this Agreement under such intellectual property, which, if not
already in such other Party’s possession, will be promptly delivered to it upon such other Party’s written request thereof. Any agreement supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for
purposes of Section 365(n) of the Bankruptcy Code. 
 5.6 Exclusivity. 

(a) Original Exclusivity Removed. The Parties will have no rights or obligations pursuant to Sections 5.6(a) and (b) of the
Original Agreement. As of the Amended CLA Effective Date and with respect to the entire Agreement, the parties have only those rights expressly provided in this Agreement. 

(b) Of 4DMT. The Parties acknowledge that as of the Amended CLA Effective Date, without otherwise detracting from the license and
intellectual property ownership rights expressly granted to uniQure hereunder (including, without limitation, with respect to uniQure’s exclusive rights to any Selected Capsid Variants in the Field (recognizing however that uniQure’s
rights to Selected Capsid Variants may be partially non-exclusive due to any non-exclusive rights granted 4DMT under Section 4.4)), 4DMT or its Affiliates or
licensees or sublicensees shall have the right to conduct pre-clinical research activities in the Field using Selected Capsid Variants and such activities shall not be deemed to violate the terms of this
Section 

  
 - 30 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
5.6(b). For any and all such pre-clinical research activities in and outside of the Field using or related to any Selected Capsid Variants, Royalty Bearing
Compounds or Royalty Bearing Products, 4DMT shall be obligated to provide to uniQure the Vector Characterization Data in accordance with the provisions of Section 4.3. 4DMT, its Affiliates, licensees and sublicensees shall have no right to
conduct any other activities, including any development, manufacturing, commercialization or other use of Selected Capsid Variants, except pursuant to any rights pursuant to Section 4.4 of this Agreement or as otherwise expressly provided in
this Agreement. Moreover, apart from any obligations of 4DMT related to the Selected Capsid Variants explicitly set forth in this Agreement, neither Party (including its Affiliates, licensees and sublicensees) shall have any exclusivity obligations
to the other Party or its Affiliates whatsoever under this Agreement with respect to other AAV Capsid Variants (i.e., other than Selected Capsid Variants) for the Field. 

(c) uniQure Independent Activities. The Parties acknowledge and agree that uniQure will conduct research, Development, manufacturing
and Commercialization activities independently of this Agreement, inside and outside of the Field, including with respect to AAV Capsid Variants, AAV Capsid Variant Libraries, Gene Therapy Constructs, Compounds and Products, and no provision of this
Agreement shall apply to any such activity. 
 5.7 UCB Agreement Pass-Through Provisions. uniQure acknowledges that 4DMT has provided
it with a copy of the executed UCB Agreements, and agrees that this Agreement is subject in all respects to the terms and conditions of the UCB Agreements. Notwithstanding the generality of the foregoing: 

(a) uniQure acknowledges that UC (and, to the extent applicable, IGT) may publish any and all technical data resulting from any research
performed by UC (and, to the extent applicable, IGT) relating to the inventions disclosed in the UC Patent Rights, and UC (and, to the extent applicable, IGT) expressly reserves the right to use such inventions, UC AAV Capsid Variants and related
technology for its educational and research purposes, to disseminate the UC AAV Capsid Variants and other tangible materials associated with, or required to practice such inventions or the UC Patent Rights to researchers at nonprofit institutions
for their educational and research purposes, and to permit other nonprofit institutions to use the UC AAV Capsid Variants to practice the UC Patent Rights for education and research purposes. 

(b) uniQure shall keep 4DMT informed of its large/small entity status, as defined in 15 U.S.C. 632. 

(c) uniQure acknowledges that certain of the inventions disclosed in the UC Patent Rights were funded in part by the U.S. Government, and
agrees that in accordance with 35 U.S.C. 204, to the extent required by Law, any products covered by the UC Patent Rights and sold in the United States will be substantially manufactured in the United States. 

(d) uniQure acknowledges that 4DMT’s exclusive rights, privileges, and licenses under the UCB Agreements will expire on the date of the last-to-expire Valid Claim under the UC Patent Rights covered in each agreement, respectively, unless earlier terminated. 

  
 - 31 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (e) For any sublicense under the UC Patent Rights that uniQure grants under
Section 5.3, uniQure shall ensure that (i) such further sublicense is subject to a written sublicense agreement and is bound by all of the applicable terms, conditions, obligations, restrictions and other covenants of the UCB Agreements
that protect or benefit UC’s (and, if applicable, the U.S. Government’s) rights and interests to the same extent that this Agreement does, and (ii) it or the Sublicensee shall, within [***] ([***]) days after executing such sublicense
agreement, furnish to 4DMT for delivery to UC, subject to any confidentiality provisions, all material terms of such sublicense pertaining to UC’s interests, including the Sublicensee’s name and address, and indemnification of UC as
provided in this Agreement. 
 (f) The Parties acknowledge and agree that upon termination of the UCB Agreements for any reason,
uniQure’s sublicenses under the UC Patent Rights under this Agreement will remain in effect and will be assigned to UC, except that UC will not be bound to perform any duties or obligations set forth herein that extend beyond the duties and
obligations of UC set forth in the UCB Agreements. 
 (g) uniQure acknowledges that nothing contained in this Agreement will be construed as
conferring any right to use in advertising, publicity or other promotional activities any name, trademark, trade name, or other designation of UC (including any contraction, abbreviation, or simulation of any of the foregoing), and that unless
required by Law, regulation, or rules of a securities exchange, or consented to in writing by UC, the use by uniQure of the name “The Regents of the University of California” or the name of any University of California campus in
advertising, publicity or other promotional activities is expressly prohibited. 
 ARTICLE VI 

PAYMENTS; ROYALTIES AND REPORTS 

6.1 Initial License Payment. In consideration of the rights to 4DMT Intellectual Property granted herein, uniQure shall pay to 4DMT non-creditable and non-refundable sums of: (a) One Hundred Thousand Dollars ($100,000) within [***] ([***]) Business Days after the later of (i) the Effective Date
and (ii) receipt of an Invoice for such amount and a duly signed original of this Agreement and, thereafter, (b) One Hundred Thousand Dollars ($100,000) within [***] ([***]) Business Days after the later of (i) the JRSC’s
approval of the initial Research Plan (including its associated budget) and (ii) receipt of an Invoice for such amount. 
 6.2
Research Program Funding. 
 (a) Out-of-Pocket
Costs. Following approval of the Research Plan (including its associated budget), uniQure shall fund all out-of-pocket costs to be incurred by 4DMT as specifically
contemplated in the Research Plan, in accordance with the agreed-upon budget for such costs set forth in the Research Plan or as otherwise agreed to by uniQure. On or before the first date of each Calendar Quarter during the Research Term, uniQure
shall pay 4DMT for such out-of-pocket costs to be incurred by 4DMT during such Calendar Quarter. Within [***] ([***]) days after the end of each Calendar Quarter during
the Research Term, 4DMT shall provide uniQure with a statement identifying such out-of-pocket costs incurred by 4DMT and paid to Third Parties in connection with the
Research Program during such Calendar Quarter, in reasonable detail and with appropriate supporting documentation. If the supporting documentation shows that uniQure has overpaid or underpaid the out-of-pocket costs for such Calendar Quarter, 4DMT will, 

  
 - 32 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
together with the supporting documentation, (i) send uniQure a credit note for the amount overpaid, upon which uniQure may credit the amount overpaid against any other payment due by uniQure
under this Agreement, or if no other payment is due under this Agreement, 4DMT shall within [***] ([***]) days refund the amount overpaid to uniQure, or (ii) send uniQure an Invoice for the amount underpaid, which uniQure shall pay within [***]
([***]) days after uniQure’s receipt of such Invoice. For clarity, no out-of-pocket costs will be paid by uniQure unless covered by an agreed-upon budget for such
expenses set forth in the Research Plan or as otherwise agreed to by uniQure. 
 (b) 4DMT Committed FTEs. It is the Parties’
intent that the Research Program will support the number of 4DMT FTEs in the performance of the activities under the Research Plan during the Research Term, as specified in the Research Plan and approved by the JRSC. Following approval of the
Research Plan (including its associated budget), on or before the first day of each Calendar Quarter during the Research Term, uniQure shall pay 4DMT the FTE Costs for FTEs in the then-current Research Plan for such Calendar Quarter; provided
that such payment may be prorated in the first and last Calendar Quarters of the Research Term. Within [***] ([***]) days after the end of each Calendar Quarter during the Research Term, 4DMT shall provide supporting documentation for the purpose of
verifying the calculation of the FTE charges paid by uniQure for such Calendar Quarter. If the supporting documentation shows that uniQure has overpaid or underpaid the FTE payments for such Calendar Quarter, 4DMT will, together with the supporting
documentation, (i) send uniQure a credit note for the amount overpaid, upon which uniQure may credit the amount overpaid against any FTE or other payment due by uniQure under this Agreement, or if no other payment is due under this Agreement,
4DMT shall within [***] ([***]) days refund the amount overpaid to uniQure, or (ii) send uniQure an Invoice for the amount underpaid, which uniQure shall pay within [***] ([***]) days after uniQure’s receipt of such Invoice. For clarity,
no FTE Costs will be paid by uniQure unless covered by an agreed-upon budget for such FTEs set forth in the Research Plan or as otherwise agreed to by uniQure. 

(c) Equipment Payment Reimbursement. Any amount paid by uniQure pursuant to Section 6.2(a) for the purchase of equipment
(“Equipment Payment”) shall be subject to partial reimbursement by 4DMT in accordance with this Section 6.2(c). For each of the first [***] ([***]) Third Party collaborations 4DMT enters into after the Effective Date, 4DMT
shall reimburse uniQure for a pro rata portion of the Equipment Payment based on the following formula: [***]. For example, if 4DMT conducts [***] ([***]) Research Selection Processes hereunder and [***] ([***]) Selection Processes for the
first such Third Party collaboration in which such equipment was actually used, 4DMT shall reimburse uniQure for [***] percent ([***]%) of the Equipment Payments. If 4DMT subsequently conducts another [***] ([***]) Selection Processes for the second
Third Party collaboration in which such equipment was actually used, 4DMT shall reimburse uniQure for a further [***] percent ([***]%) of Equipment Payments, since the [***] ([***]) Research Selection Processes it conducted for uniQure represents
[***] of the aggregate Selection Processes conducted by 4DMT for uniQure and for the first [***] ([***]) Third Party collaborations 4DMT entered into after the Effective Date. 4DMT shall pay uniQure any such amount payable under this
Section 6.2(c) within [***] ([***]) days after the end of the Calendar Quarter during which 4DMT conducted any Selection Process for either of the first [***] ([***]) Third Party collaborations 4DMT enters into after the Effective Date in which
such equipment was actually used, and shall contemporaneously provide uniQure with a written report detailing the calculation of such amount. 

  
 - 33 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 6.3 DELETED. 

6.4 Royalties. 
 On a
Royalty Bearing Product-by-Royalty Bearing Product basis, uniQure shall pay to 4DMT royalties on worldwide Net Sales as provided in this Section 6.4: 

(a) Royalty Rate. uniQure shall pay to 4DMT royalties on Net Sales of each Royalty Bearing Product by uniQure and its
Affiliates equal to [***] percent ([***]%) of all such Net Sales of such Royalty Bearing Product achieved during the applicable Calendar Year. 

(b) Royalty Term. uniQure’s royalty obligations to 4DMT under this Section 6.4 shall be in effect on a country-by-country and Royalty Bearing Product-by-Royalty Bearing Product basis during the
relevant Royalty Term. Upon expiration of the Royalty Term for a Royalty Bearing Product in a country, the license under Section 5.1(a) shall be fully paid-up, irrevocable, perpetual and exclusive under
the relevant Licensed IP for such Royalty Bearing Product in such country. 
 (c) Royalty Adjustments. 

(i) Non-Patented Product. If a Royalty Bearing Product is sold in a country and
the composition of matter, formulation, or method of use of such Royalty Bearing Product is not Covered by a Valid Claim within the Licensed IP in such country at the time of sale, then the royalty rate for such Royalty Bearing Product in such
country shall be reduced by [***] percent ([***]%) of the applicable rate determined pursuant to Section 6.4(a), unless such Royalty Bearing Product embodies an Invention with respect to which uniQure made a Trade Secret Election, in which case
no such reduction shall apply. 
 (ii) Third Party Offset. If uniQure is required, in order to avoid infringement of
any Patent Right not licensed hereunder that Covers the composition of matter, formulation, or method of use of a Royalty Bearing Product, to obtain a license from a Third Party in order to Develop, make, have made, use or Commercialize such Royalty
Bearing Product in a country in the Territory and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), then the royalty payments due under Section 6.4(a) with
respect to Net Sales for such Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the amounts payable by uniQure to such Third Party for such license that are reasonably and appropriately allocable to such Royalty
Bearing Product in such country, provided that in no event shall the foregoing reduce the amount of royalties payable to 4DMT in any [***] by more than [***] percent ([***]%) of the amount determined pursuant to Section 6.4(a), as
adjusted by application of the terms of Section 6.4(c)(i). 

  
 - 34 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (iii) Limits on Deductions. Except as expressly provided in this
Section 6.4, there shall not be any offset to or deduction from the royalties payable pursuant to this Section 6.4. Notwithstanding Sections 6.4(c)(i) and (ii) to the contrary, in no event shall the cumulative effect of the deductions
in Sections 6.4(c)(i) and (ii) reduce the royalties to less than [***] percent ([***]%) of the amounts determined pursuant to Section 6.4(a). 

On a Royalty Bearing Product-by-Royalty Bearing Product basis, for each 4DMT
Proposed Product commercialized by 4DMT and its Affiliates pursuant to Section 4.4, 4DMT shall pay to uniQure royalties on worldwide 4DMT Net Sales as provided in this Section 6.4: 

(d) Royalty Rate. 4DMT shall pay to uniQure royalties on 4DMT Net Sales of each Royalty Bearing Product by 4DMT and its Affiliates
equal to [***] percent ([***]%) of all such 4DMT Net Sales of such Royalty Bearing Product achieved during the applicable Calendar Year. 

(e) Royalty Term. 4DMT’s royalty obligations to uniQure under this Section 6.4 shall be in effect on a country-by-country and Royalty Bearing Product-by-Royalty Bearing Product basis during the
relevant Royalty Term. Upon expiration of the Royalty Term for a Royalty Bearing Product in a country, the license under Section 4.4(c) shall be fully paid-up, irrevocable, perpetual and non-exclusive under the relevant Licensed IP for such Royalty Bearing Product in such country. 
 (f)
Royalty Adjustments. 
 (i) Non-Patented Product. If a Royalty Bearing Product is sold
in a country and the composition of matter, formulation, or method of use of such Royalty Bearing Product is not Covered by a Valid Claim within the Patent Rights sublicensed and licensed from uniQure to 4DMT in such country at the time of sale,
then the royalty rate for such Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the applicable rate determined pursuant to Section 6.4(a), unless such Royalty Bearing Product embodies an Invention with
respect to which 4DMT made a Trade Secret Election, in which case no such reduction shall apply. 
 (ii) Third Party Offset. If 4DMT
is required, in order to avoid infringement of any Patent Right not licensed hereunder that Covers the composition of matter, formulation, or method of use of a Royalty Bearing Product, to obtain a license from a Third Party in order to Develop,
make, have made, use or Commercialize such Royalty Bearing Product in a country in the Territory and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), then the
royalty payments due under Section 6.4(a) with respect to 4DMT Net Sales for such Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the amounts payable by 4DMT to such Third Party for such license that are
reasonably and appropriately allocable to such Royalty Bearing Product in such country, provided that in no event shall the foregoing reduce the amount of royalties payable to uniQure in any Calendar Quarter by more than [***] percent
([***]%) of the amount determined pursuant to Section 6.4(a), as adjusted by application of the terms of Section 6.4(c)(i). 

  
 - 35 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (iii) Limits on Deductions. Except as expressly provided in this Section 6.4,
there shall not be any offset to or deduction from the royalties payable pursuant to this Section 6.4. Notwithstanding Sections 6.4(c)(i) and (ii) to the contrary, in no event shall the cumulative effect of the deductions in Sections
6.4(c)(i) and (ii) reduce the royalties to less than [***] percent ([***]%) of the amounts determined pursuant to Section 6.4(a). 

6.5 Sublicense Consideration. 

(a) uniQure shall pay to 4DMT the following percentages (“Sublicense Income Sharing Percentages”) of Sublicense Consideration
received by uniQure for sublicenses under the Licensed IP under this Agreement: 
 (i) [***] percent ([***]%) for any sublicense that
(A) is granted prior to initiating Animal POC for any Compound or Product that is subject of the sublicense and (B) does not require uniQure to manufacture any such Compound or Product for Clinical Trial or commercial purposes; 

 (ii) [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating Animal POC for any Compound or Product that
is subject of the sublicense and (B) requires uniQure to manufacture any such Compound or Product for Clinical Trial or commercial purposes;  

(iii) [***] percent ([***]%) for any sublicense that does not meet the criteria set forth in Section 6.5(a)(i) or Section 6.5(a)(ii)
above; 
 provided, however, that none of subsections (i), (ii) or (iii) shall result in uniQure paying to 4DMT under
this Section 6.5 a percentage of any Sublicense Consideration consisting of royalties from Sublicensees on sales of UC Products during the applicable Royalty Term that is less than [***] percent ([***]%) of 4DMT Net Sales by such Sublicensee of
such UC Products. 
 (b) The term “Sublicense Consideration” shall mean consideration of any kind received by uniQure from
a Sublicensee for the grant of a sublicense under this Agreement, such as upfront fees, royalties or milestone fees and including any premium paid by the Sublicensee over the Fair Market Value (as defined below) for stock of uniQure in consideration
for such sublicense; provided, however, the following are not included in Sublicense Consideration: 
 (i) Support for
activities of uniQure relating to the research, Development, manufacturing or Commercialization of Royalty Bearing Products, which shall not exceed the fully burdened cost (and in the case of manufacturing costs, the Fully Burdened Manufacturing
Cost) for undertaking such activities performed by or for uniQure (including Third Parties on uniQure’s behalf) by more than [***] percent ([***]%); 

  
 - 36 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (ii) Proceeds derived from debt financing and any loans to uniQure by the Sublicensee; 

(iii) Consideration received for the purchase of stock in uniQure or its Affiliate to the extent that the price per share for such equity does
not exceed the Fair Market Value of such stock. The term “Fair Market Value” shall mean the average price at which the stock in question is publicly trading at for [***] ([***]) days prior to the earlier of (A) the date of the
announcement of its purchase by the Sublicensee or (B) the date of its purchase by the Sublicensee, or if the stock is not publicly traded, the value of such stock as determined in good faith by the Board of Directors of uniQure or its
applicable Affiliate as of the time of receipt of payment; and 
 (iv) Reimbursement of uniQure’s patent costs related to Patent
Rights. 
 (c) 4DMT shall pay to uniQure the following percentages (“4D Sublicense Income Sharing Percentages”) of 4D
Sublicense Consideration received by 4DMT for sublicenses under the Licensed IP under this Agreement: 
 (i) [***] percent ([***]%) for any
sublicense that (A) is granted prior to initiating Animal POC for any Compound or Product that is subject of the sublicense and (B) does not require 4DMT to manufacture any such Compound or Product for Clinical Trial or commercial
purposes;  
 (ii) [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating Animal POC for any Compound
or Product that is subject of the sublicense and (B) requires 4DMT to manufacture any such Compound or Product for Clinical Trial or commercial purposes;  

(iii) [***] percent ([***]%) for any sublicense that does not meet the criteria set forth in Section 6.5(a)(i) or Section 6.5(a)(ii)
above; 
 provided, however, that none of subsections (i), (ii) or (iii) shall result in 4DMT paying to uniQure under
this Section 6.5 a percentage of any 4D Sublicense Consideration consisting of royalties from Sublicensees on sales of UC Products during the applicable Royalty Term that is less than [***] percent ([***]%) of Net Sales by such Sublicensee of
such UC Products. 
 (d) The term “4D Sublicense Consideration” shall mean consideration of any kind received by 4DMT from
a Sublicensee for the grant of a sublicense under this Agreement, such as upfront fees, royalties or milestone fees and including any premium paid by the Sublicensee over the Fair Market Value (as defined below) for stock of 4DMT in consideration
for such sublicense; provided, however, the following are not included in 4D Sublicense Consideration: 
 (i) Support for
activities of 4DMT relating to the research, Development, manufacturing or Commercialization of Royalty Bearing Products, which shall not exceed the fully burdened cost (and in the case of manufacturing costs, the Fully Burdened Manufacturing Cost)
for undertaking such activities performed by or for 4DMT (including Third Parties on 4DMT’s behalf) by more than [***] percent ([***]%); 

  
 - 37 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (ii) Proceeds derived from debt financing and any loans to 4DMT by the Sublicensee; 

(iii) Consideration received for the purchase of stock in 4DMT or its Affiliate to the extent that the price per share for such equity does
not exceed the Fair Market Value of such stock. The term “Fair Market Value” shall mean the average price at which the stock in question is publicly trading at for [***] ([***]) days prior to the earlier of (A) the date of the
announcement of its purchase by the Sublicensee or (B) the date of its purchase by the Sublicensee, or if the stock is not publicly traded, the value of such stock as determined in good faith by the Board of Directors of 4DMT or its applicable
Affiliate as of the time of receipt of payment; and 
 (iv) Reimbursement of 4DMT’s patent costs related to Patent Rights. 

(e) For purposes of this Article 6, “Sublicense Consideration received by uniQure” shall include Sublicense Consideration received
by uniQure’s Affiliates (applying the definition of Sublicense Consideration mutatis mutandis to such Affiliates) and “4D Sublicense Consideration received by 4D” shall include 4D Sublicense Consideration received by
4DMT’s Affiliates (applying the definition of Sublicense Consideration mutatis mutandis to such Affiliates). 
 6.6 Reports;
Payments. Within [***] ([***]) days after the end of each Calendar Quarter during which there are Net Sales or 4DMT Net Sales giving rise to a payment obligation under Section 6.4 or uniQure or 4DMT (as applicable) received Sublicense
Consideration or 4D Sublicense Consideration giving rise to a payment obligation under Section 6.5, (a) uniQure or 4DMT (as applicable) shall submit to 4DMT or uniQure (as applicable) a report (i) identifying for each Royalty Bearing
Product the Net Sales or 4DMT Net Sales for such Royalty Bearing Product for each country for such Calendar Quarter, the calculation of royalties (including gross sales and all deductions taken from gross sales and all reductions pursuant to
Section 6.4(c)), and the royalties payable to 4DMT or uniQure (as applicable) and (ii) identifying the Sublicense Consideration or 4D Sublicense Consideration received by uniQure or 4DMT (as applicable) in such Calendar Quarter and the one
or more Sublicense Income Sharing Percentages or 4D Sublicense Income Sharing Percentages applicable to such Sublicense Consideration, and (b) uniQure or 4DMT (as applicable) shall pay to 4DMT or uniQure (as applicable) all royalties payable
under Section 6.4 and portions of Sublicense Consideration or 4D Sublicense Consideration payable under Section 6.5. 
 6.7
Books and Records; Audit Rights. Each Party (the “Audited Party”) shall keep (and shall cause its Affiliates and Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards
in sufficient detail for the other Party (the “Auditing Party”) to determine the payments due and costs incurred under this Agreement. Each Auditing Party shall have the right, [***] at its own expense, to have an independent,
certified 

  
 - 38 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
public accounting firm of nationally recognized standing, selected by the Auditing Party and reasonably acceptable to the Audited Party, review any such records of the Audited Party in the
location(s) where such records are maintained by the Audited Party upon reasonable notice (which shall be no less than [***] ([***]) days prior notice) and during regular business hours and under obligations of strict confidence, for the sole
purpose of verifying the accuracy of the amounts paid under this Agreement within a [***] Calendar Year period preceding the date of the request for review. The report of such accounting firm shall be limited to a certificate stating whether any
report made or invoice or payment submitted by the Audited Party during such period is accurate or inaccurate, the actual amounts of 4DMT or uniQure (as applicable)
out-of-pocket expenses under Section 6.2(a), FTE Costs under Section 6.2(b), Equipment Payment reimbursements under Section 6.2(c), and any payments under
Section 3.6, and the amount of any Net Sales, milestone, royalty or other payment discrepancy. No other information shall be provided to the Auditing Party. The Audited Party shall receive a copy of each such report concurrently with receipt by
the Auditing Party. Should such inspection lead to the discovery of a discrepancy to the Auditing Party’s detriment, the Audited Party shall pay the amount of the discrepancy within [***] ([***]) days after its receipt from the accounting firm
of the certificate showing the amount of the discrepancy. The Auditing Party shall pay the full cost of the review unless (a) uniQure or 4DMT (as applicable) was the Audited Party and the audited determined an underpayment of milestones or
royalties which is greater than [***] percent ([***]%) of the amount due for the applicable period, in which case uniQure or 4DMT (as applicable) shall pay the reasonable costs charged by such accounting firm for such review, or (b) 4DMT or uniQure
(as applicable) was the Audited Party and the audit determined an overpayment of 4DMT or uniQure (as applicable) out-of-pocket expenses under Section 6.2(a) or FTE
Costs under Section 6.2(b), or underpayment of Equipment Payment reimbursements under Section 6.2(c), which is greater than [***] percent ([***]%) of the amount due for the applicable period, in which case 4DMT or uniQure (as applicable)
shall pay the reasonable costs charged by such accounting firm for such review. Any overpayment of royalties by uniQure (or 4DMT, as applicable) revealed by an inspection shall be fully creditable against future royalty payments under
Section 6.4. As of the Amended CLA Effective Date, notwithstanding anything express or implied, the Parties agree that there shall be no audits under this Section 6.7 as to accounting records for any time period prior to [***] before the
Amended CLA Effective Date. 
 6.8 Withholding Taxes. (a) Subject to the provisions of Section 12.7, if Laws require
withholding by uniQure of taxes imposed upon 4DMT on account of any royalty or other payment paid under this Agreement, such taxes shall be deducted by uniQure as required by Law from such remittable royalty or other payment and shall be paid by
uniQure to the proper tax authorities; provided that before making any such deduction or withholding, uniQure shall give 4DMT notice of the intention to make such deduction or withholding, which notice shall include the authority, basis and
method of calculation for the proposed deduction or withholding, and shall be provided to the extent practicable at least a reasonable period of time before such deduction or withholding is required, in order for 4DMT to obtain reduction of or
relief from such deduction or withholding. Official receipts of payment of withholding taxes shall be secured and sent to 4DMT as evidence of such payment. The Parties shall exercise their best efforts to ensure that any withholding tax imposed is
reduced as far as possible under the provisions of any relevant tax treaty. 

  
 - 39 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (b) Subject to the provisions of Section 12.7, if Laws require withholding by 4DMT of
taxes imposed upon uniQure on account of any royalty or other payment paid under this Agreement, such taxes shall be deducted by 4DMT as required by Law from such remittable royalty or other payment and shall be paid by 4DMT to the proper tax
authorities; provided that before making any such deduction or withholding, 4DMT shall give uniQure notice of the intention to make such deduction or withholding, which notice shall include the authority, basis and method of calculation for
the proposed deduction or withholding, and shall be provided to the extent practicable at least a reasonable period of time before such deduction or withholding is required, in order for uniQure to obtain reduction of or relief from such deduction
or withholding. Official receipts of payment of withholding taxes shall be secured and sent to uniQure as evidence of such payment. The Parties shall exercise their best efforts to ensure that any withholding tax imposed is reduced as far as
possible under the provisions of any relevant tax treaty. 
 6.9 United States Dollars. All dollar ($) amounts specified in this
Agreement are United States dollar amounts. 
 6.10 Payment Method and Currency Conversion. Except as otherwise provided herein, all
payments due to a Party hereunder shall be due and payable within [***] ([***]) days after receipt of an invoice from the other Party and shall be paid via a bank wire transfer to such bank account as such Party shall designate. For the purposes of
determining the amount of any payment due hereunder for the relevant Calendar Quarter under Section 6.4 or Section 6.5, amounts received by a Party in any foreign currency shall be converted into United States dollars in accordance with
the normal business practice of such Party, as applied consistently across its business. 
 6.11 Blocked Payments. 

(a) If, by reason of applicable Laws in any country in the Territory, it becomes impossible or illegal for uniQure or any of its Affiliates or
Sublicensees to transfer, or have transferred on its behalf, royalties or other payments to 4DMT, uniQure shall promptly notify 4DMT of the conditions preventing such transfer and such royalties or other payments shall be deposited in local currency
in the relevant country to the credit of 4DMT in a recognized banking institution with a good creditworthiness, such banking institution to be designated by 4DMT or, if none is designated by 4DMT within [***] ([***]) days, in a recognized banking
institution selected by uniQure or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to 4DMT. If so deposited in a foreign country, uniQure shall provide, or cause its Affiliate or Sublicensee to provide,
reasonable cooperation to 4DMT so as to allow 4DMT to assume control over such deposit as promptly as practicable. 
 (b) If, by reason of
applicable Laws in any country in the Territory, it becomes impossible or illegal for 4DMT or any of its Affiliates or Sublicensees to transfer, or have transferred on its behalf, royalties or other payments to uniQure, 4DMT shall promptly notify
uniQure of the conditions preventing such transfer and such royalties or other payments shall be deposited in local currency in the relevant country to the credit of uniQure in a recognized banking institution with a good creditworthiness, such
banking institution to be designated by uniQure or, if none is designated by uniQure within [***] ([***]) days, in a recognized banking institution selected by 

  
 - 40 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
4DMT or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to uniQure. If so deposited in a foreign country, 4DMT shall provide, or cause its Affiliate or
Sublicensee to provide, reasonable cooperation to uniQure so as to allow uniQure to assume control over such deposit as promptly as practicable.  

6.12 Late Payments. Any payment not made within [***] ([***]) Business Days after the due date for such payment pursuant to the terms of
this Agreement shall bear interest at a rate of the thirty-day U.S. dollar LIBOR rate effective for the date that payment was due (as published in The Wall Street Journal, Eastern Edition) plus [***].
Calculation of interest will be made for the exact number of days the payment was past due based on a year of 360 days (actual days/360). 

ARTICLE VII 
 PATENTS

 7.1 Disclosure. Each Party shall promptly disclose to the other Party any Inventions that it or its Affiliates or
Sublicensees or their employees, independent contractors, or agents solely or jointly make, conceive, reduce to practice, or otherwise discover under this Agreement, and each Party shall maintain and make available to the other Party records
regarding any Inventions that it has an obligation to assign under Section 7.2(a). 
 7.2 Ownership. 

(a) uniQure shall solely own all Core uniQure Intellectual Property, and 4DMT shall solely own all Core 4MDT Intellectual Property. Without
additional consideration, each Party shall assign and hereby does assign to the other Party such of its right, title, and interest in and to such Patent Rights (and shall require its Affiliates and Sublicensees, and all employees, independent
contractors and their employees, and agents of such Party and its Affiliates and Sublicensees to so assign to the other Party such of their right, title, and interest) as is necessary to effectuate the allocation of right, title, and interest as set
forth in this Section 7.2(a). 
 (b) Except as set forth in Section 7.2(a), as between the Parties, (i) each Party shall
solely own all Know-How and Inventions invented solely by employees, agents and consultants of such Party or its Affiliates, and any Patent Right related thereto, subject to the licenses granted under ARTICLE
V, and (ii) Know-How and Inventions invented jointly by employees, agents, or consultants of the Parties or their Affiliates (“Joint Intellectual Property”, which includes any Patent
Right Covering such Know-How and Inventions (“Joint Patent Rights”) and any Know-How included in such Joint Intellectual Property (“Joint Know-How”)) shall be jointly owned, subject to the licenses granted under ARTICLE V. Inventorship shall be determined in accordance with U.S. patent Laws for purposes of determining ownership in accordance
with the foregoing. 
 (c) Except as expressly provided in this Agreement, and subject to any restriction herein (including the licenses and
exclusivity granted under ARTICLE V), (i) each joint owner may engage in research, Development, manufacturing and Commercialization activities relating to Joint Intellectual Property, and (ii) each may assign, license, sell or otherwise
encumber or transfer any such interest without the prior written approval of the other Party and without obligation to account or provide compensation to the other Party. 

  
 - 41 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 7.3 uniQure Prosecution and Maintenance of Patent Rights. 

(a) uniQure shall be solely responsible for the Prosecution and Maintenance of the uniQure Patent Rights, including the Core uniQure Patent
Rights, at its sole expense and its sole discretion. uniQure shall give 4DMT an opportunity to review the text of each application, office action response or other substantive document for a Core uniQure Patent Right specifically relating to [***]
(but not any other uniQure Patent Right) before filing with any patent office in the Territory, shall consider 4DMT’s reasonable comments with respect thereto, and shall supply 4DMT with a copy of each such application, office action response
or other substantive document as filed, together with notice of its filing date and serial number. 
 (b) uniQure shall have the sole right
to determine whether any patent application is filed with respect to any Core uniQure Know-How and whether to maintain any Invention included in the Core uniQure
Know-How as a trade secret. uniQure shall provide 4DMT with written notice if uniQure elects not to file a patent application claiming any particular Invention included in the Core uniQure Know-How specifically relating to compositions of matter of, methods of use of, or methods of making any Selected Capsid Variant because uniQure prefers to maintain such Invention as a trade secret (each, a
“Trade Secret Election”). 
 (c) uniQure shall notify 4DMT at least [***] ([***]) days in advance of any applicable
deadline if (i) uniQure decides that it does not wish to continue the Prosecution and Maintenance of a [***] for which no substitute has been filed, or (ii) uniQure decides that it intends to abandon claim scope in a [***], which claim
scope is intended to be maintained by 4DMT, in which case, with respect to this clause (ii), 4DMT may assume responsibility for such claim scope by filing a divisional application restricted to such claim scope. In such cases (i) or (ii),
uniQure shall allow 4DMT to assume responsibility for Prosecution and Maintenance of such Core uniQure Patent Right or divisional application at 4DMT’s expense. If 4DMT assumes such responsibility, then 4DMT may designate any counsel of its
choice reasonably acceptable to uniQure to handle the Prosecution and Maintenance of such Core uniQure Patent Right or divisional application (which shall otherwise continue to be part of the Core uniQure Patent Rights). 

7.4 4DMT Prosecution and Maintenance of Patent Rights. 4DMT shall be solely responsible for the Prosecution and Maintenance of the 4DMT
Patent Rights, including the Core 4DMT Patent Rights, at its sole expense and its sole discretion. 4DMT will reasonably inform uniQure regarding the Prosecution and Maintenance of 4DMT Patent Rights (including in any case, an update at least [***]).
Notwithstanding the foregoing, the Parties acknowledge that UC will handle the Prosecution and Maintenance of the UC Patent Rights in accordance with the terms of the UCB Agreements. 

  
 - 42 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 7.5 Prosecution and Maintenance of Joint Patent Rights. The Prosecution and
Maintenance of any Joint Patent Right shall be through a mutually selected patent counsel. Within [***] ([***]) days following the Effective Date, the Parties shall agree on a patent counsel (“Joint Counsel”) who shall be
engaged by both Parties for the Prosecution and Maintenance of all such Joint Patent Rights. The following terms shall apply to each Joint Patent Right: 

(a) The Parties shall instruct Joint Counsel to conduct its activities as follows: The Joint Counsel shall give uniQure and 4DMT (or each
Party’s designee) an opportunity to review the text of each application, office action response or other substantive document for a Joint Patent Right before filing with any patent office in the Territory, shall incorporate uniQure’s and
4DMT’s (or each Party’s designee) reasonable comments with respect thereto, and shall supply uniQure and 4DMT (or each Party’s designee) with a copy of each such application, office action response or other substantive document as
filed, together with notice of its filing date and serial number. In the event that 4DMT and uniQure provide Joint Counsel with conflicting instructions regarding the Prosecution and Maintenance of a Joint Patent Right, Joint Counsel shall make the
Parties aware of such conflicting instructions and, if the Parties are not able to resolve such conflict within a reasonable time prior to the applicable filing deadline, the Joint Counsel shall take such action as would reasonably be expected to
maximize the scope, extent and coverage of such Joint Patent Right. 
 (b) Both Parties shall cooperate with Joint Counsel in Prosecution
and Maintenance of patent applications for Joint Patent Rights, including providing Joint Counsel with data and other information as appropriate with respect thereto. 

(c) Joint Counsel shall keep uniQure and 4DMT advised of the status of the Prosecution and Maintenance of Joint Patent Rights, including
actual and prospective patent filings for Joint Patent Rights, and shall provide each Party with advance copies of any and all papers related thereto. Joint Counsel shall promptly give notice to uniQure and 4DMT of the grant, lapse, revocation,
surrender, invalidation or abandonment of any Joint Patent Right. 
 (d) The Parties shall equally share all fees and costs charged by Joint
Counsel with respect to the Prosecution and Maintenance of Joint Patent Rights and all other mutually agreed and approved out-of-pocket costs and expenses incurred by
either Party in connection with such Prosecution and Maintenance of Joint Patent Rights. 
 (e) uniQure shall notify 4DMT and Joint Counsel
at least [***] ([***]) days in advance of the next deadline if (A) uniQure decides that it does not wish to continue paying for the Prosecution and Maintenance of a particular Joint Patent Right for which no substitute has been filed, or
(B) uniQure decides that it intends to abandon claim scope in a Joint Patent Right which claim scope is intended to be maintained by 4DMT, in which case, with respect to this clause (B), 4DMT may assume responsibility for such claim scope by
filing a divisional application restricted to such claim scope. In such cases (A) or (B), uniQure shall allow 4DMT to assume responsibility for Prosecution and Maintenance of the respective Patent Rights, including payments incurred after [***]
([***]) days after receipt of uniQure’s notice. If 4DMT assumes such responsibility, then: (i) 4DMT may designate any counsel of its choice to handle the Prosecution and Maintenance of such Joint Patent Right or of the divisional application
and it shall cease to be a part of the Joint Patent Rights; (ii) uniQure shall lose its licenses to such former Joint Patent Right or divisional application under ARTICLE V and such former Joint Patent Right or divisional application shall be
deemed a 4DMT Patent Right; and (iii) uniQure shall and hereby 

  
 - 43 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
does transfer and assign all right, title and interest in said former Joint Patent Right or of the divisional application to 4DMT as the sole owner. If 4DMT decides not to assume such
responsibility, then it shall instruct Joint Counsel to abandon the Prosecution and Maintenance of such Joint Patent Right or not to file such divisional application. 

(f) 4DMT shall notify uniQure and Joint Counsel at least [***] ([***]) days in advance of the next deadline if (A) 4DMT decides that it does
not wish to continue paying for the Prosecution and Maintenance of a particular Joint Patent Right for which no substitute has been filed, or (B) 4DMT decides that it intends to abandon claim scope in a Joint Patent Right which claim scope is
intended to be maintained by uniQure, in which case, with respect to this clause (B), uniQure may assume responsibility for such claim scope by filing a divisional application restricted to such claim scope. In such cases (A) or (B), 4DMT shall
allow uniQure to assume responsibility for Prosecution and Maintenance of the respective Patent Rights, including payments incurred after [***] ([***]) days after receipt of 4DMT’s notice. If uniQure assumes such responsibility, then:
(i) uniQure may designate any counsel of its choice to handle the Prosecution and Maintenance of such Joint Patent Right or of the divisional application and it shall cease to be a part of the Joint Patent Rights and no further uniQure royalty
obligations shall exist under this Agreement with respect thereto; (ii) 4DMT shall lose its licenses to such former Joint Patent Right or divisional application under ARTICLE V and such former Joint Patent Right or divisional application shall be
deemed a uniQure Patent Right; and (iii) 4DMT shall and hereby does transfer and assign all right, title and interest in said former Joint Patent Right or of the divisional application to uniQure as the sole owner. If uniQure decides not to assume
such responsibility, then it shall instruct Joint Counsel to abandon the Prosecution and Maintenance of such Joint Patent Right or not to file such divisional application. 

7.6 Third Party Infringement. 

(a) Notice. Each Party shall promptly report in writing to the other Party any known or suspected (i) infringement of any of the
4DMT Patent Rights, uniQure Patent Rights or Joint Patent Rights, or (ii) unauthorized use or misappropriation of any of the 4DMT Know-How, uniQure Know-How or
Joint Know-How, of which such Party becomes aware and shall provide the other Party with all available evidence regarding such known or suspected infringement or unauthorized use. 

(b) Enforcement of Solely Owned Patent Rights. uniQure shall have the sole right to enforce the uniQure Patent Rights, including the
Core uniQure Patent Rights. Subject to UC’s rights under the UCB Agreements with respect to any UC Patent Right included in the 4DMT Patent Rights, 4DMT shall have the sole right to enforce any 4DMT Patent Right, including the Core 4DMT Patent
Rights. Each Party shall cooperate in the prosecution of any such suit brought by the enforcing Party as may be reasonably requested by the enforcing Party; provided that the enforcing Party shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by the non-enforcing Party in connection with
such cooperation. 

  
 - 44 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (c) Enforcement of Joint Patent Rights. 

(i) In the Field. uniQure shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to
enforce the Joint Patent Rights against any infringement in the Field. 4DMT shall cooperate in the prosecution of any such suit as may be reasonably requested by uniQure, including joining any action as party-plaintiff at uniQure’s sole
discretion; provided that uniQure shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by 4DMT
in connection with such cooperation. 
 (ii) Outside the Field. 4DMT shall retain any and all rights to initiate a lawsuit or take
other reasonable action to enforce the Joint Patent Rights against any infringement outside the Field. uniQure shall cooperate in the prosecution of any such suit as may be reasonably requested by 4DMT, including joining any action as
party-plaintiff at 4DMT’s sole discretion; provided that 4DMT shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and
expenses) actually incurred by uniQure in connection with such cooperation. 
 (iii) Step-In
Right. If either Party does not initiate a lawsuit or take other reasonable action pursuant to this Section 7.6(c) (the “Non-Enforcing Party”), then the other Party (the
“Enforcing Party”) shall have the right, but not the obligation, to initiate such lawsuit or take such other action, after providing [***] ([***]) days’ notice to the Non-Enforcing Party
and giving good faith consideration to the Non-Enforcing Party’s reason(s) for not initiating a lawsuit or taking other action. For this purpose, the Non-Enforcing
Party shall cooperate in the prosecution of any such suit as may be reasonably requested by the Enforcing Party, including joining any action as party-plaintiff at the Non-Enforcing Party’s sole
discretion; provided, that the Enforcing Party shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually
incurred by the Non-Enforcing Party in connection with such cooperation. 
 (d) Conduct of
Certain Actions; Costs. The Party initiating legal action shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to Section 7.6(b) or 7.6(c) (the “Initiating Party”). The Initiating
Party shall bear its own out-of-pocket costs incurred in any such legal action, including the fees and expenses of the counsel selected by it. The other Party shall have
the right to participate and be represented in any such legal action (in cases where such other Party has standing) by its own counsel at its own expense. The Initiating Party shall have the final say about the strategy and decisions in the suit and
any settlement. 
 (e) Recoveries. Any amount recovered in any action or settlement of any such action shall be allocated first to
equally reimburse each Party’s actual out-of-pocket costs (including reasonable attorneys’ fees and expenses) incurred in such action and any amount remaining
shall be allocated to the Initiating Party; provided that if uniQure is the Initiating Party with respect to any such suit to enforce any Patent Right included in the Licensed IP in the Field, then, with respect to any remaining portion of
such recovery, (i) any amount that reflects punitive or exemplary damages shall be allocated [***] percent ([***]%) to uniQure and [***] ([***]%) to 4DMT, and (ii) any other amounts shall be treated as Net Sales and subject to payment of
royalties under Section 6.4(a); and provided further that if uniQure is the Initiating Party with respect to any such suit to enforce any Joint Patent Right outside the Field, or if 4DMT is the Initiating Party with respect to any
such suit to enforce any Joint Patent Right in the Field, any amount remaining shall be allocated [***]. 

  
 - 45 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 7.7 Patent Invalidity Claim. Each Party shall promptly notify the other in the event
of any legal or administrative action by any Third Party against a 4DMT Patent Right, uniQure Patent Right or Joint Patent Right of which it becomes aware, including any nullity, revocation, reexamination or compulsory license proceeding. To the
extent such action is in connection with an enforcement of such Patent Right under Section 7.6, the Parties’ rights with respect to defending any such Patent Right in any such proceeding shall correspond to those set forth in
Section 7.6. 
 7.8 Patent Term Extensions. 

(a) uniQure shall have full and exclusive right to determine and control all filings of requests for any patent term extension or supplemental
patent certificate or their equivalents in any country in the Territory for any uniQure Patent Right, including any Core uniQure Patent Right, and all costs and expenses relating thereto shall be paid by uniQure. 

(b) 4DMT shall have full and exclusive right to determine and control all filings of requests for any patent term extension or supplemental
patent certificate or their equivalents in any country in the Territory for any 4DMT Patent Right, including any Core 4DMT Patent Right, and all costs and expenses relating thereto shall be paid by 4DMT. 

(c) The Parties shall jointly determine how to defend any such action relating to any Joint Patent Right. 

(d) The Parties shall reasonably cooperate with each other in obtaining patent term extensions or supplemental protection certificates or
their equivalents in any country in the Territory. 
 7.9 Orange Book; Paragraph IV Certification. 

(a) uniQure shall have the right, but not the obligation, to list any uniQure Patent Rights in the then-current edition of the FDA publication
“Approved Drug Products With Therapeutic Equivalence Evaluations” (the “Orange Book”), or equivalent patent listings in other countries. 

(b) With respect to any notification provided by a Third Party to uniQure or 4DMT under 21 U.S.C. § 355(j)(2)(B) making a
certification described in 21 U.S.C. § 355(j)(2)(A)(vii)(IV) with respect to any uniQure Patent Right that is listed for a Royalty Bearing Product in the Orange Book, or equivalent actions in other countries, (each a “Paragraph IV
Certification”), the following shall apply notwithstanding Sections 7.6 and 7.7: 
 (i) Without any avoidable delay, however at the
latest within [***] ([***]) Business Days after receipt of any notification of a Paragraph IV Certification, such Party shall notify the other Party in writing and attach of copy of such notification. uniQure and 4DMT shall thereafter consult and
cooperate fully to determine a course of action with respect to any such proceeding, including the negotiation of the offer of confidential access. 

  
 - 46 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (ii) With respect to any uniQure Patent Right, uniQure shall have the sole right to initiate
any infringement proceeding as a result of such Paragraph IV Certification (a “Paragraph IV Proceeding”) with respect to a Royalty Bearing Product, including by commencing a patent infringement action under 35 U.S.C.
§ 271(e)(2)(A), and shall bear the expense of any such Paragraph IV Proceeding and, if legally required, may commence such action in 4DMT’s or the relevant 4DMT Affiliate’s name and on 4DMT’s or the relevant 4DMT
Affiliate’s behalf. 
 (iii) Section 7.6(e) shall apply if any amount is recovered in any Paragraph IV Proceeding or settlement of
any Paragraph IV Proceeding under this Section 7.9(b). 
 7.10 CREATE Act. Each Party acknowledges and agrees that this Agreement
is a “joint research agreement” as contemplated by 35 U.S.C. § 102(c), and that all Inventions are intended to have the benefit of the rights and protections conferred by the Cooperative Research and Enhancement Act of 2004 (the
“CREATE Act”). In the event that a Party seeks to rely on the foregoing and to invoke the CREATE Act with respect to any Invention, such Party will give prior written notice to the other Party of its intent to invoke the CREATE Act
and of each submission or disclosure such Party intends to make to the United States Patent and Trademark Office (the “USPTO”) pursuant to the CREATE Act, including: (a) any disclosure of the existence or contents of this
Agreement to the USPTO, (b) the disclosure of any “subject matter developed by the other Party” (as such term is used in the CREATE Act) in an information disclosure statement or otherwise, or (c) the filing of any terminal
disclaimer over the intellectual property of the other Party, it being agreed that no such submission, disclosure or filing shall be made by such Party without the prior written consent of the other Party, such consent not to be unreasonably
withheld, conditioned or delayed, except that no such consent shall be required to disclose to the USPTO, through an information disclosure statement or otherwise, any “subject matter developed by the other Party” that was previously
published or included in a published patent application by the other Party. The other Party will provide reasonable cooperation to such Party in connection with such Party’s efforts to invoke and rely on the CREATE Act. 

ARTICLE VIII 

CONFIDENTIALITY AND PUBLICATION 

8.1 Confidentiality Obligations. Each Party shall (a) maintain in confidence the Confidential Information of the other Party to
the same extent such Party maintains its own confidential information, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the other Party, and (c) not use such Confidential Information
for any purpose except those permitted by this Agreement. Such obligations shall survive for a period of [***] ([***]) years after termination or expiration of this Agreement, except that such obligations shall survive with respect to any
Confidential Information identified by the disclosing Party as a trade secret for so long as such Confidential Information remains a trade secret. 

  
 - 47 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 8.2 Exceptions to Confidentiality. Notwithstanding the foregoing, the obligations of
confidentiality set forth in Section 8.1 shall not apply to information that, in each case as demonstrated by competent written documentation: 

(a) is publicly disclosed or made generally available to the public by the disclosing Party, either before or after it becomes known to the
receiving Party; 
 (b) was known to the receiving Party, without any obligation to keep it confidential, prior to the date of first
disclosure by the disclosing Party to the receiving Party, as shown by the receiving Party’s files and records; 
 (c) is subsequently
disclosed to the receiving Party by a Third Party lawfully in possession thereof without obligation to keep it confidential and without a breach of such Third Party’s obligations of confidentiality; 

(d) has been publicly disclosed or made generally available to the public other than through any act or omission of the receiving Party or its
Affiliates in breach of this Agreement; or 
 (e) has been independently developed by the receiving Party without the aid, application or
use of the disclosing Party’s Confidential Information (the competent written proof of which must be contemporaneous with such independent development). 

8.3 Authorized Disclosure. Notwithstanding Section 8.1, a Party may disclose Confidential Information of the other Party to
the extent such disclosure is reasonably necessary in the following instances: 
 (a) Prosecuting and Maintaining Patent Rights in
accordance with this Agreement; 
 (b) making filings with Regulatory Authorities in accordance with this Agreement; 

(c) complying with applicable Laws or submitting information to tax or other Governmental Authorities; provided that if a Party is
required by Law to make any public disclosure of Confidential Information of the other Party, to the extent it may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to
secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise); 

(d) to its Affiliates, and to prospective and actual acquirers, licensees, sublicensees, employees, consultants, agents, accountants, lawyers,
advisors, investors and underwriters, on a need to know basis, each of whom prior to disclosure must be bound by written or professional ethical obligations of confidentiality and non-use equivalent in scope
to those set forth in this ARTICLE VIII and that are of reasonable duration in view of the circumstances of the disclosure; or 
 (e) to the
extent mutually agreed to in writing by the Parties. 

  
 - 48 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 8.4 Scientific Publications. During the Research Term, neither Party shall first
publish or first present in a public forum the scientific or technical results of any activity performed pursuant to this Agreement without the opportunity for prior review and comment by the other Party. Each Party agrees to provide the other Party
with the opportunity to review any proposed abstract, manuscript or scientific presentation (including any verbal presentation) that relates to its activities performed pursuant to this Agreement during the Research Term, at least [***] ([***]) days
prior to its intended submission for publication and agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given a reasonable period of time up to [***] ([***]) months to secure patent
protection for any material in such publication that it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications first with respect to
activities performed or results obtained pursuant to this Agreement during the Research Term, or not to publish at all if necessary to preserve trade secrets. The Parties agree to review and decide whether to delay publication of such information to
permit filing of patent applications. Neither Party shall have the right to publish or present any Confidential Information of the other Party, except as provided in Section 8.3. After the Research Term, each Party and its Affiliates may
publish or present results, data or scientific findings of any of their activities performed after the Research Term without the prior review of the other Party, provided that such publication or presentation does not disclose any of
the other Party’s Confidential Information. After the Research Term, neither Party nor its Affiliates may publish or present any of the results, data or scientific findings of any activity performed by the other Party or its Affiliates pursuant
to this Agreement without prior review and prior written consent of such other Party. Nothing contained in this Section 8.4 shall prohibit the inclusion of information necessary for a patent application; provided that the non-filing Party is given a reasonable opportunity to review the information to be included prior to submission of such patent application. For clarity, any publication under this Section 8.4 shall be
consistent with uniQure’s internal publication strategy, which shall be made available to 4DMT upon request. Nothing contained in this Section 8.4 shall prohibit either Party from disclosing the results, data or scientific findings of any
activity performed by the other Party or its Affiliates pursuant to this Agreement without prior review and prior written consent of the other Party, where required, as reasonably determined by the disclosing Party’s legal counsel, by
applicable Law; provided that if a Party is required by Law to make any such disclosure, to the extent it may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to
secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise). 
 8.5 Press
Releases and Other Permitted Disclosures. 
 (a) 4DMT and uniQure each agree not to disclose any of the terms and conditions of this
Agreement to any Third Party, except as described below in this Section 8.5. The Parties will cooperate in the release of a mutually agreed upon press release announcing the collaboration contemplated by this Agreement as soon as practicable
after the Effective Date. Subject to the other provisions of this Agreement, no other press release, public statement or public disclosure concerning the existence or terms of this Agreement shall be made, either directly or indirectly, by either
Party, without first obtaining the written approval of the other Party, which 

  
 - 49 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
such approval shall not be unreasonably withheld or delayed beyond [***] ([***]) Business Days (or [***] ([***]) Business Days if the Party wishing to make such disclosure or any of its
controlling Affiliates is then a public company) following submission to the approving Party of a draft of the respective press release, public statement or public disclosure. In no event shall any such subsequent press release, public statement or
public disclosure by 4DMT disclose, if previously undisclosed, the identity of any Compound or Product or the stage of development of any Compound or Product that uniQure is researching, Developing, manufacturing, or Commercializing; provided
that for clarity, uniQure may disclose, without the written approval of 4DMT, the identity of any Compound or Product or the stage of development of any Compound or Product that uniQure is researching, Developing, manufacturing, or Commercializing.
In no event shall any such subsequent press release, public statement or public disclosure by a Party disclose, if previously undisclosed, the financial terms of this Agreement; provided that 4DMT may disclose the receipt of, and uniQure may
disclose the payment of, any milestone payment but not the amount of such milestone payment; provided, further, however, that if disclosure of the amount of a milestone payment is required by applicable Law, by applicable stock
exchange regulation, or by order or other ruling of a competent court, as set forth in Section 8.5(c), then 4DMT or uniQure, as the case may be, may also disclose such amount in a public statement or disclosure. Once any public statement or
public disclosure has been approved in accordance with this Section 8.5, then either Party may appropriately communicate information contained in such permitted statement or disclosure. 

(b) Either Party may disclose the existence and terms of this Agreement in confidence to its attorneys, to UC, and to each of the following,
under an agreement with terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement and, as applicable, to use such information solely for the purpose permitted pursuant to
the applicable subsection of this Section 8.5(b): 
 (i) professional accountants, consultants, or auditors; 

(ii) bankers or other financial advisors, in connection with an initial public offering, private financing or other strategic transaction, or
corporate valuation for internal purposes; 
 (iii) potential acquirers (and their respective attorneys and professional advisors), in
connection with a potential merger, acquisition or reorganization; provided that the Party making the disclosure has a bona fide offer (e.g., a signed term sheet or letter of intent, even if
non-binding) from such Third Party for such a transaction; 
 (iv) to actual or potential investors,
lenders or permitted assignees of such Party (and their respective attorneys and professional advisors); or 
 (v) to actual or potential
licensees or sublicensees of such Party (and their respective attorneys and professional advisors); provided that such disclosure in the case of 4DMT shall not include any financial terms, the Candidate Success Criteria, the Delivery Success
Criteria, or Schedule 1.76. 

  
 - 50 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (c) Notwithstanding the foregoing provisions of this ARTICLE VIII, a Party may disclose the
existence and terms of this Agreement, however excluding, as far as legally possible, Schedule 1.76, or the Parties’ activities under this Agreement, where required, as reasonably determined by the legal counsel of the disclosing Party,
by applicable Law, by applicable stock exchange regulation or by order or other ruling of a competent court, although, to the extent practicable, the other Party shall be given [***] ([***]) Business Days advance notice of any such legally required
disclosure to comment and reasonably consider such comments provided by such other Party on the proposed disclosure. In case either Party is obliged to publish this Agreement as a “material agreement” in accordance with the U.S. stock
exchange regulations (“SEC Filing”), this Agreement shall be redacted by the filing Party as far as legally possible, and the filing Party shall cooperate with the other Party reasonably in advance to such SEC Filing to enable the
other Party to review and comment on the scope of such redaction. 
 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION 

9.1 Representations and Warranties of the Parties. uniQure and 4DMT each represent, warrant and covenant to the other that: 

(a) as of the Effective Date, it has the authority and right to enter into and perform this Agreement and grant the rights embodied herein,
and it is not aware of any legal impediment that could inhibit its ability to perform its obligations under this Agreement; 
 (b) as of the
Effective Date, its execution, delivery and performance of this Agreement does not conflict with, or constitute a breach of, any order, judgment, agreement or instrument to which it is a party or is otherwise bound; 

(c) it shall comply in all material respects with all Laws applicable to its actions under this Agreement; and 

(d) as of the Effective Date, no consent of any Third Party is required for such Party to grant the licenses and rights granted to the other
Party under this Agreement or to perform its obligations hereunder. 
 9.2 Representations and Warranties of 4DMT. 4DMT represents,
warrants and covenants to uniQure that: 
 (a) as of the Effective Date, Schedule 1.5 is compiled accurately and, to the extent set
forth in Section 1.5, is complete regarding the subject matter set forth therein; 
 (b) as of the Effective Date, 4DMT has not
previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in 4DMT Intellectual Property in a manner inconsistent with the terms hereof; 

(c) as of the Effective Date, 4DMT has valid and existing licenses, free and clear of all liens, charges and encumbrances, to the 4DMT Patent
Rights not owned by 4DMT; 

  
 - 51 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (d) as of the Effective Date, to 4DMT’s knowledge, the conception, development
and reduction to practice of the 4DMT Intellectual Property has not constituted or involved the misappropriation of trade secrets of any Third Party or the infringement of issued Patent Rights of any Third Party; 

(e) as of the Effective Date, 4DMT has not received any written notice of any unauthorized use, infringement, or misappropriation by any
person or entity, including any current or former employee or consultant of 4DMT, of any 4DMT Intellectual Property; 
 (f) as of the
Effective Date, to 4DMT’s knowledge, there are no claims, judgments, settlements pending or any action with respect to the 4DMT Intellectual Property; 

(g) as of the Effective Date, to 4DMT’s knowledge, uniQure’s use of the 4DMT Intellectual Property, as reasonably anticipated to be
used in the conduct of the Research Program, will not infringe any valid Patent Right existing as of the Effective Date and owned by any Third Party; 

(h) all of 4DMT’s personnel and employees, and Third Parties, including agents and consultants, hired by 4DMT and involved in the
Research Program are, or when hired will be, under a written obligation to assign to 4DMT any right they may have in any Invention first invented, discovered, made, conceived or reduced to practice in the conduct of activities pursuant to the
Research Program, and all intellectual property rights therein; 
 (i) it will not, after the Effective Date, enter into any written or oral
contractual obligation with any Third Party that would be inconsistent with the obligations that arise on its part out of this Agreement or that would deprive uniQure of the benefits of or rights granted under this Agreement; 

(j) as of the Effective Date, each of the UCB Agreements is in full force and effect, and 4DMT will not, after the Effective Date, terminate,
amend or otherwise modify any of the terms thereof without prior written consent from uniQure, or take any action or refrain from taking any action that would permit UC to terminate any UCB Agreement (it being recognized that if the Selected Capsid
Variants are not UC AAV Capsid Variants, and UC terminates any UCB Agreement, 4DMT shall not be deemed to be in breach of the foregoing), and 4DMT shall promptly provide uniQure with a copy of each notice it receives from UC under any UCB Agreement;
and 
 (k) if, during the Term, 4DMT has reason to believe that it or any of its employees, officers, subcontractors, or consultants
rendering services hereunder (i) is or shall be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or shall be under indictment under said Section 335a, then 4DMT shall immediately notify uniQure in
writing. 
 For purposes of this Section 9.2, “knowledge” shall mean the actual knowledge of 4DMT, including [***]. 

  
 - 52 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 9.3 Representations and Warranties of uniQure. uniQure represents, warrants and
covenants to 4DMT that: 
 (a) all of uniQure’s personnel and employees, and Third Parties, including agents and consultants, hired by
uniQure and involved in the Research Program are, or when hired will be, under a written obligation to assign to uniQure any right they may have in any Invention first invented, discovered, made, conceived or reduced to practice in the conduct of
activities pursuant to the Research Program, and all intellectual property rights therein; 
 (b) it will not, after the Effective Date,
enter into any written or oral contractual obligation with any Third Party that would be inconsistent with the obligations that arise on its part out of this Agreement or that would deprive 4DMT of the benefits of or rights granted under this
Agreement; 
 (c) if, during the Term, uniQure has reason to believe that it or any of its employees, officers, subcontractors, or
consultants rendering services hereunder (i) is or shall be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or shall be under indictment under said Section 335a, then uniQure shall immediately notify
4DMT in writing. 
 9.4 No Other Warranties. 

(a) EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED, AND PARTICULARLY THAT PRODUCT(S) WILL BE SUCCESSFULLY DEVELOPED HEREUNDER, AND IF PRODUCT(S) ARE DEVELOPED, WITH RESPECT TO SUCH PRODUCT(S), THE PARTIES DISCLAIM ALL IMPLIED WARRANTIES OF TITLE,
NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 (b) uniQure acknowledges
that UC has not warranted to 4DMT under the UCB Agreements as to the validity of any Patent Rights or that practice under such Patent Rights shall be free of infringement. UNIQURE, ITS AFFILIATES AND ITS SUBLICENSEE(S) AGREE THAT (I) THE
LICENSES GRANTED PURSUANT TO THE UCB AGREEMENTS, THE UC AAV CAPSID VARIANTS, AND THE ASSOCIATED INVENTIONS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED; (II) UC
MAKES NO REPRESENTATION OR WARRANTY THAT ANY INVENTION CLAIMED BY THE UC PATENT RIGHTS, THE UC AAV CAPSID VARIANTS, THE UC PATENT RIGHTS, OR THE UC PRODUCTS WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT; AND (III) IN NO EVENT WILL UC
BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THE LICENSES GRANTED PURSUANT TO THE UCB AGREEMENTS OR THE USE OF ANY INVENTION CLAIMED BY THE UC PATENT RIGHTS, THE UC AAV CAPSID VARIANTS, THE UC PATENT
RIGHTS, OR THE UC PRODUCTS. 
 9.5 Indemnification by uniQure. uniQure shall indemnify, hold harmless and defend 4DMT, its Affiliates
and all of their respective officers, directors, employees, agents and shareholders (collectively, the “4DMT Indemnitees”) from and against any and all losses, damages, liabilities, judgments, fines, amounts paid in settlement,
expenses and costs of defense 

  
 - 53 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
(including reasonable attorneys’ fees and witness fees) (collectively, “Damages”) resulting from any demand, claim, action or proceeding brought or initiated by a Third
Party (each a “Third Party Claim”) against any 4DMT Indemnitee to the extent arising out of: (a) a Default by uniQure; (b) the negligence or willful misconduct of a uniQure Indemnitee; or (c) the use, Development,
Commercialization, storage or other exploitation of any Compound or Product by uniQure, its Affiliates, Sublicensees, Third Party Distributors, or Third Party independent contractors; provided that (i) the 4DMT Indemnitees shall comply
with the procedures set forth in Section 9.7(a); and (ii) such indemnity shall not apply to the extent such Third Party Claim is subject to indemnification by 4DMT under Section 9.6. 

9.6 Indemnification by 4DMT. 4DMT shall indemnify, hold harmless and defend uniQure, its Affiliates and all of their respective
officers, directors, employees, agents, and shareholders (collectively, the “uniQure Indemnitees”) from and against any and all Damages resulting from any Third Party Claim against any uniQure Indemnitee to the extent arising out
of: (a) a Default by 4DMT; (b) the negligence or willful misconduct of a 4DMT Indemnitee; or (c) the use, Development, Commercialization, storage or other exploitation of any 4DMT AAV Capsid Vector, Compound, Product (other than a
Royalty Bearing Compound or Royalty Bearing Product), or 4DMT Product with which 4DMT proceeds under Section 4.4, in each case by 4DMT, its Affiliates, sublicensees or Third Party independent contractors; provided that (i) the
uniQure Indemnitees shall comply with the procedures set forth in Section 9.7(b); and (ii) such indemnity shall not apply to the extent such Third Party Claim is subject to indemnification by uniQure under Section 9.5. 

9.7 Procedure. 
 (a) To be
eligible for the 4DMT Indemnitees to be indemnified hereunder, 4DMT shall provide uniQure with prompt notice of the Third Party Claim giving rise to the indemnification obligation under Section 9.5 and the exclusive ability to defend or settle
any such claim; provided however that uniQure shall not enter into any settlement for damages, or that imposes upon 4DMT any obligation or liability, without 4DMT’s prior written consent, such consent not to be unreasonably
withheld, delayed or conditioned. 4DMT shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by uniQure. 

(b) To be eligible for the uniQure Indemnitees to be indemnified hereunder, uniQure shall provide 4DMT with prompt notice of the Third Party
Claim giving rise to the indemnification obligation under Section 9.6 and the exclusive ability to defend or settle any such claim; provided however that 4DMT shall not enter into any settlement for damages, or that imposes upon
uniQure any obligation or liability, without uniQure’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. uniQure shall have the right to participate, at its own expense and with counsel of its choice,
in the defense of any claim or suit that has been assumed by 4DMT. 

  
 - 54 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 9.8 uniQure Indemnity to UC. uniQure shall, and shall require its Sublicensees to,
indemnify, defend, and hold harmless UC and IGT, and their officers, employees, and agents; sponsor(s) of the research that led to the inventions disclosed in the UC Patent Rights and the UC AAV Capsid Variants; and the inventors of any UC Patent
Rights and their employers against any and all losses, damages, costs, fees, and expenses resulting from Third Party claims and suits arising out of uniQure’s activities under this Agreement or of any Sublicensee activities under any sublicense
agreement granting rights under the UC Patent Rights or the UC AAV Capsid Variants, or any use or possession of the UC AAV Capsid Variants resulting from uniQure’s exploitation of its rights thereto. This indemnification will include any
product liability claims. uniQure will keep UC informed of its defense of any claims pursuant to this Section 9.8, and UC will cooperate reasonably in any such suit. If UC invokes the provisions of this Section 9.8, UC will not make any
admissions or take any actions in such claim or suit that may prejudice or impair uniQure’s ability to defend such claim or suit without uniQure’s prior written consent, and uniQure will not admit liability or wrongdoing on behalf of UC
without UC’s prior written consent. 
 9.9 Insurance. Each Party shall procure and maintain insurance or self-insurance,
including general liability insurance and product liability insurance, adequate to cover its obligations hereunder and that are consistent with normal business practices of prudent companies similarly situated, at all times during which any Research
Compound, Royalty Bearing Compound, or Royalty Bearing Product is being Developed, clinically tested in human subjects or Commercialized by or on behalf of such Party, its Affiliates or sublicensees, including, in the case of uniQure, its
Sublicensees. It is understood that any such insurance or self-insurance shall not be construed to create a limit of a Party’s liability with respect to its indemnification obligations under this ARTICLE IX. Each Party shall provide the other
Party with written evidence of such insurance or self-insurance upon request. Each Party shall provide the other Party with written notice at least [***] ([***]) days prior to the cancellation, non-renewal or
material change in such insurance or self-insurance which could adversely affect rights hereunder. Without limiting the generality of the foregoing: 

(a) uniQure, at its sole cost and expense, will ensure that the applicable entity performing activities in connection with any work performed
hereunder, whether uniQure, an Affiliate, or a Sublicensee, will obtain, keep in force, and maintain the following insurance: 
 (i) prior
to the start of Clinical Trials of a UC Product, commercial form general liability insurance (contractual liability included) with limits as follows: 
  

			
	Each Occurrence	  	$[***]
	Products/Completed Operations Aggregate	  	$[***]
	Personal and Advertising Injury	  	$[***]
	General Aggregate	  	$[***]

 (ii) Upon the start of any Clinical Trials of a UC Product, commercial form general liability insurance
(contractual liability included), and product liability insurance if not otherwise included, with limits as follows: 
  

			
	Each Occurrence	  	$[***]
	Products/Completed Operations Aggregate	  	$[***]
	Personal and Advertising Injury	  	$[***]
	General Aggregate	  	$[***]

  
 - 55 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (iii) upon the First Commercial Sale of a UC Product, commercial form general liability
insurance (contractual liability included), and product liability insurance if not otherwise included, with limits as follows: 
  

			
	Each Occurrence	  	$[***]
	Products/Completed Operations Aggregate	  	$[***]
	Personal and Advertising Injury	  	$[***]
	General Aggregate	  	$[***]

 If the above insurance is written on a claims-made form, it shall continue for [***] ([***]) years following
termination or expiration of this Agreement. 
 (iv) worker’s compensation as legally required in the jurisdiction in which uniQure, an
Affiliate, or a Sublicensee, as applicable, is doing business. 
 uniQure will promptly notify UC of any material reduction in the insurance coverages below
the amounts required hereunder. 
 (b) Within [***] ([***]) days after the Effective Date, uniQure will furnish 4DMT with certificates of
insurance evidencing compliance with all requirements. Such certificates will: 
 (i) where possible, provide for [***] ([***])
days’ ([***] ([***]) days for non-payment of premium) advance written notice to 4DMT and UC of any cancellation of insurance coverages described above in Section 9.9(a); 

(ii) indicate that 4DMT and UC have been endorsed as additional insureds under the coverage described above in Section 9.9(a); and 

(iii) include a provision that the coverages described above in Section 9.9(a) will be primary and will not participate with, nor will be
excess over, any valid and collectable insurance or program of self-insurance maintained by 4DMT or UC. 
 9.10 No Consequential or
Punitive Damages. EXCEPT WITH RESPECT TO (a) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER THIS AGREEMENT WITH RESPECT TO THIRD PARTY CLAIMS, (b) A BREACH OF THE CONFIDENTIALITY OBLIGATIONS OF ARTICLE VIII, (c) A
BREACH OF SECTION 5.6, OR (d) A PARTY’S WILLFUL MISCONDUCT, NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS
AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. 

  
 - 56 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 ARTICLE X 

TERM AND TERMINATION 

10.1 Term and Expiration. This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to
Section 10.2, this Agreement shall continue in effect until the expiration of all of uniQure’s and 4DMT’s payment obligations hereunder (the “Term”). Upon expiration, all licenses granted hereunder shall be fully paid-up, perpetual and irrevocable. 
 10.2 Termination. 

(a) Termination of Agreement for Cause. 

(i) This Agreement may be terminated at any time during the Term upon written notice by either Party (the “Non-Defaulting Party”) upon Default of the other Party (the “Defaulting Party”), which Default remains uncured for ninety (90) days after written notice requesting cure of such
Default. The Non-Defaulting Party shall provide written notice to the Defaulting Party, which notice shall identify the Default, the intent to so terminate and the actions or conduct that it considers would be
an acceptable cure of such Default. If the Defaulting Party disputes the Default under this Section 10.2(a), then the issue of whether the Non-Defaulting Party may properly terminate this Agreement on
expiration of the applicable cure period shall be resolved in accordance with ARTICLE XI. If, as a result of such dispute resolution process, it is determined that the alleged Defaulting Party committed a Default and the Defaulting Party does not
cure such Default within sixty (60) days after the date of such dispute resolution award (the “Additional Cure Period”), then such termination shall be effective as of the expiration of the Additional Cure Period. If the
Parties dispute whether such Default was so cured, either Party alone may request the same tribunal to determine whether it was so cured, and the Parties shall cooperate to allow such determination to be made within thirty (30) days after such
request by either Party. Any such dispute resolution proceeding does not suspend any obligation of either Party hereunder, and each Party shall use reasonable efforts to mitigate any damage. If, as a result of any such dispute resolution proceeding,
it is determined that the alleged Defaulting Party did not commit such Default (or such Default was cured in accordance with this Section 10.2(a)), then no termination shall be effective, and this Agreement shall continue in full force and
effect. Notwithstanding the foregoing, if 4DMT is the Non-Defaulting Party and the claimed Default by uniQure as the Defaulting Party relates to one or more Compounds or Products, and not this entire
Agreement, then this Agreement shall be terminated only with respect to the Indication for which such Compound(s) or Product(s) were intended to treat and such Indication shall be removed from the Field.  

(ii) Notwithstanding Section 10.2(a)(i), uniQure shall have the right to terminate this Agreement during the Research Term immediately
upon written notice to 4DMT if David Schaffer ceases to be a representative of 4DMT on the JRSC or is otherwise unavailable to direct 4DMT’s Research Program activities during any consecutive fifteen (15) Business Day period, in each case
for any reason other than his death, illness or disability, which shall be deemed a Default by 4DMT. 

  
 - 57 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (b) Termination for Bankruptcy. To the extent allowed under applicable Law, either
Party shall have the right to terminate this Agreement in the event of the commencement of any proceeding in or for bankruptcy, insolvency, dissolution or winding up by or against the other Party (other than pursuant to a corporate restructuring)
that is not dismissed or otherwise disposed of within sixty (60) days thereafter. 
 (c) Termination for Futility. uniQure shall
have the right terminate this Agreement immediately upon written notice to 4DMT summarizing the basis for such termination if, at any point prior to the first (1st) anniversary of the Effective
Date, the JRSC determines that (i) it would be futile to continue the Research Program, including if the JRSC determines that any Candidate Success Criteria or Delivery Success Criteria cannot be met through use of the 4DMT Intellectual
Property following the reasonable efforts of 4DMT to achieve such Candidate Success Criteria or Delivery Success Criteria or (ii) 4DMT is not making bona fide efforts to achieve the timelines set forth in the Research Plan. 

(d) Termination for Convenience. uniQure shall have the right terminate this Agreement at any time after the Research Term, for any
reason or for no reason, by giving 4DMT ninety (90) days’ prior written notice thereof. 
 (e) Special Termination Right of
4DMT. In the event that (i) uniQure B.V. does not complete an underwritten public offering of its ordinary shares pursuant to an effective registration statement under the U.S. Securities Act of 1933 and the listing of its ordinary shares
on the Nasdaq Global Market by September 1, 2014, December 31, 2014, or December 31, 2015, as the case may be, and (ii) uniQure B.V. has not agreed in writing to pay the applicable
“Cash-Out Amount” provided for in Article 4c of each of the Grant Letters in respect of options that will vest on the first vesting date following such applicable date, 4DMT shall have the right to
terminate this Agreement by providing written notice thereof to uniQure within thirty (30) days following such applicable date, and any such termination shall be effective as of the thirtieth
(30th) day following such applicable date. 
 10.3 Effect of Termination 

(a) If uniQure terminates this Agreement under Section 10.2(a) or Section 10.2(b): 

(i) uniQure’s licenses pursuant to this Agreement shall continue; provided however that uniQure shall continue to fulfill
uniQure’s payment obligations with respect to milestones and royalties under ARTICLE VI; and provided further that uniQure may reduce such payment obligations by the amount of monetary damage suffered by uniQure as a direct result
of 4DMT’s Default, as determined (A) in a final decision of the arbitrators in accordance with Section 11.2 or, with respect to an Excluded Claim, a court of competent jurisdiction, which decision is not appealable or has not been
appealed within the time allowed for appeal, or (B) by the Parties in a settlement agreement; 
 (ii) 4DMT shall, within [***] ([***])
days after the effective date of such termination, return or cause to be returned to uniQure, copies of all uniQure’s Confidential Information and uniQure Intellectual Property and all Materials provided by uniQure, except that 4DMT may retain
one copy of uniQure’s Confidential Information solely for legal archive purposes and to exercise the licenses granted to 4DMT which survive termination of this Agreement; 

  
 - 58 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (iii) For clarity, uniQure shall be released of its ongoing diligence obligations under
Section 4.2 and uniQure and 4DMT shall be released of their disclosure and information exchange obligations under ARTICLE III and ARTICLE IV; 

(iv) For clarity, the JRSC and its subcommittees shall not meet anymore; 

(v) No further options under each Grant Letter shall vest from and after the effective date of such termination; and 

(vi) If this Agreement is terminated pursuant to Section 10.2(a)(ii), uniQure shall continue to fund the FTEs included in the Research
Plan pursuant to Section 6.2(b) for the [***] ([***]) months immediately following the effective date of such termination. 
 (b) Upon
termination of this Agreement by uniQure under Section 10.2(c) or Section 10.2(d), or by 4DMT under Section 10.2(a), Section 10.2(b), or Section 10.2(e): 

(i) For clarity, uniQure’s licenses pursuant to Section 5.1 and 4DMT’s exclusivity obligations pursuant to Section 5.6
shall terminate as of the effective date of such termination; 
 (ii) Effective as of the effective date of such termination, the license
granted to 4DMT under Section 5.2(b) shall be automatically expanded to include the Selected Capsid Variants and all fields of use; 

(iii) uniQure shall, within [***] ([***]) days after the effective date of such termination, return or cause to be returned to 4DMT, copies of
all 4DMT’s Confidential Information and 4DMT Intellectual Property and all Materials provided by 4DMT; except that uniQure may retain one copy of the 4DMT Confidential Information solely for legal archive purposes; 

(iv) 4DMT shall, within [***] ([***]) days after the effective date of such termination, return or cause to be returned to uniQure, copies of
all uniQure’s Confidential Information and uniQure Intellectual Property and all Materials provided by uniQure, except that 4DMT may retain one copy of uniQure’s Confidential Information solely for legal archive purposes and to exercise
the licenses granted to 4DMT which survive termination or are granted upon termination of this Agreement; 
 (v) For a period of [***]
([***]) months, if termination occurs after Regulatory Approval of Royalty Bearing Products, uniQure and its Affiliates shall be entitled to finish work in progress and to sell any of the Royalty Bearing Products remaining in inventory in accordance
with the terms of this Agreement to the extent such Royalty Bearing Products were being sold in the Territory at the time of termination, provided that such sales shall be subject to the royalty and milestone provisions of this Agreement;

  
 - 59 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (vi) If this Agreement is terminated pursuant to Section 10.2(c), (A) uniQure shall
continue to fund the FTEs included in the Research Plan pursuant to Section 6.2(b) for the [***] ([***]) months immediately following the effective date of such termination, but in no event for less than [***] after the Effective Date, and
(B) no further options under each Grant Letter shall vest from and after the date that [***] percent ([***]%) of all options under such Grant Letter have vested; and 

(vii) If this Agreement is terminated pursuant to Section 10.2(e), uniQure shall continue to fund the FTEs included in the Research Plan
pursuant to Section 6.2(b) for the [***] ([***]) months immediately following the effective date of such termination, but in no event for less than [***] after the Effective Date. 

Notwithstanding the foregoing, if such termination is under Section 10.2(a) solely with respect to one or more given Indication(s), then
uniQure’s licenses pursuant to Section 5.1 do not terminate but the Field is automatically narrowed to exclude the relevant Indication(s), and 4DMT’s exclusivity obligations pursuant to Section 5.6 terminate solely with respect
to the relevant Indication(s); subsection (ii) shall not apply; the license granted to 4DMT under Section 5.2(b) shall be automatically expanded to include the relevant Indication(s) rather than all fields of use; and uniQure’s
obligations under subsection (iii) shall be limited to copies of 4DMT’s Confidential Information and 4DMT Intellectual Property and Materials that relate solely to the relevant Indication(s). 

10.4 Effect of Expiration or Termination; Survival. 

(a) Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or
termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including the obligation to pay
royalties for Royalty Bearing Product(s) sold prior to such expiration or termination. Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’
ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for the termination. 

(b) The provisions of ARTICLE I, ARTICLE VII, ARTICLE VIII, ARTICLE XI, ARTICLE XII, and Sections 4.5, 5.2(b), 5.4, 5.5, 6.2(c), 9.4, 9.5,
9.6, 9.7, 9.8, 9.9, 9.10, 10.3 and 10.4 shall survive any expiration or termination of this Agreement, and with respect to those Royalty Bearing Products in such countries for which uniQure retains a Development and Commercialization license after
the expiration or termination of this Agreement, the provisions of ARTICLE VI shall also survive. 

  
 - 60 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 ARTICLE XI 

DISPUTE RESOLUTION 

11.1 Seeking Consensus. If any dispute arises out of, in connection with or related to this Agreement, including disputes over the
interpretation, performance, enforcement or breach of this Agreement, including any dispute that is not within the jurisdiction of the JRSC, (a “Dispute”), excluding any dispute resolved in accordance with Section 2.5(c)
(subject to Section 2.5(d)), then upon the written request of either Party, the matter shall be referred to the Executives, who shall meet in a good faith effort to resolve the dispute within [***] ([***]) days. If the Parties’ Executives
cannot agree on a resolution of the Dispute within such [***] ([***]) day period, then it shall be resolved pursuant to the remaining provisions of this ARTICLE XI. 

11.2 Arbitration. If the Parties do not fully settle a Dispute pursuant to Section 2.5 (only as to those matters that may be
referred to arbitration) or 11.1, as applicable, and a Party wishes to pursue the matter, each such Dispute that is not an Excluded Claim (as defined below) shall be finally resolved by binding arbitration in accordance with the Rules of Arbitration
of the ICC (International Chamber of Commerce) and judgment on the arbitration award may be entered in any court having jurisdiction thereof. 

(a) The arbitration shall be conducted by a panel of three (3) persons. Within [***] ([***]) days after initiation of arbitration, each
Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within [***] ([***]) days after their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon
the third arbitrator, the third arbitrator shall be appointed by the ICC. The place of arbitration shall be New York City, New York, and all proceedings and communications shall be in English. 

(b) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the Dispute is
otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the
arbitration award. The scope of the authority of the arbitrators shall be limited to the strict application of law. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory
damages, except as permitted by Section 9.10. Each Party participating in an arbitration pursuant to the terms of this Agreement shall, [***]. The arbitrators shall have the power to award recovery of all costs (including reasonable
attorney’s fees, administrative fees, arbitrators’ fees and court costs) to the prevailing Party. 
 (c) Neither Party shall be
required to give general discovery of documents, but may be required to produce documents or testimony that are relevant or considered relevant by the arbitrators to the Dispute. It is the objective and intent of the Parties that any arbitration
proceeding be conducted in such a manner that a decision will be rendered by the arbitrators within [***] ([***]) days after the third arbitrator is appointed to the panel, and the Parties and the panel selected in the manner provided above will
adopt rules and procedures intended to implement such objective and intent. 

  
 - 61 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 (d) Except to the extent necessary to confirm or vacate an award or as may be required by
Law (including applicable securities laws or the rules of any stock exchange on which a Party’s securities may then be listed), neither a Party nor an arbitrator may disclose the existence, content, or results of arbitration without the prior
written consent of both Parties. In no event shall arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of
limitations. 
 (e) The Parties agree that any payment made pursuant to this Agreement pending resolution of the Dispute shall be refunded
or credited if the arbitrators or court determines that such payments are not due. 
 As used in this Section 11.2, the term “Excluded
Claim” shall mean a Dispute that concerns (a) the validity, enforceability, scope or infringement of a patent, trademark or copyright; or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.

 ARTICLE XII 

MISCELLANEOUS 

12.1 Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of New York, other than
any principle of conflict or choice of laws that would cause the application of the Laws of any other jurisdiction. 
 12.2 Waiver.
Waiver by a Party of a breach hereunder by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision. No delay or omission by a Party to exercise or avail itself of any right, power or privilege
that it has or may have hereunder shall operate as a waiver of any right, power or privilege by such Party. No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a
duly authorized representative of the Party granting the waiver. 
 12.3 Notices. All notices, instructions and other communications
hereunder or in connection herewith shall be in writing, shall be sent to the address specified in this Section 12.3 and shall be: (a) delivered personally; (b) transmitted by facsimile; (c) sent by registered or certified mail,
return receipt requested, postage prepaid; or (d) sent via a reputable international overnight delivery service. Any such notice, instruction or communication shall be deemed to have been delivered (i) upon receipt if delivered by hand,
(ii) when transmitted with electronic confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business Day; otherwise, on the next Business Day following such transmission), provided that an original document
is sent via an internationally recognized overnight delivery service (receipt requested), (iii) three (3) Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) Business
Day after it is sent via a reputable international overnight delivery service. 

  
 - 62 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 
			
	If to 4DMT, to:	  	 4D Molecular Therapeutics, Inc.
 5858 Horton St.
Emerystation North, Suite 460,
 Emeryville, CA 94608

Facsimile: (650) 463-2600

		
	with a copy to:	  	 Latham & Watkins LLP
 140 Scott
Drive
 Menlo Park, CA 94025
 Attention: Alan Mendelson and
Judith Hasko
 Facsimile: (650) 463-2600
  

And
  

[***]

		
	If to uniQure, to:	  	 uniQure biopharma B.V.
 P.O. Box 22506

1100 DA Amsterdam
 The Netherlands

Attention: CEO
 Facsimile: +31 20 566 9272

		
	with a copy to:	  	[***]

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 
 12.4 Entire Agreement; Amendment. This Agreement (including its Exhibits and Schedules) contains the complete
understanding of the Parties with respect to the subject matter hereof and supersedes all prior understandings and writings relating to such subject matter. In particular, it supersedes and replaces the Prior Confidentiality Agreement and any
and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties or their Affiliates prior to the Effective Date. No amendment, change or addition to this Agreement will be effective or binding on
either Party unless reduced to writing and duly executed on behalf of both Parties. 
 12.5 Headings. Headings in this Agreement are
for convenience of reference only and shall not be considered in construing this Agreement. 
 12.6 Severability. If any provision or
portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such
fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement shall be construed as if such clause of portion thereof had never been contained in this Agreement, and there shall
be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by applicable Law. 

  
 - 63 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 12.7 Assignment. Neither this Agreement nor any right or obligation hereunder may be
assigned or otherwise transferred by any Party without the consent of the other Party; provided, however, that any Party may, without such consent, assign this Agreement, in whole or in part: (a) to any of its respective
Affiliates; provided that the assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or (b) to any successor in interest by way of merger, acquisition or sale of all or
substantially all of its assets to which this Agreement relates (an “M&A Event”). Any assignment not in accordance with this Section 12.7 shall be void. Each Party agrees that, notwithstanding any provision of this
Agreement to the contrary, neither the assignment of this Agreement by a Party in connection with an M&A Event, nor the occurrence of such M&A Event (whether or not a formal assignment of this Agreement occurs), shall provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party or its Affiliates that were not Affiliates of the assigning Party prior to such M&A
Event. If uniQure assigns its rights and obligations hereunder to an Affiliate or Third Party outside the United States or The Netherlands pursuant to this Section 12.7, and if such Affiliate or Third Party shall be required by applicable Law
to withhold additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable under this Agreement shall be increased to take into account the additional taxes withheld as may
be necessary so that, after making all required withholdings, 4DMT receives an amount equal to the sum it would have received had no such assignment been made. 

12.8 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument. Signatures provided by facsimile transmission or in Adobe Portable Document Format (PDF) sent by electronic mail shall be deemed to be original signatures. 

12.9 Force Majeure. No Party shall be liable for failure of or delay in performing obligations (other than payment obligations) set
forth in this Agreement, and no Party shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, explosion, fire, flood, tornado, thunderstorm, hurricane, earthquake, war, terrorism, riot, embargo, loss or
shortage of power, labor stoppage, substance or material shortage, events caused by reason of laws of any Governmental Authority, events caused by acts or omissions of a Third Party or any other cause reasonably beyond the control of such Party, if
the Party affected gives prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled,
provided, however, that such affected Party commences and continues to use its Commercially Reasonable Efforts to cure such cause. 

12.10 Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party,
other than a 4DMT Indemnitee under Section 9.5 or uniQure Indemnitee under Section 9.6. No such Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of
any debt, liability or obligation (or otherwise) against either Party. 

  
 - 64 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 12.11 Relationship of the Parties. Each Party shall bear its own costs incurred in the
performance of its obligations hereunder without charge or expense to the other, except as expressly provided in this Agreement. Neither Party shall have any responsibility for the hiring, termination or compensation of the other Party’s
employees or for any employee compensation or benefits of the other Party’s employees. No employee or representative of a Party shall have any authority to bind or obligate the other Party for any sum or in any manner whatsoever, or to create
or impose any contractual or other liability on the other Party without said other Party’s approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, the legal relationship under this Agreement of
each Party to the other Party shall be that of independent contractor. Nothing in this Agreement shall be construed to establish a relationship of partners or joint ventures between the Parties. 

12.12 Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party or permits a Party to
exercise its rights or perform its obligations through its Affiliates, such Party agrees to cause its Affiliates to perform such obligations and shall guarantee performance of this Agreement by its Affiliates. If any disagreement arises out of the
performance of this Agreement by an Affiliate of a Party, or the alleged failure of an Affiliate to comply with the conditions and obligations of this Agreement, the Party seeking to resolve such dispute shall have the right do so directly with the
other Party, without any obligation to first pursue an action against, or recovery from, the Affiliate which is alleged to have caused a breach of this Agreement. 

12.13 Construction. Each Party acknowledges that it has been advised by counsel during the course of negotiation of this Agreement, and,
therefore, that this Agreement shall be interpreted without regard to any presumption or rule requiring construction against the Party causing this Agreement to be drafted. Any reference in this Agreement to an ARTICLE, Section, subsection,
paragraph, clause, or Schedule shall be deemed to be a reference to any article, section, subsection, paragraph, clause, schedule or exhibit, of or to, as the case may be, this Agreement. Except where the context otherwise requires,
(a) wherever used, the use of any gender will be applicable to all genders; (b) the word “or” is used in the inclusive sense (and/or); (c) any definition of or reference to any agreement, instrument or other document refers to
such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restriction on such amendments, supplements or modifications set forth herein or therein); (d) any reference to any Law refers
to such Law as from time to time enacted, repealed or amended; (e) the words “herein”, “hereof” and hereunder”, and words of similar import, refer to this Agreement in its entirety and not to any particular provision
hereof; and (f) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “but not limited to”, “without limitation” or words of similar import. 

[Signature page follows] 

  
 - 65 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated Collaboration and License
Agreement as of the Amended CLA Effective Date. 
  

					
	 UNIQURE BIOPHARMA B.V.
  

BY: /s/ Lilly
Burggraaf                                        
                    
 NAME: Lilly Burggraaf

TITLE: Vice President, Global Human Resources
	 		 	 4D MOLECULAR THERAPEUTICS, INC.
  

BY: /s/ David
Kirn                                         
               
 NAME: David Kirn, MD

TITLE: Chief Executive Officer

 List of Schedules 
  

	Exhibit A	 Commitment Letter from uniQure B.V. 

	Schedule 1.5	 4DMT Patent Rights 

	Schedule 1.41	 Outline of Budget for Research Plan 

	Schedule 1.54	 Draft Invoice 

	Schedule 1.76	 Outline of Research Plan 

  
 - 66 - 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 Exhibit A 

COMMITMENT LETTER FROM UNIQURE B.V. 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 Schedule 1.5 

4DMT PATENT RIGHTS 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 Schedule 1.41 

OUTLINE OF BUDGET FOR RESEARCH PLAN 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 Schedule 1.54 

DRAFT INVOICE 
 Omitted
pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 Schedule 1.76 

OUTLINE OF RESEARCH PLAN 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 SCHEDULE 1.83 

SELECTED CAPSID VARIANTS 

Omitted pursuant to Regulation S-K, Item 601(a)(5).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]